US20190167695A1 - Compositions and methods for preventing or treating muscle conditions - Google Patents

Compositions and methods for preventing or treating muscle conditions Download PDF

Info

Publication number
US20190167695A1
US20190167695A1 US16/148,976 US201816148976A US2019167695A1 US 20190167695 A1 US20190167695 A1 US 20190167695A1 US 201816148976 A US201816148976 A US 201816148976A US 2019167695 A1 US2019167695 A1 US 2019167695A1
Authority
US
United States
Prior art keywords
muscle
pge2
compound
myotoxin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/148,976
Other languages
English (en)
Inventor
Helen M. Blau
Adelaida R. Palla
Andrew Tri Van Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to US16/148,976 priority Critical patent/US20190167695A1/en
Assigned to THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY reassignment THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PALLA, ADELAIDA R., BLAU, HELEN M., TRI VAN HO, Andrew
Publication of US20190167695A1 publication Critical patent/US20190167695A1/en
Priority to US17/399,490 priority patent/US11738031B2/en
Priority to US18/317,752 priority patent/US20240115583A1/en
Priority to US19/386,538 priority patent/US20260144801A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/583—Snakes; Lizards, e.g. chameleons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • Muscle injuries are an extremely common phenomenon which range from being relatively mild to extremely severe and can take many forms.
  • muscle injuries arise from any number of causes.
  • muscles are often incidentally injured during surgical procedures (e.g., surgical treatments). This is especially apparent in the context of surgical procedures such as Caesarean sections and joint replacement surgeries (e.g., knee and hip replacement surgeries).
  • many muscle injuries are the result of trauma and accidental events that produce cutting, compression, and/or crushing of muscle tissue.
  • immobilization e.g., limb immobilization
  • nerve injuries e.g., peripheral nerve injuries
  • Peripheral nerve injuries are a common result of trauma or immobilization due to illness and can produce severe motor deficits that ultimately impact the physical, psychological, and social well-being of those affected.
  • peripheral nerves are prevalently injured in combat from high velocity gunshot wounds and explosive fragments.
  • combat PNIs are increasingly common because improvements in body armor and rapid evacuations allow more soldiers to survive severe extremity trauma. PNIs occurred in 8% of UK combat casualties from the Iraq and Afghanistan conflicts. Of those with combat PNIs, only about 9% return to full duty.
  • Compression PNIs are a category of nerve injury caused by constriction of the nerve. Compression PNIs are especially common in the military veteran population. For example, in 2007-2008 120,000 veterans received a diagnosis of CTS and 10,000 of them underwent carpal tunnel release.
  • CTS carpal tunnel syndrome
  • a primary morbidity after PNI is muscle atrophy that occurs when a muscle is denervated.
  • Recovery of denervated muscle is a complex process that is not fully understood; however intrinsic regenerative factors of the muscle are known to be critical and can be influenced by factors such as age.
  • the denervated muscle is the abductor pollicis brevis (APB), which brings the thumb out of the plane of the palm and is integral to many fine motor activities ( FIG. 1 ).
  • APB abductor pollicis brevis
  • the only means of medical intervention is by surgery to release the band constricting the median nerve. This allows for regeneration of the motor nerve and potential recovery of the muscle.
  • many of those with severe CTS have poor functional recovery even after the nerve has been released.
  • the present invention satisfies this need, and provides related advantages as well.
  • the composition comprises a prostaglandin E2 (PGE2) compound and a myotoxin.
  • PGE2 prostaglandin E2
  • the pharmaceutical composition comprises a composition described herein that comprises a PGE2 compound and a myotoxin.
  • a method for promoting muscle regeneration and/or increasing muscle mass in a subject in need thereof comprises administering a combination of a PGE2 compound and a myotoxin to the subject.
  • a method for preventing or treating a muscle condition in a subject in need thereof comprises administering a combination of a PGE2 compound and a myotoxin to the subject. In other embodiments, the method comprises administering a PGE2 receptor agonist and a myotoxin to the subject.
  • kits for promoting muscle regeneration, increasing muscle strength, and/or increasing muscle mass in a subject in need thereof, or for preventing or treating a muscle condition in a subject in need thereof comprises a composition described herein that comprises a combination of a PGE2 compound and a myotoxin.
  • the kit comprises a pharmaceutical composition described herein.
  • a composition for preventing or treating a muscle condition comprising a prostaglandin E2 (PGE2) compound and a myotoxin.
  • PGE2 compound is selected from the group consisting of PGE2, a PGE2 prodrug, a PGE2 receptor agonist, a compound that attenuates PGE2 catabolism, a compound that neutralizes PGE2 inhibition, a derivative thereof, an analog thereof, and a combination thereof.
  • the PGE2 receptor agonist comprises a compound of Formula (I), a derivative thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer thereof, or a combination thereof,
  • ring A is a substituted cyclopentyl ring or a substituted cyclopentenyl ring.
  • the one or more additional substituents on ring A are selected from the group consisting of deuterium, hydroxy, amino, oxo, Cl-C6 alkyl, and halogen.
  • the one or more additional substituents on ring A are hydroxy or oxo.
  • ring A has two additional substituents that are taken together to form a covalent bond to form a heterocycloalkyl ring.
  • ring A is selected from the group consisting of
  • ring A is selected from the group consisting of
  • ring A is
  • R 1 is substituted C 1 -C 10 alkyl. In some embodiments, R 1 is substituted C 2 -C 10 alkenyl. In some embodiments, the substituent on R 1 is selected from the group consisting of deuterium, hydroxy, oxo, C 1 -C 6 alkyl, —COOR 3 , and halogen, wherein R 3 is hydrogen or C 1 -C 6 alkyl. In some embodiments, R 1 is selected from the group consisting of
  • R 1 is selected from the group consisting of
  • R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R 2 is substituted C 1 -C 10 alkyl.
  • R 2 is substituted C 2 -C 10 alkenyl.
  • the substituent on R 2 is selected from the group consisting of deuterium, hydroxy, oxo, C 1 -C 6 alkyl, —COOR 3 , and halogen, wherein R 3 is hydrogen or C 1 -C 6 alkyl.
  • R 2 is selected from the group consisting of
  • R 2 is selected from the group consisting of
  • R 2 is
  • the compound of Formula (I), the pharmaceutically acceptable salt thereof, the solvate thereof, or the stereoisomer thereof is a compound of Formula (Ia), Formula (Ib), Formula (Ic), or Formula (Id), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
  • the compound of Formula (I), the pharmaceutically acceptable salt thereof, the solvate thereof, or the stereoisomer thereof is a compound of Formula (Id), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
  • the PGE2 derivative comprises 16,16-dimethyl prostaglandin E2.
  • the compound that attenuates PGE2 catabolism comprises a compound, neutralizing peptide, or neutralizing antibody that inactivates or blocks 15-hydroxyprostaglandin dehydrogenase (15-PGDH) or inactivates or blocks a prostaglandin transporter (PGT or SLCO2A1).
  • the PGE2 compound is PGE2.
  • the myotoxin is selected from the group consisting of an anesthetic, a divalent cation, snake venom, lizard venom, bee venom, and a combination thereof.
  • the anesthetic is selected from the group consisting of an amino-amide anesthetic, an amino-ester anesthetic, and a combination thereof.
  • the amino-amide anesthetic is selected from the group consisting of bupivacaine, levobupivacaine, articaine, ropivacaine, butanilicaine, carticaine, dibucaine, etidocaine, lidocaine, mepivacaine, prilocaine, trimecaine, and a combination thereof.
  • the amino-ester anesthetic is selected from the group consisting of an aminobenzoic acid ester anesthetic, a benzoic acid ester anesthetic, and a combination thereof.
  • the aminobenzoic acid ester anesthetic is selected from the group consisting of benzocaine, butacaine, butamben, chloroprocaine, dimethocaine, lucaine, meprylcaine, metabutethamine, metabutoxycaine, nitracaine, orthocaine, propoxycaine, procaine, proxymetacaine, procaine, tetracaine, and a combination thereof.
  • the benzoic acid ester anesthetic is selected from the group consisting of amylocaine, cocaine, cyclomethycaine, ⁇ -eucaine, ⁇ -eucaine, hexylcaine, isobucaine, piperocaine, and a combination thereof.
  • the snake venom or the lizard venom is selected from the group consisting of notexin, cardiotoxin, bungarotoxin, and a combination thereof.
  • the divalent cation is selected from the group consisting of Ba 2+ , Sr 2+ , Mg 2+ , Ca 2+ , Mn 2+ , Ni 2+ , Co 2+ , a salt thereof, and a combination thereof.
  • PGE2 compound is PGE2 and/or 16,16-dimethyl prostaglandin E2 and the myotoxin is bupivacaine.
  • PGE2 compound is PGE2 and/or 16,16-dimethyl prostaglandin E2 and the myotoxin is bupivacaine.
  • the muscle condition is associated with muscle damage, injury, or atrophy.
  • a pharmaceutical composition comprising the composition described herein and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier comprises an aqueous base.
  • the pharmaceutically acceptable carrier comprises a low viscosity compound.
  • the low viscosity compound comprises gelatin.
  • the low viscosity compound comprises a hydrogel.
  • Described herein is a method for promoting muscle regeneration and/or increasing muscle mass in a subject in need thereof, the method comprising administering a combination of a PGE2 compound and a myotoxin to the subject.
  • the PGE2 compound is selected from the group consisting of PGE2, a PGE2 prodrug, a PGE2 receptor agonist, a compound that attenuates PGE2 catabolism, a compound that neutralizes PGE2 inhibition, a derivative thereof, an analog thereof, and a combination thereof.
  • the PGE2 derivative comprises 16,16-dimethyl prostaglandin E2.
  • the compound that attenuates PGE2 catabolism comprises a compound, neutralizing peptide, or neutralizing antibody that inactivates or blocks 15-hydroxyprostaglandin dehydrogenase (15-PGDH) or inactivates or blocks a prostaglandin transporter (PGT or SLCO2A1).
  • the PGE2 compound is PGE2.
  • the myotoxin is selected from the group consisting of an anesthetic, a divalent cation, snake venom, lizard venom, bee venom, and a combination thereof.
  • the anesthetic is selected from the group consisting of an amino-amide anesthetic, an amino-ester anesthetic, and a combination thereof.
  • the amino-amide anesthetic is selected from the group consisting of bupivacaine, levobupivacaine, articaine, ropivacaine, butanilicaine, carticaine, dibucaine, etidocaine, lidocaine, mepivacaine, prilocaine, trimecaine, and a combination thereof.
  • the amino-ester anesthetic is selected from the group consisting of an aminobenzoic acid ester anesthetic, a benzoic acid ester anesthetic, and a combination thereof.
  • the aminobenzoic acid ester anesthetic is selected from the group consisting of benzocaine, butacaine, butamben, chloroprocaine, dimethocaine, lucaine, meprylcaine, metabutethamine, metabutoxycaine, nitracaine, orthocaine, propoxycaine, procaine, proxymetacaine, risocaine, tetracaine, and a combination thereof.
  • the benzoic acid ester anesthetic is selected from the group consisting of amylocaine, cocaine, cyclomethycaine, ⁇ -eucaine, ⁇ -eucaine, hexylcaine, isobucaine, piperocaine, and a combination thereof.
  • the snake venom or the lizard venom is selected from the group consisting of notexin, cardiotoxin, bungarotoxin, and a combination thereof.
  • the divalent cation is selected from the group consisting of Ba 2+ , Sr 2+ , Mg 2+ , Ca 2+ , Mn 2+ , Ni 2+ , Co 2+ , a salt thereof, and a combination thereof.
  • PGE2 compound is PGE2 and/or 16,16-dimethyl prostaglandin E2 and the myotoxin is bupivacaine. In some embodiments, the PGE2 compound and the myotoxin are administered concomitantly. In some embodiments, the PGE2 compound and the myotoxin are administered sequentially. In some embodiments, the PGE2 compound is administered before the myotoxin. In some embodiments, the PGE2 compound is administered after the myotoxin.
  • administering the PGE2 compound, the myotoxin, or both comprises topical, oral, intraperitoneal, intramuscular, intra-arterial, intradermal, subcutaneous, intravenous, or intracardiac administration. In some embodiments, administering comprises intramuscular administration. In some embodiments, a dose of the PGE2 compound, the myotoxin, or both, is determined based upon a target muscle size. In some embodiments, the target muscle is an abductor pollicis brevis muscle and the dose of the PGE2 compound, the myotoxin, or both, is about 10 ⁇ g.
  • the method further comprises subjecting a target muscle to mechanical injury.
  • the mechanical injury comprises cutting, burning, freezing, needle puncture, exercise, a surgical procedure, traumatic injury, or a combination thereof.
  • the method further comprises administering a population of isolated muscle cells to the subject.
  • the population of isolated muscle cells is autologous to the subject.
  • the population of isolated muscle cells is allogeneic to the subject.
  • the population of isolated muscle cells is purified.
  • population of isolated muscle cells is cultured with the PGE2 compound, the myotoxin, or both, prior to being administered to the subject.
  • culturing the population of isolated muscle cells with the PGE2 compound, the myotoxin, or both comprises acute, intermittent, or continuous exposure of the population of isolated muscle cells to the PGE2 compound, the myotoxin, or both.
  • administering the population of isolated muscle cells comprises injecting or transplanting the cells into the subject.
  • administration of the population of isolated muscle cells and administration of the PGE2 compound and the myotoxin are performed concomitantly.
  • administration of the population of isolated muscle cells and administration of the PGE2 compound and the myotoxin are performed sequentially.
  • the subject has a muscle condition.
  • the muscle condition is associated with muscle damage, injury, atrophy, or any combination thereof.
  • the muscle condition is selected from the group consisting of traumatic injury, acute muscle injury, acute nerve injury, chronic nerve injury, soft tissue hand injury, carpal tunnel syndrome (CTS), Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, limb girdle muscular dystrophy, amyotrophic lateral sclerosis (ALS), distal muscular dystrophy (DD), inherited myopathies, myotonic muscular dystrophy (MDD), mitochondrial myopathies, myotubular myopathy (MM), myasthenia gravis (MG), congestive heart failure, periodic paralysis, polymyositis, rhabdomyolysis, dermatomyositis, cancer cachexia, AIDS cachexia, cardiac cachexia, stress induced urinary incontinence, sarcopenia, spinal muscular atrophy, fecal sphincter dysfunction, Bell's palsy, rotator c
  • the PGE2 compound and the myotoxin are administered immediately after the traumatic injury.
  • the subject receives a surgical procedure.
  • the surgical procedure is for the prevention of a nerve injury, reduction of a nerve injury, repair of a nerve injury, or any combination thereof.
  • the surgical procedure comprises cutting a muscle, repairing a muscle, or both.
  • the subject receives the surgical procedure before administration of the PGE2 compound and the myotoxin.
  • the subject receives the surgical procedure at the same time as administration of the PGE2 compound and the myotoxin.
  • the subject receives the surgical procedure after administration of the PGE2 compound and the myotoxin.
  • the nerve injury is a peripheral nerve injury.
  • the surgical procedure comprises a carpal tunnel release procedure.
  • Described herein is a method for preventing or treating a muscle condition in a subject in need thereof, the method comprising administering a combination of a PGE2 compound and a myotoxin to the subject.
  • the PGE2 compound is selected from the group consisting of PGE2, a PGE2 prodrug, a PGE2 receptor agonist, a compound that attenuates PGE2 catabolism, a compound that neutralizes PGE2 inhibition, a derivative thereof, an analog thereof, and a combination thereof.
  • the PGE2 derivative comprises 16,16-dimethyl prostaglandin E2.
  • the compound that attenuates PGE2 catabolism comprises a compound, neutralizing peptide, or neutralizing antibody that inactivates or blocks 15-hydroxyprostaglandin dehydrogenase (15-PGDH) or inactivates or blocks a prostaglandin transporter (PGT or SLCO2A1).
  • the PGE2 compound is PGE2.
  • the myotoxin is selected from the group consisting of an anesthetic, a divalent cation, snake venom, lizard venom, bee venom, and a combination thereof.
  • the anesthetic is selected from the group consisting of an amino-amide anesthetic, an amino-ester anesthetic, and a combination thereof.
  • the amino-amide anesthetic is selected from the group consisting of bupivacaine, levobupivacaine, articaine, ropivacaine, butanilicaine, carticaine, dibucaine, etidocaine, lidocaine, mepivacaine, prilocaine, trimecaine, and a combination thereof.
  • the amino-ester anesthetic is selected from the group consisting of an aminobenzoic acid ester anesthetic, a benzoic acid ester anesthetic, and a combination thereof.
  • the aminobenzoic acid ester anesthetic is selected from the group consisting of benzocaine, butacaine, butamben, chloroprocaine, dimethocaine, lucaine, meprylcaine, metabutethamine, metabutoxycaine, nitracaine, orthocaine, propoxycaine, procaine, proxymetacaine, risocaine, tetracaine, and a combination thereof.
  • the benzoic acid ester anesthetic is selected from the group consisting of amylocaine, cocaine, cyclomethycaine, ⁇ -eucaine, ⁇ -eucaine, hexylcaine, isobucaine, piperocaine, and a combination thereof.
  • the snake venom or the lizard venom is selected from the group consisting of notexin, cardiotoxin, bungarotoxin, and a combination thereof.
  • the divalent cation is selected from the group consisting of Ba 2+ , Sr 2+ , Mg 2+ , Ca 2+ , Mn 2+ , Ni 2+ , Co 2+ , a salt thereof, and a combination thereof.
  • the PGE2 compound is PGE2 and the myotoxin is bupivacaine. In some embodiments, the PGE2 compound and the myotoxin are administered concomitantly. In some embodiments, the PGE2 compound and the myotoxin are administered sequentially. In some embodiments, the PGE2 compound is administered before the myotoxin. In some embodiments, the PGE2 compound is administered after the myotoxin. In some embodiments, administering the PGE2 compound, the myotoxin, or both, comprises topical, oral, intraperitoneal, intramuscular, intra-arterial, intradermal, subcutaneous, intravenous, or intracardiac administration. In some embodiments, administering comprises intramuscular administration.
  • a dose of the PGE2 compound, the myotoxin, or both is determined based upon a target muscle size.
  • the target muscle is an abductor pollicis brevis muscle and the dose of the PGE2 compound, the myotoxin, or both, is about 10 ⁇ g.
  • the method further comprises subjecting a target muscle to mechanical injury.
  • the mechanical injury comprises cutting, burning, freezing, needle puncture, exercise, a surgical procedure, traumatic injury, or a combination thereof.
  • the method further comprises administering a population of isolated muscle cells to the subject.
  • the population of isolated muscle cells is autologous to the subject.
  • the population of isolated muscle cells is allogeneic to the subject.
  • the population of isolated muscle cells is purified.
  • the population of isolated muscle cells is cultured with the PGE2 compound, the myotoxin, or both, prior to being administered to the subject.
  • culturing the population of isolated muscle cells with the PGE2 compound, the myotoxin, or both comprises acute, intermittent, or continuous exposure of the population of isolated muscle cells to the PGE2 compound, the myotoxin, or both.
  • the population of isolated muscle cells comprises injecting or transplanting the cells into the subject. In some embodiments, administration of the population of isolated muscle cells and administration of the PGE2 compound and the myotoxin are performed concomitantly. In some embodiments, administration of the population of isolated muscle cells and administration of the PGE2 compound and the myotoxin are performed sequentially.
  • the muscle condition is associated with muscle damage, injury, atrophy, or any combination thereof.
  • the muscle condition is selected from the group consisting of traumatic injury, acute muscle injury, acute nerve injury, chronic nerve injury, soft tissue hand injury, carpal tunnel syndrome (CTS), Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, limb girdle muscular dystrophy, amyotrophic lateral sclerosis (ALS), distal muscular dystrophy (DD), inherited myopathies, myotonic muscular dystrophy (MDD), mitochondrial myopathies, myotubular myopathy (MM), myasthenia gravis (MG), congestive heart failure, periodic paralysis, polymyositis, rhabdomyolysis, dermatomyositis, cancer cachexia, AIDS cachexia, cardiac cachexia, stress induced urinary incontinence, sarcopenia, spinal muscular atrophy, fecal sphincter dysfunction, Bell's palsy, rotator c
  • the PGE2 receptor agonist and the myotoxin are administered immediately after the traumatic injury.
  • the subject receives a surgical procedure.
  • the surgical procedure is for the prevention of a nerve injury, reduction of a nerve injury, repair of a nerve injury, or any combination thereof.
  • the surgical procedure comprises cutting a muscle, repairing a muscle, or both.
  • the subject receives the surgical procedure before administration of the PGE2 compound and the myotoxin.
  • the subject receives the surgical procedure at the same time as administration of the PGE2 compound and the myotoxin.
  • the subject receives the surgical procedure after administration of the PGE2 compound and the myotoxin.
  • the nerve injury is a peripheral nerve injury.
  • the surgical procedure comprises a carpal tunnel release procedure. In some embodiments, treating the subject results in an improvement in muscle strength, muscle coordination, or both, in the subject.
  • a method for preventing or treating a muscle condition in a subject in need thereof comprising administering a prostaglandin E2 (PGE2) receptor agonist to the subject.
  • PGE2 receptor agonist comprises a compound of Formula (I), a derivative thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer thereof, or a combination thereof,
  • A is a substituted cyclopentyl ring or a substituted cyclopentenyl ring.
  • the one or more additional substituents on ring A are selected from the group consisting of deuterium, hydroxy, amino, oxo, C 1 -C 6 alkyl, and halogen.
  • the one or more additional substituents on ring A are hydroxy or oxo.
  • ring A has two additional substituents that are taken together to form a covalent bond to form a heterocycloalkyl ring.
  • ring A is selected from the group consisting of
  • ring A is selected from the group consisting of
  • ring A is
  • R 1 is substituted C 1 -C 10 alkyl.
  • R 1 is substituted C 2 -C 10 alkenyl.
  • the substituent on R 1 is selected from the group consisting of deuterium, hydroxy, oxo, C 1 -C 6 alkyl, —COOR 3 , and halogen, wherein R 3 is hydrogen or C 1 -C 6 alkyl.
  • R 1 is selected from the group consisting of
  • R 1 is selected from the group consisting of
  • R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R 2 is substituted C 1 -C 10 alkyl. In some embodiments, R 2 is substituted C 2 -C 10 alkenyl. In some embodiments, the substituent on R 2 is selected from the group consisting of deuterium, hydroxy, oxo, C 1 -C 6 alkyl, —COOR 3 , and halogen, wherein R 3 is hydrogen or C 1 -C 6 alkyl. In some embodiments, R 2 is selected from the group consisting of
  • R 2 is selected from the group consisting of
  • R 2 is
  • the compound of Formula (I), the pharmaceutically acceptable salt thereof, the solvate thereof, or the stereoisomer thereof is a compound of Formula (Ia), Formula (Ib), Formula (Ic), or Formula (Id), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
  • the compound of Formula (I), the pharmaceutically acceptable salt thereof, the solvate thereof, or the stereoisomer thereof is a compound of Formula (Id), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
  • the PGE2 receptor agonist comprises PGE2, 16,16-dimethyl prostaglandin E2, or both.
  • the method further comprises administering a myotoxin to the subject.
  • the myotoxin is selected from the group consisting of an anesthetic, a divalent cation, snake venom, lizard venom, bee venom, and a combination thereof.
  • the anesthetic is selected from the group consisting of an amino-amide anesthetic, an amino-ester anesthetic, and a combination thereof.
  • the amino-amide anesthetic is selected from the group consisting of bupivacaine, levobupivacaine, articaine, ropivacaine, butanilicaine, carticaine, dibucaine, etidocaine, lidocaine, mepivacaine, prilocaine, trimecaine, and a combination thereof.
  • the amino-ester anesthetic is selected from the group consisting of an aminobenzoic acid ester anesthetic, a benzoic acid ester anesthetic, and a combination thereof.
  • the aminobenzoic acid ester anesthetic is selected from the group consisting of benzocaine, butacaine, butamben, chloroprocaine, dimethocaine, lucaine, meprylcaine, metabutethamine, metabutoxycaine, nitracaine, orthocaine, propoxycaine, procaine, proxymetacaine, risocaine, tetracaine, and a combination thereof.
  • the benzoic acid ester anesthetic is selected from the group consisting of amylocaine, cocaine, cyclomethycaine, ⁇ -eucaine, ⁇ -eucaine, hexylcaine, isobucaine, piperocaine, and a combination thereof.
  • the snake venom or the lizard venom is selected from the group consisting of notexin, cardiotoxin, bungarotoxin, and a combination thereof.
  • the divalent cation is selected from the group consisting of Ba 2+ , Sr 2+ , Mg 2+ , Ca 2+ , Mn 2+ , Ni 2+ , Co 2+ , a salt thereof, and a combination thereof.
  • the PGE2 receptor agonist is PGE2, 16,16-dimethyl prostaglandin E2, or both, and the myotoxin is bupivacaine.
  • the method further comprises subjecting a target muscle to mechanical injury.
  • the mechanical injury comprises cutting, burning, freezing, needle puncture, exercise, a surgical procedure, traumatic injury, or a combination thereof.
  • the method further comprises administering a population of isolated muscle cells to the subject.
  • the population of isolated muscle cells is autologous to the subject.
  • the population of isolated muscle cells is allogeneic to the subject.
  • the population of isolated muscle cells is purified.
  • the population of isolated muscle cells is cultured with the PGE2 receptor agonist prior to being administered to the subject.
  • culturing the population of isolated muscle cells with the PGE2 compound comprises acute, intermittent, or continuous exposure of the population of isolated muscle cells to the PGE2 compound.
  • administering the population of isolated muscle cells comprises injecting or transplanting the cells into the subject.
  • administration of the population of isolated muscle cells and administration of the PGE2 receptor agonist are performed concomitantly.
  • administration of the population of isolated muscle cells and administration of the PGE2 receptor agonist are performed sequentially.
  • the muscle condition is associated with muscle damage, injury, atrophy, or any combination thereof.
  • the muscle condition is selected from the group consisting of traumatic injury, acute muscle, acute nerve injury, chronic nerve injury, soft tissue hand injury, carpal tunnel syndrome (CTS), Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, limb girdle muscular dystrophy, amyotrophic lateral sclerosis (ALS), distal muscular dystrophy (DD), inherited myopathies, myotonic muscular dystrophy (MDD), mitochondrial myopathies, myotubular myopathy (MM), myasthenia gravis (MG), congestive heart failure, periodic paralysis, polymyositis, rhabdomyolysis, dermatomyositis, cancer cachexia, AIDS cachexia, cardiac cachexia, stress induced urinary incontinence, sarcopenia, spinal muscular atrophy, fecal sphincter dysfunction, Bell's palsy, rotator cuff
  • the PGE2 receptor agonist is administered immediately after the traumatic injury.
  • the subject receives a surgical procedure.
  • the surgical procedure is for the prevention of a nerve injury, reduction of a nerve injury, repair of a nerve injury, or any combination thereof.
  • the surgical procedure comprises cutting a muscle, repairing a muscle, or both.
  • the subject receives the surgical procedure before administration of the PGE2 receptor agonist.
  • the subject receives the surgical procedure at the same time as administration of the PGE2 receptor agonist.
  • the subject receives the surgical procedure after administration of the PGE2 receptor agonist.
  • the nerve injury is a peripheral nerve injury.
  • the surgical procedure comprises a carpal tunnel release procedure. In some embodiments, no anesthetic is administered to the subject.
  • kits for promoting muscle regeneration in a subject in need thereof, increasing muscle mass in a subject in need thereof, or both, or for preventing or treating a muscle condition in a subject in need thereof comprising a composition described herein or a pharmaceutical composition described herein.
  • the subject has a muscle condition.
  • the muscle condition is associated with muscle damage, injury, atrophy, or any combination thereof.
  • muscle condition is selected from the group consisting of traumatic injury (e.g., acute muscle trauma, acute nerve trauma), acute muscle injury, acute nerve injury, chronic nerve injury, soft tissue hand injury, carpal tunnel syndrome (CTS), Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, limb girdle muscular dystrophy, amyotrophic lateral sclerosis (ALS), distal muscular dystrophy (DD), inherited myopathies, myotonic muscular dystrophy (MDD), mitochondrial myopathies, myotubular myopathy (MM), myasthenia gravis (MG), congestive heart failure, periodic paralysis, polymyositis, rhabdomyolysis, dermatomyositis, cancer cachexia, AIDS cachexia, cardiac cachexia, stress induced urinary incontinence, sarcopenia, spinal muscular atrophy, fecal sphincter dysfunction, Bell's palsy, rotator cuff injury, spinal cord injury, hip replacement, knee replacement
  • CTS
  • the kit further comprises isolated muscle cells. In some embodiments, the kit further comprises instructions for use. In some embodiments, the kit further comprises one or more reagents. In some embodiments, the kit further comprises a delivery device for administering the composition, pharmaceutical composition, isolated muscle cells, or any combination thereof, to the subject.
  • Described herein is a method for treating a pelvic floor disorder in a subject in need thereof, the method comprising administering a combination of a PGE2 compound and a myotoxin to the subject.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to a pelvic floor muscle of the subject.
  • the pelvic floor muscle is the levator ani, the coccygeus muscle, or both.
  • the levator ani comprises the pubococcygeus muscle, the iliococcygeus muscle, the puborectalis muscle, or a combination thereof.
  • the pelvic floor disorder is selected from the group consisting of stress urinary incontinence, overactive bladder/urinary urgency incontinence, mixed urinary incontinence, pelvic organ prolapse, and fecal incontinence.
  • the method further comprises administering a therapy suitable to treat, prevent, or ameliorate symptoms associated with pelvic floor disorders to the subject.
  • the additional therapy is selected from the group consisting of muscle training/biofeedback, neuromodulation, pharmacotherapy, surgery, and a combination thereof.
  • Described herein is a method for treating an ocular disease or disorder in a subject in need thereof, the method comprising administering a combination of a PGE2 compound and a myotoxin to the subject.
  • the ocular disease or disorder comprises impaired eyelid function.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to an eyelid muscle of the subject.
  • the eyelid muscle is selected from the group consisting of Muller's muscle, ocipitofrontalis muscle, temporoparietalis muscle, procerus muscle, nasalis muscle, depressor septi nasi muscle, orbicularis oculi muscle, corrugator supercilii muscle, depressor supercilii muscle, anterior auricular muscles, superior auricular muscle, posterior auricular muscle, orbicularis oris muscle, depressor anguli oris muscle, risorius, zygomaticus major muscle, zygomaticus minor muscle, levator labii superioris, levator labii superioris alaeque nasi muscle, depressor labii inferioris muscle, levator anguli oris, buccinator muscle, mentalis, frontalis muscle, and a combination thereof.
  • the impaired eyelid function is selected from the group consisting of eyelid drooping, ptosis, dermatochalasis, and a combination thereof.
  • the method further comprises, prior to, during, or after the administering, performing eyelift surgery on the subject.
  • the impaired eyelid function is associated with irregular astigmatism.
  • the ocular disease or disorder is selected from the group consisting of impaired blinking, wet eye syndrome, dry eye syndrome, lacrimal gland atrophy, 7th facial nerve palsy, recurring styes, and a combination thereof.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to an eye muscle of the subject.
  • the eye muscle is selected from the group consisting of muscle of Riolan, Horner's muscle, frontalis muscle, ocipitofrontalis muscle, temporoparietalis muscle, procerus muscle, nasalis muscle, depressor septi nasi muscle, orbicularis oculi muscle, corrugator supercilii muscle, depressor supercilii muscle, anterior auricular muscles, superior auricular muscle, posterior auricular muscle, orbicularis oris muscle, depressor anguli oris muscle, risorius, zygomaticus major muscle, zygomaticus minor muscle, levator labii superioris, levator labii superioris alaeque nasi muscle, depressor labii inferioris muscle, levator anguli oris, buccinator muscle, mentalis, and a combination thereof.
  • the ocular disease or disorder is ectropion or entropion.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to an eye muscle of the subject.
  • the eye muscle is selected from the group consisting of frontalis muscle, ocipitofrontalis muscle, temporoparietalis muscle, procerus muscle, nasalis muscle, depressor septi nasi muscle, orbicularis oculi muscle, corrugator supercilii muscle, depressor supercilii muscle, anterior auricular muscles, superior auricular muscle, posterior auricular muscle, orbicularis oris muscle, depressor anguli oris muscle, risorius, zygomaticus major muscle, zygomaticus minor muscle, levator labii superioris, levator labii superioris alaeque nasi muscle, depressor labii inferioris muscle, levator anguli oris
  • the method further comprises, prior to, during, or after the administering, performing eyelid surgery on the subject.
  • the eyelid surgery is a lateral tarsal strip procedure.
  • the ocular disease or disorder is strabismus or nystagmus.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to an extraocular muscle of the subject.
  • the extraocular muscle is selected from the group consisting of lateral rectus, medial rectus, superior rectus, inferior rectus, superior oblique, inferior oblique, and a combination thereof.
  • the strabismus is associated with any one of the following Apert syndrome, cerebral palsy, congenital rubella, hemangioma, Incontinentia Pigmenti, Noonan syndrome, Prader-Willi syndrome, retinopathy of prematurity, retinoblastoma, traumatic brain injury, trisomy-18, botulism, diabetes mellitus, Graves' disease, Guillain-Barre syndrome, injury to an eye, shellfish poisoning, stroke, and vision loss from an eye disease or injury.
  • the nystagmus is associated with any one of the following infantile nystagmus syndrome, intake of drugs or medications, excessive alcohol consumption, sedating medicine that impairs a function of the labyrinth, head injury, an inner ear disorder, stroke, thiamine or vitamin B12 deficiency, and Parkinson's disease.
  • the method further comprises, prior to, during, or after the administering, performing eye surgery on the subject.
  • the ocular disease or disorder is associated with impaired iris function.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to an iris sphincter muscle or an iris dilator muscle of the subject.
  • the ocular disease or disorder is presbyopia.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to a ciliary muscle of the subject.
  • the ocular disease or disorder is myopia.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to a ciliary muscle, a muscle in the sclera, a muscle around the sclera, an intraocular muscle, or a combination thereof, of the subject.
  • Described herein is a method for treating a musculoskeletal disorder of a subject in need thereof, the method comprising administering a combination of a PGE2 compound and a myotoxin to the subject.
  • the musculoskeletal disorder comprises impaired hand function.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to a hand muscle of the subject.
  • the hand muscle is selected from the group consisting of abductor pollicis brevis, flexor pollicis brevis, opponens pollicis, abductor digiti minimi, flexor digiti minimi brevis, opponens digiti minimi, a dorsal interossei muscle, a volar interossei muscle, a lumbrical muscle, palmaris brevis, adductor pollicis, abductor pollicis longus, extensor pllicis brevis, flexor pollicis longus, flexor carpi radialis, flexor digitorum profundus, flexor digitorum superficialis, flexor carpi ulnaris, extensor carpi radialis longus, extensor carpi radialis brevis, extensor indicis, extensor digitorum communis, extensor digiti minimi, extensor carp
  • the method further comprises, prior to, during, or after the administering, performing hand surgery on the subject.
  • the musculoskeletal disorder comprises impaired thumb function.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to a hand muscle of the subject.
  • the hand muscle is selected from the group consisting of abductor pollicis brevis, opponens pollicis, flexor pollicis brevis, and a combination thereof.
  • the impaired thumb function is due to thenar atrophy.
  • the method further comprises, prior to, during, or after the administering, performing hand surgery on the subject.
  • the hand surgery is carpal tunnel syndrome surgery.
  • the impaired thumb function is associated with cubital tunnel syndrome or thoracic outlet syndrome.
  • the musculoskeletal disorder comprises impaired foot function.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to a foot muscle of the subject.
  • the foot muscle is selected from the group consisting of flexor digitorum brevis, abductor hallucis, abductor digiti minimi, quadratus plantae, lumbricals, flexor digitorum longus, adductor hallucis, flexor hallucis brevis, flexor hallucis longus, flexor digiti minimi brevis, dorsal interossei, plantar interossei, flexor hallucis medialis, flexor hallucis brevis lateralis, adductor hallucis transverse, adductor hallucis oblique, and a combination thereof.
  • the impaired foot function is due to plantar fasciitis. In some embodiments, the impaired foot function is foot drop. In some embodiments, the administering comprises administering the combination of a PGE2 compound and a myotoxin to a foot muscle or a lower leg muscle of the subject. In some embodiments, the foot muscle or lower leg muscle is selected from the group consisting of anterior tibialis muscle, fibularis tertius, extensor digitorum longus, extensor hallucis longus, and a combination thereof.
  • the method further comprises, prior to, during, or after the administering, performing surgery on the subject.
  • the foot drop is associated with any one of the following: compression of a peroneal nerve; a nerve root injury; muscular dystrophy; amyotrophic lateral sclerosis; multiple sclerosis; or stroke.
  • the musculoskeletal disorder is disuse-induced muscle atrophy.
  • the disuse-induced muscle atrophy is caused by a distal radius fracture.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to a hand muscle or lower arm muscle of the subject.
  • the hand muscle or lower arm muscle is selected from the group consisting of flexor carpi radialis, flexor pollicis longus, flexor digitorum superficialis, flexor digitorum profundus, flexor carpi ulnaris, extensor carpi radialis brevis, extensor carpi radialis longus, extensor pollicis longus, extensor digitorum communis, extensor carpi ulnaris, and a combination thereof.
  • the method further comprises prior to, during, or after the administering, performing surgery on the subject.
  • the surgery is wrist arthroscopy.
  • the disuse-induced muscle atrophy is caused by a hip fracture.
  • the administering comprises administering the combination of a PGE2 compounds and a myotoxin to a hip muscle of the subject.
  • the hip muscles is selected from the group consisting of iliacus, psoas major, gluteus maximus, gluteus minimus, tensor fasciae latae, superior gemellus, inferior gemellus, obturator internus, obturator externus, quadratus femoris, piriformis, adductor magnus, adductor longus, adductor brevis, adductor minimus, pectineus, rectus femoris, vastus lateralis, vastus medialis, vastus intermedius, quadriceps femoris, Sartorius, biceps femoris, semitendinosus, semimembranosus, psoas minor, iliopsoas, gracilis, and a combination thereof.
  • the method further comprises, prior to, during, or after the administering, performing surgery on the subject.
  • the surgery is joint arthroplasty.
  • the disuse-induced muscle atrophy is caused by a rotator cuff injury.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to a rotator cuff muscle of the subject.
  • the rotator cuff muscle is selected from the group consisting of supraspinatus, infraspinatus, subscapularis, teres minor, and a combination thereof.
  • Described herein is a method for treating gastroesophageal reflux disease (GERD) in a subject in need thereof, the method comprising administering a combination of a PGE2 compound and a myotoxin to the subject.
  • the administering comprises administering the combination of a PGE2 compounds and a myotoxin to a crural diaphragm of the subject.
  • Described herein is a method for treating obstructive sleep apnea in a subject in need thereof, the method comprising administering a combination of a PGE2 compound and a myotoxin to the subject.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to an upper airway muscle of the subject.
  • the upper airway muscle is selected from the group consisting of genioglossus, tensor palatine, a geniohyoid muscle, and a combination thereof.
  • Described herein is a method for treating oculopharyngeal muscular dystrophy in a subject in need thereof, the method comprising administering a combination of a PGE2 compound and a myotoxin to the subject.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to a muscle of the upper eyelid or a muscle of the throat.
  • Described herein is a method for treating diabetic neuropathy in a subject in need thereof, the method comprising administering a combination of a PGE2 compound and a myotoxin to the subject.
  • the administering comprises administering the combination of a PGE2 compound and a myotoxin to a small muscle of a foot, a lower leg muscle, or an intrinsic muscle of a foot.
  • the PGE2 compound is selected from the group consisting of PGE2, a PGE2 prodrug, a PGE2 receptor agonist, a compound that attenuates PGE2 catabolism, a compound that neutralizes PGE2 inhibition, a derivative thereof, an analog thereof, and a combination thereof.
  • the PGE2 derivative comprises 16,16-dimethyl prostaglandin E2.
  • the compound that attenuates PGE2 catabolism comprises a compound, neutralizing peptide, or neutralizing antibody that inactivates or blocks 15-hydroxyprostaglandin dehydrogenase (15-PGDH) or inactivates or blocks a prostaglandin transporter (PGT or SLCO2A1).
  • the PGE2 compound is PGE2.
  • the myotoxin is selected from the group consisting of an anesthetic, a divalent cation, snake venom, lizard venom, bee venom, and a combination thereof.
  • the anesthetic is selected from the group consisting of an amino-amide anesthetic, an amino-ester anesthetic, and a combination thereof.
  • the amino-amide anesthetic is selected from the group consisting of bupivacaine, levobupivacaine, articaine, ropivacaine, butanilicaine, carticaine, dibucaine, etidocaine, lidocaine, mepivacaine, prilocaine, trimecaine, and a combination thereof.
  • the amino-ester anesthetic is selected from the group consisting of an aminobenzoic acid ester anesthetic, a benzoic acid ester anesthetic, and a combination thereof.
  • the aminobenzoic acid ester anesthetic is selected from the group consisting of benzocaine, butacaine, butamben, chloroprocaine, dimethocaine, lucaine, meprylcaine, metabutethamine, metabutoxycaine, nitracaine, orthocaine, propoxycaine, procaine, proxymetacaine, risocaine, tetracaine, and a combination thereof.
  • the benzoic acid ester anesthetic is selected from the group consisting of amylocaine, cocaine, cyclomethycaine, ⁇ -eucaine, ⁇ -eucaine, hexylcaine, isobucaine, piperocaine, and a combination thereof.
  • the snake venom or the lizard venom is selected from the group consisting of notexin, cardiotoxin, bungarotoxin, and a combination thereof.
  • the divalent cation is selected from the group consisting of Ba 2+ , Sr 2+ , Mg 2+ , Ca 2+ , Mn 2+ , Ni 2+ , Co 2+ , a salt thereof, and a combination thereof.
  • the PGE2 compound is PGE2 and/or 16,16-dimethyl prostaglandin E2 and the myotoxin is bupivacaine.
  • the PGE2 compound and the myotoxin are administered concomitantly.
  • the PGE2 compound and the myotoxin are administered sequentially.
  • the PGE2 compound is administered before the myotoxin.
  • the PGE2 compound is administered after the myotoxin.
  • administering the PGE2 compound, the myotoxin, or both comprises topical, oral, intraperitoneal, intramuscular, intra-arterial, intradermal, subcutaneous, intravenous, or intracardiac administration.
  • administering comprises intramuscular administration.
  • a dose of the PGE2 compound, the myotoxin, or both is determined based upon a target muscle size.
  • the target muscle is an abductor pollicis brevis muscle and the dose of the PGE2 compound, the myotoxin, or both, is about 10 ⁇ g.
  • the method further comprises subjecting a target muscle to mechanical injury.
  • the mechanical injury comprises cutting, burning, freezing, needle puncture, exercise, a surgical procedure, traumatic injury, or a combination thereof.
  • the method further comprises administering a population of isolated muscle cells to the subject.
  • the population of isolated muscle cells is autologous to the subject.
  • the population of isolated muscle cells is allogeneic to the subject.
  • the population of isolated muscle cells is purified.
  • the population of isolated muscle cells is cultured with the PGE2 compound, the myotoxin, or both, prior to being administered to the subject.
  • culturing the population of isolated muscle cells with the PGE2 compound, the myotoxin, or both comprises acute, intermittent, or continuous exposure of the population of isolated muscle cells to the PGE2 compound, the myotoxin, or both.
  • administering the population of isolated muscle cells comprises injecting or transplanting the cells into the subject.
  • administration of the population of isolated muscle cells and administration of the PGE2 compound and the myotoxin are performed concomitantly.
  • administration of the population of isolated muscle cells and administration of the PGE2 compound and the myotoxin are performed sequentially.
  • FIG. 1 shows an illustration of the abductor pollicis brevis (APB) muscle (left). The arrows mark the locations of APB atrophy, also shown in the photo on the right.
  • APB abductor pollicis brevis
  • FIGS. 2A-2H show that transient PGE2 treatment promotes young MuSC proliferation in vitro.
  • FIGS. 2E-2G Proliferation of EP4 null MuSCs.
  • EP4 f/f (null) MuSCs were transduced with a lentiviral vector encoding GFP/luciferase and treated with lentiviral vector encoding Cre (+Cre) or without ( ⁇ Cre; empty vector) to delete EP4 alelles. Subsequently MuSCs were treated with vehicle ( ⁇ ) or PGE2 (10 ng/ml) for 24 hr and cultured on hydrogels for three days.
  • FIG. 2E Scheme depicting EP4-null MuSC analysis.
  • FIGS. 3A-3J show an aberrant response of aged MuSCs to PGE2.
  • FIG. 3C Scheme showing PGE2 catabolism via degrading enzyme 15-PGDH to its inactive PGE metabolite, 13,14-dihydro-15-keto PGE2 (PGEM).
  • FIG. 3H Scheme depicting PGE2 effects on MuSCs.
  • PGE2 acts through the EP4 receptor/cAMP (cyclic AMP) signaling pathway to promote proliferation.
  • PGT prostaglandin transporter
  • PGE2 catabolism is mediated by 15-PGDH to the inactive form, PGEM.
  • FIG. 3I Trajectories from a clone of aged MuSCs tracked by time-lapse microscopy for 48 h in a microwell for control (left) and after acute treatment with PGE2 (right). The trajectory of the original cell and each of its newborn progeny are represented by a different color.
  • FIG. 3H Scheme depicting PGE2 effects on MuSCs.
  • PGT prostaglandin transporter
  • the proportion of live cells in each generation (G1-G6) at all timepoints is shown as cell number normalized to a starting population of 100 single MuSCs. The percent increase in live cell count was 4.0% (control) and 5.4% (PGE2-treated) (top panels).
  • the proportion of dead cells in each generation (G1-G6) at all timepoints is shown as cell number normalized to a starting population of 100 single MuSCs.
  • the percent increase in dead cell count was 1.0% (control) and 0.1% (PGE2-treated) (bottom panels).
  • ANOVA test with Bonferroni correction for multiple comparisons FIGS. 3A and 3F ); Mann-Whitney test ( FIGS. 3B, 3D, 3E, and 3G ). Means ⁇ s.e.m. n. s., non-significant.
  • FIGS. 4A-4D show that acute PGE2 treatment promotes MuSC engraftment and regeneration in vivo.
  • FIG. 4B Engraftment of GFP/luc-labeled EP4 f/f MuSCs (1,000 cells) treated with Cre (+Cre) or without ( ⁇ Cre; empty vector) in culture to delete EP 4 alelles.
  • FIGS. 5A-5R show that intramuscular injection of PGE2 alone promotes MuSC expansion, improves regeneration, and increases force.
  • FIGS. 5E-5G Increase in endogenous MuSCs assayed by Pax7-luciferase.
  • FIG. 5E Scheme of experimental procedure.
  • Aged: ( FIGS. 5H-5K ) TAs of aged mice were treated in vivo with vehicle ( ⁇ ) or dmPGE2 treatment 48 hr post-cardiotoxin (CTX) injury; (n 3 mice per condition).
  • FIG. 5I Increase in endogenous MuSCs as in FIG. 5B for aged mice.
  • FIG. 5J Myofiber cross-sectional area (CSA) as in FIG. 5C for aged TAs.
  • FIG. 5K Distribution of CSA as in FIG. 5D for aged TAs.
  • FIGS. 5L-5P Increase in strength in aged mice measured in vivo as muscle contractile force after downhill treadmill run.
  • mice were subject to a 20° downhill treadmill run for 2 consecutive weeks and force was assayed at week 5.
  • medial and lateral gastrocnemius (GA) of aged mice were injected either with vehicle ( ⁇ ) or dmPGE2.
  • n 10 or 8 biological replicates for vehicle ( ⁇ ) treated or dmPGE2 treated, respectively, with 5 technical replicates each.
  • FIG. 5L Experimental scheme. Representative twitch force ( FIG. 5M ) and tetanic force ( FIG. 5N ).
  • Specific muscle twitch forces ( FIG. 5O ) and specific muscle tetanic force ( FIG. 5P ) were calculated by normalizing force to physiological cross sectional areas (PCSA). Paired t-test ( FIGS.
  • FIG. 5B, 5D, 5I and 5K ANOVA test for group comparison and significant difference for the endpoint by Fisher's test ( FIG. 5F ); Mann-Whitney test ( FIGS. 5O and 5P ). *P ⁇ 0.05, **P ⁇ 0.001 and ****P ⁇ 0.0001. Means+s.e.m.
  • FIG. 5Q Muscle twitch forces in aged mice that were administered PGE2 or vehicle only.
  • FIG. 5R Muscle tetanic force in mice that were administered PGE2 or vehicle only.
  • FIGS. 6A-6K show that PGE2 promotes MuSC expansion.
  • FIG. 6B Representative image of dividing muscle stem cells (MuSCs) labelled with EdU (red) during 1 hr after treatment with PGE2 (10 ng/ml) for 24 h (d0 to d1) or vehicle ( ⁇ ), and stained for MYOGENIN (green). Bar represents 40 ⁇ m.
  • FIG. 6B Representative image of dividing muscle stem cells (MuSCs) labelled with Ed
  • FIGS. 6I-6J EP4 f/f MuSCs were transduced with a lentiviral vector encoding GFP/luciferase and treated with lentiviral vector encoding Cre (+Cre) or without ( ⁇ Cre; empty vector) to delete EP4 alelles.
  • FIG. 6I Bar graphs show percentage of +Cre MuSCs ( FIG. 6I ) and GFP/Luc + MuSCs ( FIG. 6J ).
  • FIG. 6K Representative image of MuSCs in hydrogel culture after 7 days in myoblast medium containing charcoal stripped fetal bovine supplemented with vehicle ( ⁇ ) or PGE2 (10 ng/ml) every two days. Bar represents 40 ⁇ m. *P ⁇ 0.05, **P ⁇ 0.001, ***P ⁇ 0.0005. Paired t-test ( FIGS. 6A, 6E, 6G, and 6H ); Mann-Whitney test ( FIG. 6C ). Means+s.e.m. n.s., non-significant.
  • FIGS. 7A-7C show mass spectrometry analysis of young and aged muscle to detect prostaglandins and PGE2 metabolites.
  • FIG. 7A Chemical structures, chemical formula, exact mass and molecular weight of analyzed prostaglandins (PGE2, PGF2 ⁇ and PGD2) and PGE2 metabolites (15-keto PGE2 and 13,14-dihydro-15-keto PGE2). The internal standards PGF2 ⁇ -D9 and PGE2-D9 were added to all composite standards.
  • FIG. 7A Chemical structures, chemical formula, exact mass and molecular weight of analyzed prostaglandins (PGE2, PGF2 ⁇ and PGD2) and PGE2 metabolites (15-keto PGE2 and 13,14-dihydro-15-keto PGE2).
  • the internal standards PGF2 ⁇ -D9 and PGE2-D9 were added to all composite standards.
  • FIG. 7B Calibration lines for liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) analysis were prepared by diluting stock solutions to final concentrations of 0.1 ng/ml to 500 ng/ml. Standard curve equations and correlation coefficients are shown for each standard.
  • FIG. 7C Representative chromatogram. The separate peaks show excellent chromatographic resolution of the analyzed prostaglandins and their metabolites. cps, counts per second.
  • FIGS. 8A-8G show that aged MuSCs increase proliferation and cell survival in response to PGE2 treatment.
  • FIG. 8A Prostaglandin transporter (PGT) encoded by the Slco2a1 gene.
  • FIG. 8B PGE2 synthesizing enzymes, Ptges and Ptges2.
  • FIG. 8C EP1-4 receptors encoded by the genes Ptger 1-4.
  • FIG. 8E Single aged MuSC clones tracked by time-lapse microscopy after acute treatment with vehicle ( ⁇ ; top) or PGE2 (bottom). For each clone the resulting number of live (open bar) and dead (black bar) cells after 48 h timelapse tracking is shown.
  • FIG. 8F Proliferation curve of tracked live aged MuSCs assessed by time-lapse microscopy for vehicle ( ⁇ ) or transient PGE2 treatment during 48 h.
  • FIGS. 9A-9B show Baxter Algorithms for Myofiber Analysis of muscle cross-sectional area.
  • FIG. 9A Representative cross-sectional images of tibialis anterior myofibers of young mice treated in vivo with vehicle ( ⁇ ) or PGE2 48 hr post-cardiotoxin (CTX) injury. Images show staining with LAMININ, green and DAPI, blue.
  • FIG. 9B The corresponding segmentation images from FIG. 9A analyzed by the Baxter Algorithms for Myofiber Analysis to determine the cross sectional area (CSA) of transverse sections of myofibers (bottom) at day 14 post-injury. Bar represents 40 ⁇ m.
  • CSA cross sectional area
  • FIGS. 10A-10G show that deletion of PGE2 receptor EP4 in MuSCs decreases regeneration and force of skeletal muscle after injury.
  • FIG. 10A Experimental scheme.
  • FIG. 10A Experimental scheme.
  • FIG. 10B Expression of Ptger4 (EP4 receptor) in sorted MuSCs ( ⁇ 7+ CD34 + lin ⁇ ) from control or EP4 KO mice post-injury.
  • FIG. 10D Percentage of eMyHC+fibers.
  • FIG. 10E Myofiber cross-sectional areas (CSA) in control and Pax7-specific EP4 knockout TAs.
  • FIG. 10F Muscle twitch forces and ( FIG. 10G ) muscle tetanic force at day 14 post-notexin injury. Mann-Whitney test ( FIGS.
  • FIGS. 11A-11C show that blockage of endogenous PGE2 signaling in muscle at an early time point of regeneration reduces regeneration and force.
  • FIG. 11A Experimental scheme.
  • FIGS. 12A-12K show that a transient increase in PGE2 in damaged muscle tissues accelerates MuSC proliferation.
  • TA tibialis anterior
  • FIG. 12G Trajectories of a MuSC clone treated with vehicle (top) or PGE2 (bottom) by time-lapse microscopy for 38 hr.
  • FIG. 12I Plot of time to division after plating for each MuSC clone treated with vehicle or PGE2.
  • Clones showing a 38 hr time to division refers to clones that never divided during the recorded time-lapse.
  • FIG. 12J Violin plot of time to division post-plating in MuSC clones treated with vehicle or PGE2.
  • FIG. 12K Cell sizes of tracked MuSCs treated with vehicle or PGE2. *P ⁇ 0.05, **P ⁇ 0.001, ***P ⁇ 0.0005 ****P ⁇ 0.0001. Mann-Whitney test ( FIGS. 12A, 12E, 12J, 12K ); ANOVA test with Bonferroni correction for multiple comparisons ( FIGS. 12B, 12D ); Paired t-test ( FIG. 12F ). Means+s.e.m.
  • FIGS. 13A-13G show that PGE2 treatment augments muscle regeneration.
  • CTX post-cardiotoxin
  • FIG. 13C Quantification of PAX7 + satellite cells per 100 fibers.
  • FIG. 13D Representative myofiber cross-sectional areas (CSA) in vehicle (open white bar) and PGE2 treated (filled blue bar) TAs.
  • FIG. 13E Distribution of small ( ⁇ 1,000 ⁇ m 2 CSA) and large (>1,000 ⁇ m 2 CSA) myofibers.
  • FIG. 13F Experimental scheme.
  • ANOVA test for group comparisons and significant difference for endpoint by Fisher's test FIGS. 13A, 13G ); Paired t-test ( FIGS. 13C, 13E ). Means+s.e.m.
  • FIGS. 14A-14E show that EP4 mediates PGE2 signaling in MuSCs.
  • FIG. 14C MuSC numbers after 24 hr treatment with vehicle or PGE2 in the absence or presence of EP4 antagonist (ONO-AE3-208, 1 ⁇ M).
  • FIG. 14D Proliferation of EP4 null MuSCs treated with vehicle or PGE2.
  • EP4 f/f MuSCs were treated with lentiviral vector encoding Cre (+Cre, EP4-null) or without ( ⁇ Cre; control) to delete EP4 alelles.
  • EP4-null and control MuSC numbers; (n 6 mice in 2 independent experiments) (bottom).
  • FIG. 14E Engraftment of GFP/luc-labeled EP4 f/f MuSCs (1,000 cells) treated with Cre (+Cre) or without ( ⁇ Cre; empty vector) in culture to delete EP4 alelles.
  • EP4 f/f MuSCs were transduced with a lentiviral vector encoding GFP/luciferase for BLI. Transplant scheme (top).
  • FIGS. 15A-15G show that Nurr1 is a downstream effector of PGE2/EP4 signaling in MuSCs.
  • FIG. 15A Heat map of differentially expressed transcription factors in vehicle or PGE2 treated MuSCs after 24 hr.
  • FIG. 15 D Flow cytometric analysis of NURR1 or IgG control in myogenic progenitors treated with vehicle or PGE2 for 24 hr.
  • FIG. 15A Heat map of differentially expressed transcription factors in vehicle or PGE2 treated MuSCs after 24 hr.
  • FIG. 15C Expression of Nurr1 by MuSCs after 24 hr treatment with
  • FIG. 15G Expression of Nurr1 in MuSCs, primary myoblasts cultured in growth medium (Myob. GM) and differentiating primary myoblasts cultured in differentiation medium for 24 hr (Myob.
  • FIGS. 16A-16L show that loss of function of PGE2 signaling in MuSCs impairs muscle regeneration and strength.
  • FIG. 16A Experimental scheme.
  • FIG. 16A Experimental scheme.
  • FIG. 16B Expression of Ptger4 (EP4 receptor) in sorted MuSCs ( ⁇ 7+ CD34 + lin ⁇ ) from control or EP4 cKO mice 21 days post-injury.
  • FIG. 16C Percentage of embryonic Myosin Heavy Chain (eMyHC) positive fibers 7 days post-injury.
  • FIG. 16D Myofiber cross-sectional areas (CSA) in control and EP4 cKO TAs 21 days post-injury.
  • FIGS. 16F In vivo muscle contractile force assay scheme.
  • FIG. 16G Representative twitch force (left) and tetanic force (right) at day 14 post-notexin injury.
  • FIG. 16I, 16J Endogenous muscle stem cells (MuSCs) assayed in Pax7 CreERT2 ;Rosa26-LSL-Luc mice treated with tamoxifen (TAM) by non-invasive bioluminescence imaging (BLI) after injection with vehicle or NSAID (Indomethacin) post-cardiotoxin injury into the TA.
  • FIG. 16K, 16L Muscle force was measured after vehicle or NSAID (Indomethacin) at day 14 post-cardiotoxin in C57Bl/6 mice (2-4 month old).
  • FIG. 16K Representative twitch force.
  • FIG. 17 shows a model for PGE2 signaling to expand MuSC function in regeneration. Shown is achematic of the role of PGE2 in MuSCs. After injury, PGE2 released into the muscle niche acts on the EP4 receptor, which signals through cAMP/phospho-CREB leading to the expression of Nurr1 proliferation-inducing transcription factor. This promotes MuSC expansion for efficient muscle regeneration. Loss of PGE2/EP4 signaling by NSAID treatment or specific loss of EP4 receptor leads to aberrant MuSC function and impaired muscle regeneration and strength recovery.
  • FIGS. 18A-18G show that PGE2 promotes MuSC proliferation.
  • FIG. 18C Representative image of MuSCs labeled with EdU during 1 hr (red) and costained with MYOGENIN (green) after treatment with PGE2 (10 ng/ml) for 24 h or vehicle.
  • FIG. 18F Time to first division after plating for each individual MuSC clone analyzed by time-lapse after vehicle (left) or PGE2 (right) treatment.
  • FIGS. 19A-19E show that PGE2 direct injection augments muscle regeneration without promoting hypertrophy.
  • FIG. 19A Representative cross-sectional images of the TA showing a GFP + MuSC after engraftment of freshly sorted GFP/luc-labeled MuSCs (250 cells) coinjected with PGE2 at 8 weeks post-engraftment. Images show staining with GFP, green, LAMININ, red and DAPI, blue. Bar represents 40 ⁇ m.
  • FIG. 19B Representative cross-sectional images of the TA showing GFP + myofibers after engraftment of freshly sorted GFP/luc-labeled MuSCs (250 cells) coinjected with PGE2 at 8 weeks post-engraftment.
  • FIG. 19C Representative cross-sectional images of TA myofibers of C57Bl/6 mice at day 14 post-cardiotoxin (CTX) injury treated in vivo with vehicle or PGE2 48 hr post-injury. Images show staining with LAMININ, green and DAPI, blue. Bar represents 40 ⁇ m.
  • CTX post-cardiotoxin
  • FIG. 19D The corresponding segmentation images from (A) analyzed by the Baxter Algorithms for Myofiber Analysis to determine the cross sectional area (CSA) of transverse sections of myofibers (bottom) at day 14 post-injury. Bar represents 40 ⁇ m.
  • FIG. 19E Mass of vehicle or PGE2-treated TAs at day 14 post-injury. Mann-Whitney test ( FIG. 19E ). Means+s.e.m. n.s., non-significant.
  • FIGS. 20A-20G show that EP4 loss of function in MuSC leads to decreased proliferation.
  • FIGS. 20A-20D EP4 f/f MuSCs treated with lentiviral vector encoding mCherry/Cre (+Cre) or without ( ⁇ Cre; empty vector) to delete EP4 alelles. Bar graphs show percentage of Cre + MuSCs ( FIG. 20A ) and GFP/Luc + MuSCs ( FIG. 20B ).
  • FIG. 20D Expression of Ptger4 by EP4 f/f MuSCs ⁇ Cre.
  • FIG. 20E Experimental scheme.
  • FIG. 20F MuSC numbers after 7 days of culture.
  • FIG. 20G Expression of prostaglandin receptors (Ptger 1-4) by qRT-PCR. *P ⁇ 0.05, **P ⁇ 0.001, ***P ⁇ 0.0005, ****P ⁇ 0.0001. Mann-Whitney test ( FIG. 20D ); ANOVA test with Bonferroni correction for multiple comparisons ( FIGS. 20F, 20G ). Means+s.e.m. n.s., non-significant.
  • FIGS. 21A-21E show transcriptome analysis of PGE2-treated MuSCs.
  • FIG. 21A Heat map of the transcriptome of vehicle or PGE2 treated MuSCs after 24 hr shown as expression fold-change over vehicle-treated MuSCs.
  • FIG. 21B Enriched molecular and cellular function pathways of the differentially expressed upregulated genes in the PGE2-treated MuSCs indicated by Ingenuity Pathway Analysis.
  • FIG. 21C Enriched pathway maps of the differentially expressed upregulated genes in the PGE2-treated MuSCs indicated by Metacore Analysis.
  • FIG. 21D Flow cytometric analysis of NURR1 in shSCR (control) or shNurr1 transfected cells.
  • FIGS. 22A and 22B show that muscle mass is not altered after PGE2 loss of function post-injury.
  • FIG. 22A Mass of TAs of control or MuSC-specific EP4 conditional knockout mice at day 14 post-injury.
  • FIG. 22B Mass of vehicle or NSAID-treated TAs at day 14 post-injury. Mann-Whitney test. Means+s.e.m. n.s., non significant.
  • FIGS. 23A-23C show that a composition comprising a combination of a PGE2 derivative (16,16-dimethyl prostaglandin E2; dmPGE2) and bupivacaine (BPV) enhances muscle stem cell expansion during regeneration.
  • FIG. 23A shows a scheme illustrating experimental procedures for the in vivo analysis of endogenous muscle stem cell (MuSC) expansion during regeneration in Pax7 CreERT2 ;Rosa26-LSL-Luc mice treated with tamoxifen (TAM) via bioluminescent imaging (BLI).
  • FIG. 24 shows a dose-dependent effect of bupivacaine, when administered in combination with dmPGE2, in inducing muscle stem cell expansion during regeneration.
  • the graph shows the relative endogenous mouse muscle stem cell expansion in Pax7 CreERT2 ;Rosa26-LSL-Luc mice as measured by the radiance fold change of bioluminescent imaging (BLI) from day 3 post-injection.
  • Statistical significance for the difference between the control vs. treatment group was determined by one-way ANOVA test with Bonferroni's multiple comparison correction. Error bar represents s.e.m. and n>3 per condition.
  • FIGS. 25A-25D describe a handheld microendoscope for use in assessing the benefits of compositions and methods of the present invention.
  • FIG. 25A shows photographs of the microendoscope and associated workstation.
  • FIG. 25B shows a schematic of the microendoscope.
  • FIG. 25C shows an exemplary image generated by the microendoscope.
  • FIG. 25D shows a more highly magnified exemplary image generated by the microendoscope.
  • FIG. 26 shows an exemplary timeline for a clinical trial.
  • FIGS. 27A-27C show the synergistic effect of combining a PGE2 compound and a myotoxin to induce muscle regeneration and improve muscle function.
  • Pax7-CreERT2; Rosa-LSL-Luciferase mice (2-4 months old) were treated with tamoxifen for five consecutive days in order to obtain Pax7 promoter expressing luciferase mice in vivo.
  • baseline tetanic force of the tibialis anterior was measured using a foot plate force measurement instrument before injection of drugs (timepoint day 0).
  • FIG. 27A shows bioluminescence (BLI, measured as radiance) measured every 3 days for 2 weeks to measure muscle stem cell expansion.
  • FIG. 27B shows the resulting tetanic force measured at week 4 from the same mice, where the percent difference to baseline force was calculated.
  • the present invention is based, in part, on the discovery that a combination of prostaglandin E2 (PGE2) compounds and myotoxins such as bupivacaine invoke dormant MuSCs to engage in muscle regeneration and restore strength.
  • PGE2 prostaglandin E2
  • myotoxins such as bupivacaine invoke dormant MuSCs to engage in muscle regeneration and restore strength.
  • the addition of a myotoxin induces muscle regeneration.
  • the addition of a mytoxin to a PGE2 compound improves muscle regeneration, better than muscle regeneration induced by a PGE2 compound alone.
  • the compositions and methods of the present invention are particularly useful for promoting regeneration of atrophic abductor pollicis brevis (APB) muscle post nerve release surgery to promote neuromuscular junction establishment and restoration of muscle contractile function and volume.
  • APB atrophic abductor pollicis brevis
  • PGE2 refers to prostaglandin that can be synthesized via arachidonic acid via cyclooxygenase (COX) enzymes and terminal prostaglandin E synthases (PGES). PGE2 plays a role in a number of biological functions including vasodilation, inflammation, and modulation of sleep/wake cycles.
  • PGE2 receptor agonist refers to a chemical compound, small molecule, polypeptide, biological product, etc. that can bind to and activate any PGE2 receptor, thereby stimulating the PGE2 signaling pathway.
  • compound that attenuates PGE2 catabolism refers to a chemical compound, small molecule, polypeptide, biological product, etc. that can reduce or decrease the breakdown of PGE2.
  • compound that neutralizes PGE2 inhibition refers to a chemical compound, small molecule, polypeptide, biological product, etc. that can block or impede an inhibitor of PGE2 synthesis, activity, secretion, function, and the like.
  • the term “compound that attenuates PGE2 catabolism” refers to a physical process that attenuates the transport of PGE2 via a transporter for the breakdown of PGE2 intracellularly. This process can be the physical block of a prostaglandin transporter, which transports PGE2 inside cells for catabolism by 15-PGDH.
  • the prostaglandin transporter is also known as 2310021C19Rik, MATR1, Matrin F/Q, OATP2A1, PGT, PHOAR2, SLC21A2, solute carrier organic anion transporter family member 2A1, and SLCO2A1.
  • derivative in the context of a compound, includes but is not limited to, amide, ether, ester, amino, carboxyl, acetyl, and/or alcohol derivatives of a given compound.
  • treating refers to any one of the following: ameliorating one or more symptoms of disease; preventing the manifestation of such symptoms before they occur; slowing down or completely preventing the progression of the disease (as may be evident by longer periods between reoccurrence episodes, slowing down or prevention of the deterioration of symptoms, etc.); enhancing the onset of a remission period; slowing down the irreversible damage caused in the progressive-chronic stage of the disease (both in the primary and secondary stages); delaying the onset of said progressive stage; or any combination thereof.
  • administer refers to the methods that may be used to enable delivery of agents or compositions such as the compounds and cells described herein to a desired site of biological action. These methods include, but are not limited to, parenteral administration (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular, intra-arterial, intravascular, intracardiac, intrathecal, intranasal, intradermal, intravitreal, and the like), transmucosal injection, oral administration, administration as a suppository, and topical administration.
  • parenteral administration e.g., intravenous, subcutaneous, intraperitoneal, intramuscular, intra-arterial, intravascular, intracardiac, intrathecal, intranasal, intradermal, intravitreal, and the like
  • transmucosal injection e.g., intravenous, subcutaneous, intraperitoneal, intramuscular, intra-arterial, intravascular, intracardiac, intrathecal, intranasal, intradermal
  • therapeutically effective amount refers to an amount of a compound, therapeutic agent (e.g., cells), and/or pharmaceutical drug that is sufficient to bring about a beneficial or desired clinical effect.
  • a therapeutically effective amount or dose may be based on factors individual to each patient, including, but not limited to, the patient's age, size, type or extent of disease, stage of the disease, route of administration of the regenerative cells, the type or extent of supplemental therapy used, ongoing disease process and type of treatment desired (e.g., aggressive vs. conventional treatment).
  • Therapeutically effective amounts of a pharmaceutical compound or compositions, as described herein can be estimated initially from cell culture and animal models. For example, IC 50 values determined in cell culture methods can serve as a starting point in animal models, while IC 50 values determined in animal models can be used to find a therapeutically effective dose in humans.
  • pharmaceutically acceptable carrier refers to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
  • subject refers to a vertebrate, preferably a mammal, more preferably a human.
  • Mammals include, but are not limited to, murines, rats, simians, humans, farm animals, sport animals, and pets.
  • mechanical injury refers to myotoxic effects that are induced by physical processes, non-limiting examples including cutting, burning, freezing, needle puncture, and exercise.
  • mechanical injury occurs as the result of a surgical procedure (e.g., a surgical procedure or treatment that comprises cutting, incising, suturing, and/or repairing a muscle) or a traumatic injury (e.g., accidental trauma or injury), non-limiting examples being blunt and/or crush injuries (e.g., involving limbs or appendages such as the arms, legs, hand, feet, and digits).
  • myotoxin means a compound that induces damage or death in muscle cells.
  • the toxic effects produced in muscle cells (e.g., muscle cell damage, muscle cell death) by the myotoxin may trigger, either directly or indirectly, the subsequent activation of muscle stem cells, muscle regeneration, or both.
  • myotoxins include anesthetics (e.g., bupivacaine), divalent cations, snake venom, lizard venom, bee venom, and compounds contained within (e.g., notexin, cardiotoxin, and bungarotoxin).
  • the myotoxin is a mild myotoxin.
  • a mild myotoxin as used herein means that muscle tissue is subjected to minor damage assessed by histology.
  • a mild myotoxin as used herein may include any compound that causes transient but reversible muscle damage or cell death.
  • Myotoxicity of excipients administered intramuscularly can be assessed by monitoring recruitment of inflammatory cells (leucocytes, macrophages and other monocytes), induction of transient cytokine levels, growth factors and inflammatory metabolites.
  • myotoxicity could be assessed by disruption of myofiner architecture and the encompassing matrix, induction of acute cell death and necrosis, induction of acute muscle resident cell proliferation (including muscle stem cells), induction of embryonic myosin heavy chain (eMHC) expression, and presence of central nuclei position within myofibers.
  • myotoxicity can also be detected by muscle creatin kinase level.
  • myotoxicity can be detected by reduction in muscle force and disruption in langeromuscular junction.
  • Reversibility of the myotoxicity can be assessed by restoration in the damaged myofiber histology in a short duration (for example, in about 21 days in a mouse model), lack of fibrosis in the tissue (lack of excess collagen deposition or other matrix constituents) and lack of lipid deposition (adipocyte transdifferentiation).
  • Non-limiting examples of mild myotoxins may include anesthetics, such as, e.g., bupivacaine or lidocaine.
  • an acute exposure in the context of administration of a compound, refers to a temporary or brief application of a compound to a subject, e.g., human subject, or cells.
  • an acute exposure includes a single administration of a compound over the course of treatment or over an extended period of time.
  • intermittent exposure in the context of administration of a compound, refers to a repeated application of a compound to a subject, e.g., human subject, or cells, wherein a desired period of time lapses between applications.
  • an acute regimen in the context of administration of a compound, refers to a temporary or brief application of a compound to a subject, e.g., human subject, or to a repeated application of a compound to a subject, e.g., human subject, wherein a desired period of time (e.g., 1 day) lapses between applications.
  • an acute regimen includes an acute exposure (e.g., a single dose) of a compound to a subject over the course of treatment or over an extended period of time.
  • an acute regimen includes intermittent exposure (e.g., repeated doses) of a compound to a subject in which a desired period of time lapses between each exposure.
  • continuous exposure in the context of administration of a compound, refers to a repeated, chronic application of a compound to a subject, e.g., human subject, or cells, over an extended period of time.
  • chronic regimen in the context of administration of a compound, refers to a repeated, chronic application of a compound to a subject, e.g., human subject, over an extended period of time such that the amount or level of the compound is substantially constant over a selected time period.
  • a chronic regimen includes a continuous exposure of a compound to a subject over an extended period of time.
  • the composition comprises a prostaglandin E2 (PGE2) compound and a myotoxin.
  • PGE2 compound is selected from the group consisting of PGE2, a PGE2 prodrug, a PGE2 receptor agonist, a compound that attenuates PGE2 catabolism, a compound that neutralizes PGE2 inhibition, a derivative thereof, an analog thereof, and a combination thereof.
  • a prodrug of PGE2 can be metabolized into a pharmacologically active PGE2 drug, for example, at the site of administration or muscle regeneration, or when the prodrug is exposed to muscle cells.
  • the PGE2 compound is a PGE2 derivative or analog that contains one or more modifications to PGE2 that increase its stability, activity, resistance to degradation, transport into muscle cells (e.g., promote cellular uptake), and/or retention in muscle cells (e.g., reduce secretion from muscle cells after uptake).
  • PGE2 derivatives and analogs include 2,2-difluoro-16-phenoxy-PGE2 compounds, 2-decarboxy-2-hydroxymethyl-16-fluoro-PGE2 compounds, 2-decarboxy-2-hydroxymethyl-11-deoxy-PGE2 compounds, 19(R)-hydroxy PGE2, 16,16-dimethyl PGE2, 16,16-dimethyl PGE2 p-(p-acetamidobenzamido) phenyl ester, 11-deoxy-16,16-dimethyl PGE2 (dmPGE2), 9-deoxy-9-methylene-16,16-dimethyl PGE2, 9-deoxy-9-methylene PGE2, butaprost, sulprostone, enprostil, PGE2 serinol amide, PGE2 methyl ester, 16-phenyl tetranor PGE2, 5-trans-PGE2, 15(S)-15-methyl PGE2, and 15(R)-15-methyl PGE2. Additional PGE2 derivatives and analogs
  • PGE2 derivatives and analogs include hydantoin derivatives of PGE2, the more stable PGE2 analogs described in Zhao et al. ( Bioorganic & Medicinal Chemistry Letters, 17:6572-5 (2007)) in which the hydroxy cyclopentanone ring is replaced by heterocyclic rings and the unsaturated alpha-alkenyl chain is substituted with a phenethyl chain, the PGE2 analogs described in Ungrin et al. ( Mol. Pharmacol., 59:1446-56 (2001)), the 13-dehydro derivatives of PGE2 described in Tanami et al. ( Bioorg. Med. Chem. Lett., 8:1507-10 (1998)), and the substituted cyclopentanes described in U.S. Pat. Nos. 8,546,603 and 8,158,676.
  • the PGE2 compound is an agonist of a PGE2 receptor, e.g., EP1 receptor, EP2 receptor, EP3 receptor, and EP4 receptor.
  • PGE2 receptor agonists include ONO-DI-004, ONO-AE1-259, ONO-AE-248, ONO-AE1-329, ONO-4819CD (Ono Pharmaceutical Co., Japan), L-902688 (Cayman Chemical), CAY10598 (Cayman Chemical), and CP-533536 (Pfizer). Additional PGE2 receptor agonists are described, e.g., in U.S. Pat. Nos. 6,410,591; 6,610,719; 6,747,037; 7,696,235; 7,662,839; 7,652,063; 7622,475; and 7,608,637.
  • the PGE2 receptor agonist comprises a compound of Formula (I), a derivative thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer thereof, or a combination thereof,
  • ring A is a substituted 4- to 6-membered cycloalkyl ring or a substituted 4- to 6-membered cycloalkenyl ring that comprises substituents R 1 and R 2 that are independently selected from the group consisting of substituted C 1 -C 10 alkyl and substituted C 2 -C 10 alkenyl, and ring A further comprises one or more additional substituents.
  • ring A is a substituted cyclopentyl ring or a substituted cyclopentenyl ring.
  • the one or more additional substituents on ring A are selected from the group consisting of deuterium, hydroxy, amino, oxo, C 1 -C 6 alkyl, and halogen.
  • the one or more additional substituents on ring A are hydroxy or oxo.
  • ring A has two additional substituents that are taken together to form a covalent bond to form a heterocycloalkyl ring.
  • ring A is selected from the consisting of
  • ring A is selected from the group consisting of from the group consisting of
  • ring A is
  • R 1 is substituted C 1 -C 10 alkyl. In other embodiments, R 1 is substituted C 2 -C 10 alkenyl. In some embodiments, R 1 is selected from the group consisting of deuterium, hydroxy, oxo, C 1 -C 6 alkyl, —COOR 3 , and halogen, wherein R 3 is hydrogen or C 1 -C 6 alkyl.
  • R 1 is selected from the group consisting of
  • R 1 is selected from the group consisting of
  • R 1 is
  • R 2 is substituted C 1 -C 10 alkyl. In other embodiments, R 2 is substituted C 2 -C 10 alkenyl. In some embodiments, the substituent on R 2 is selected from the group consisting of deuterium, hydroxy, oxo, C 1 -C 6 alkyl, —COOR 3 , and halogen, wherein R 3 is hydrogen or C 1 -C 6 alkyl.
  • R 2 is selected from the group consisting of
  • R 2 is selected from the group consisting of
  • R 2 is
  • the compound of Formula (I), the pharmaceutically acceptable salt thereof, the solvate thereof, or the stereoisomer thereof is a compound of Formula (Ia), Formula (Ib), Formula (Ic), or Formula (Id), or is a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof:
  • the compound is of Formula (Id).
  • the PGE2 compound is PGE2. In other embodiments, the PGE2 compound is a derivative of PGE2. In some instances, the derivative is 16,16-dimethyl prostaglandin E2 (dmPGE2). In particular embodiments, the PGE2 compound is PGE2 and/or dmPGE2.
  • the PGE2 compound is a derivative of PGE2.
  • the derivative is PGE2 conjugated to a moiety.
  • the PGE2 compound is PGE2-Biotin or PGE2-PEG (Polyethylene glycol) hydrogel. Exemplary embodiments are shown below:
  • the PGE2 derivative comprises a PGE2 compound conjugated to a molecular probe.
  • the molecular probe is a peptide sequence, a fragment antigen-binding (Fab), a heavy-chain only antibody (HcAbs), a full-length antibody (Ab), a single-domain antibody/nanobody (Nb), or a nanoparticle, or a combination.
  • the molecular probe is capable of homing to and targeting muscle tissue via systemic delivery.
  • a PGE2 derivative comprising a PGE2 compound conjugated to a molecular probe may increase the half-life of the PGE2 compound, increase the specificity of the PGE compound, and reduce adverse off-target effects of the PGE2 compund.
  • PGE2 conjugated to a molecular probe include PGE2-Integrin-alpha7 antibody or nanobody; PGE2-M-cadherin antibody or nanobody; and PGE2-anti PGE2 antibody.
  • a PGE2 derivative comprising a PGE2 compound conjugated to a molecular probe may be used to treat sarcopenia or cachexia.
  • the PGE2 compound is a compound that attenuates PGE2 catabolism.
  • a compound that attenuates PGE2 catabolism can be a compound, a neutralizing peptide, or a neutralizing antibody that inactivates or blocks 15-hydroxyprostaglandin dehydrogenase (15-PGDH) or inactivates or blocks a prostaglandin transporter, which transports PGE2 inside cells for catabolism by 15-PGDH.
  • the prostaglandin transporter is also known as 2310021C19Rik, MATR1, Matrin F/Q, OATP2A1, PGT, PHOAR2, SLC21A2, solute carrier organic anion transporter family member 2A1, and SLCO2A1.
  • the composition may include a stem-cell inducing molecule.
  • the stem-cell inducing molecule is a PGE2 compound as described herein.
  • the composition includes a stem-cell inducing molecule in combination with a myotoxin.
  • stem-cell inducing molecules include oxytocin, beta integrin activating antibody, rapamycin, SetD7 inhibitors, p38 MAPK inhibitors (such as SB202190 and SB203580), neuregulin, nerve growth factor (NGF), Hif2alpha inhibitors, basic fibroblast growth factor (bFGF), fibroblast growth factor 4 (FGF4), epidermal growth factor (EGF), Interleukin-1 ⁇ , Interleukin-13, TNF ⁇ , LIF, IL6, interferon gamma, oncostatin M (OSM), ghrelin, and apelin.
  • MAPK inhibitors such as SB202190 and SB203580
  • neuregulin nerve growth factor
  • NGF nerve growth factor
  • Hif2alpha inhibitors basic fibroblast growth factor
  • bFGF basic fibroblast growth factor
  • FGF4 fibroblast growth factor 4
  • EGF epidermal growth factor
  • Interleukin-1 ⁇ Interleukin-13
  • TNF ⁇ TNF ⁇
  • the myotoxin is selected from the group consisting of an anesthetic, a divalent cation, venom from snakes, venom from lizards, venom from bees, and a combination thereof.
  • Suitable divalent cations include but are not limited to Ba 2+ , Sr 2+ , Mg 2+ , Ca 2+ , Mn 2+ , Ni 2+ , Co 2+ , salts thereof, and combinations thereof.
  • the snake or lizard venom is selected from the group consisting of notexin, cardiotoxin, bungarotoxin, and a combination thereof.
  • the anesthetic is selected from the group consisting of an amino-amide anesthetic, an amino-ester anesthetic, and a combination thereof.
  • the anesthetic is a mild myotoxin.
  • amino-amide anesthetics include bupivacaine, levobupivacaine, articaine, ropivacaine, butanilicaine, carticaine, dibucaine, etidocaine, lidocaine, mepivacaine, prilocaine, and trimecaine.
  • the composition comprises a combination of amino-amide anesthetics.
  • the anesthetic is an amino-ester anesthetic.
  • the amino-ester anesthetic is an aminobenzoic acid ester anesthetic, a benzoic acid ester anesthetic, or a combination thereof.
  • Non-limiting examples of aminobenzoic acid ester anesthetics include benzocaine, butacaine, butamben, chloroprocaine, dimethocaine, lucaine, meprylcaine, metabutethamine, metabutoxycaine, nitracaine, orthocaine, propoxycaine, procaine, proxymetacaine, risocaine, and tetracaine.
  • Non-limiting examples of benzoic acid anesthetics include amylocaine, cocaine, cyclomethycaine, ⁇ -eucaine, ⁇ -eucaine, hexylcaine, isobucaine, and piperocaine.
  • the composition comprises a combination of one or more aminobenzoic acid ester anesthetics and/or one or more benzoic acid ester anesthetics.
  • anesthetics that may have mild myotoxic effects include benzonatate, diperodon, fomocaine, fotocaine, hydroxyprocaine, oxetacaine, oxybuprocaine, paraethoxycaine, phenacaine, piridocaine, pramocaine, primacaine, procainamide, proparacaine, pyrrocaine, quinisocaine, tolycaine, and tropacocaine.
  • the composition comprises a PGE2 compound that comprises PGE2 and/or dmPGE2 and a myotoxin that is bupivacaine.
  • compositions of the present invention may be suitable for treating any number of muscle conditions, including but not limited to muscle conditions that are associated with muscle damage, injury, or atrophy.
  • the compositions are also useful for promoting muscle regeneration in a subject in need thereof, for increasing muscle mass in a subject in need thereof, or both.
  • Non-limiting examples of suitable conditions for prevention or treatment with compositions of the present invention include traumatic injury (e.g., acute muscle trauma, acute nerve trauma), acute muscle injury, acute nerve injury, chronic nerve injury, soft tissue hand injury, carpal tunnel syndrome (CTS), Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, limb girdle muscular dystrophy, amyotrophic lateral sclerosis (ALS), distal muscular dystrophy (DD), inherited myopathies, myotonic muscular dystrophy (MDD), mitochondrial myopathies, myotubular myopathy (MM), myasthenia gravis (MG), congestive heart failure, periodic paralysis, polymyositis, rhabdomyolysis, dermatomyositis, cancer cachexia, AIDS cachexia, cardiac cachexia, stress induced urinary incontinence, sarcopenia, spinal muscular atrophy, fecal sphincter dysfunction, Bell's palsy, rotator cuff injury, spinal cord injury,
  • suitable conditions for prevention or treatment with compositions of the present invention may include muscle disorders that affect small isolated muscles that can be regenerated with localized transplantation of small numbers of cells, including: atrophy and muscle dysfunction in the face or hand after nerve injury or direct trauma that does not recover after reinnervation; extraocular muscle injury causing inability to move the eye and dipoplia seen in Graves' disease, traumatic injury, and progressive external ophthalmoplegia; and urinary and fecal incontinence.
  • the pharmaceutical composition comprises a pharmaceutically acceptable carrier and a composition described herein that comprises a PGE2 compound and a myotoxin.
  • pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES, 18 TH E D ., Mack Publishing Co., Easton, Pa. (1990)).
  • pharmaceutically acceptable carrier comprises any of standard pharmaceutically accepted carriers known to those of ordinary skill in the art in formulating pharmaceutical compositions.
  • the cells or compounds, by themselves, such as being present as pharmaceutically acceptable salts, or as conjugates may be prepared as formulations in pharmaceutically acceptable diluents; for example, saline, phosphate buffer saline (PBS), aqueous ethanol, or solutions of glucose, mannitol, dextran, propylene glycol, oils (e.g., vegetable oils, animal oils, synthetic oils, etc.), microcrystalline cellulose, carboxymethyl cellulose, hydroxylpropyl methyl cellulose, magnesium stearate, calcium phosphate, gelatin, polysorbate 80 or the like, or as solid formulations in appropriate excipients.
  • PBS phosphate buffer saline
  • aqueous ethanol or solutions of glucose, mannitol, dextran, propylene glycol
  • oils e.g., vegetable oils, animal oils, synthetic oils, etc.
  • the pharmaceutical compositions will often further comprise one or more buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants (e.g., ascorbic acid, sodium metabisulfite, butylated hydroxytoluene, butylated hydroxyanisole, etc.), bacteriostats, chelating agents such as EDTA or glutathione, solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents, preservatives, flavoring agents, sweetening agents, and coloring compounds as appropriate.
  • buffers e.g., neutral buffered saline or phosphate buffered saline
  • carbohydrates e.g., glucose, mannose, sucrose or dextrans
  • compositions of the invention may be administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective.
  • the quantity to be administered may depend on a variety of factors including, e.g., the age, body weight, physical activity, and diet of the individual, the condition or disease to be treated, and the stage or severity of the condition or disease.
  • the size of the dose may also be determined by the existence, nature, and extent of any adverse side effects that accompany the administration of a therapeutic agent(s) in a particular individual.
  • the specific dose level and frequency of dosage for any particular patient may be varied and may depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, hereditary characteristics, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
  • the dose of the compound may take the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, pills, pellets, capsules, powders, solutions, suspensions, emulsions, suppositories, retention enemas, creams, ointments, lotions, gels, aerosols, foams, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
  • unit dosage form refers to physically discrete units suitable as unitary dosages for humans and other mammals, each unit containing a predetermined quantity of a therapeutic agent calculated to produce the desired onset, tolerability, and/or therapeutic effects, in association with a suitable pharmaceutical excipient (e.g., an ampoule).
  • a suitable pharmaceutical excipient e.g., an ampoule
  • more concentrated dosage forms may be prepared, from which the more dilute unit dosage forms may then be produced.
  • the more concentrated dosage forms thus may contain substantially more than, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times the amount of the therapeutic compound.
  • the dosage forms typically include a conventional pharmaceutical carrier or excipient and may additionally include other medicinal agents, carriers, adjuvants, diluents, tissue permeation enhancers, solubilizers, and the like.
  • Appropriate excipients can be tailored to the particular dosage form and route of administration by methods well known in the art (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES, supra).
  • excipients include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, saline, syrup, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, and polyacrylic acids such as Carbopols, e.g., Carbopol 941, Carbopol 980, Carbopol 981, etc.
  • Carbopols e.g., Carbopol 941, Carbopol 980, Carbopol 981, etc.
  • the dosage forms can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying agents; suspending agents; preserving agents such as methyl-, ethyl-, and propyl-hydroxy-benzoates (i.e., the parabens); pH adjusting agents such as inorganic and organic acids and bases; sweetening agents; and flavoring agents.
  • lubricating agents such as talc, magnesium stearate, and mineral oil
  • wetting agents such as talc, magnesium stearate, and mineral oil
  • emulsifying agents such as methyl-, ethyl-, and propyl-hydroxy-benzoates (i.e., the parabens)
  • pH adjusting agents such as inorganic and organic acids and bases
  • sweetening agents and flavoring agents.
  • the dosage forms may also comprise biodegradable polymer beads, dextran, hydrogels, and cyclodextrin inclusion complexes.
  • the therapeutically effective dose can be in the form of tablets, capsules, emulsions, suspensions, solutions, syrups, sprays, lozenges, powders, and sustained-release formulations.
  • Suitable excipients for oral administration include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, gelatin, sucrose, magnesium carbonate, and the like.
  • the therapeutically effective dose can also be provided in a lyophilized form.
  • dosage forms may include a buffer, e.g., bicarbonate, for reconstitution prior to administration, or the buffer may be included in the lyophilized dosage form for reconstitution with, e.g., water.
  • the lyophilized dosage form may further comprise a suitable vasoconstrictor, e.g., epinephrine.
  • the lyophilized dosage form can be provided in a syringe, optionally packaged in combination with the buffer for reconstitution, such that the reconstituted dosage form can be immediately administered to an individual.
  • a pharmaceutical composition of the present invention comprises a pharmaceutically acceptable carrier that comprises an aqueous base.
  • the pharmaceutically acceptable carrier comprises a low viscosity compound.
  • the low viscosity compound comprises gelatin.
  • the low viscosity compound comprises a hydrogel.
  • a method for promoting muscle regeneration in a subject in need thereof, increasing muscle mass in a subject in need thereof, or both comprises administering a combination of a PGE2 compound and a myotoxin to the subject.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and combination of a PGE2 compound and a myotoxin is administered to the subject.
  • a therapeutically effective amount of the PGE2 compound is administered to the subject.
  • a therapeutically effective amount of the myotoxin is administered to the subject.
  • a therapeutically effective amount of the PGE2 compound and the myotoxin are administered to the subject.
  • a method for preventing or treating a muscle condition in a subject in need thereof comprises administering a combination of a PGE2 compound and a myotoxin to the subject.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and combination of a PGE2 compound and a myotoxin is administered to the subject.
  • a therapeutically effective amount of the PGE2 compound is administered to the subject.
  • a therapeutically effective amount of the myotoxin is administered to the subject.
  • a therapeutically effective amount of the PGE2 compound and the myotoxin are administered to the subject.
  • the method comprises administering a PGE2 receptor agonist to the subject. In other embodiments, the method further comprises administering a myotoxin to the subject.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier, a PGE2 receptor agonist, and optionally a myotoxin is administered to the subject.
  • a therapeutically effective amount of the PGE2 receptor agonist is administered to the subject.
  • a therapeutically effective amount of the myotoxin is administered to the subject.
  • a therapeutically effective amount of the PGE2 receptor agonist and the myotoxin are administered to the subject.
  • the methods comprise administering a PGE2 compound that is selected from the group consisting of PGE2, a PGE2 prodrug (e.g. PGE2 coupled to neural cadherin (NCAD) that targets NCAD receptor), a PGE2 receptor agonist, a compound that attenuates PGE2 catabolism, a compound that neutralizes PGE2 inhibition, a derivative thereof, an analog thereof, and a combination thereof.
  • a prodrug of PGE2 can be metabolized into a pharmacologically active PGE2 drug, for example, at the site of administration or muscle regeneration, or when the prodrug is exposed to muscle cells.
  • the PGE2 compound is a biotinylated drug or other modification that retains PGE2 receptor engagement and signaling but prevents internalization—leading to prolonged activity and overcoming the degradative pathway.
  • the PGE2 compound that is administered is a PGE2 derivative or analog that contains one or more modifications to PGE2 that increase its stability, activity, resistance to degradation, transport into muscle cells (e.g., promote cellular uptake), and/or retention in muscle cells (e.g., reduce secretion from muscle cells after uptake).
  • examples of PGE2 derivatives and analogs that are suitable for administration according to methods of the present invention include 2,2-difluoro-16-phenoxy-PGE2 compounds, 2-decarboxy-2-hydroxymethyl-16-fluoro-PGE2 compounds, 2-decarboxy-2-hydroxymethyl-11-deoxy-PGE2 compounds, 19(R)-hydroxy PGE2, 16,16-dimethyl PGE2, 16,16-dimethyl PGE2 p-(p-acetamidobenzamido) phenyl ester, 11-deoxy-16,16-dimethyl PGE2 (dmPGE2), 9-deoxy-9-methylene-16,16-dimethyl PGE2, 9-deoxy-9-methylene PGE2, butaprost, sulprostone, enprostil, PGE2 serinol amide, PGE2 methyl ester, 16-phenyl tetranor PGE2, 5-trans-PGE2, 15(S)-15-methyl PGE2, and 15(R)-15-methyl
  • PGE2 derivatives and analogs for administration include hydantoin derivatives of PGE2, the more stable PGE2 analogs described in Zhao et al. ( Bioorganic & Medicinal Chemistry Letters, 17:6572-5 (2007)) in which the hydroxy cyclopentanone ring is replaced by heterocyclic rings and the unsaturated alpha-alkenyl chain is substituted with a phenethyl chain, the PGE2 analogs described in Ungrin et al. ( Mol. Pharmacol., 59:1446-56 (2001)), the 13-dehydro derivatives of PGE2 described in Tanami et al. ( Bioorg. Med. Chem. Lett., 8:1507-10 (1998)), and the substituted cyclopentanes described in U.S. Pat. Nos. 8,546,603 and 8,158,676.
  • a PGE2 compound that is an agonist of a PGE2 receptor is administered, e.g., EP1 receptor, EP2 receptor, EP3 receptor, and EP4 receptor.
  • PGE2 receptor agonists include ONO-DI-004, ONO-AE1-259, ONO-AE-248, ONO-AE1-329, ONO-4819CD (Ono Pharmaceutical Co., Japan), L-902688 (Cayman Chemical), CAY10598 (Cayman Chemical), and CP-533536 (Pfizer). Additional PGE2 receptor agonists are described, e.g., in U.S. Pat. Nos. 6,410,591; 6,610,719; 6,747,037; 7,696,235; 7,662,839; 7,652,063; 7622,475; and 7,608,637.
  • the PGE2 receptor agonist that is administered per methods of the present invention comprises a compound of Formula (I), a derivative thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer thereof, or a combination thereof,
  • ring A is a substituted 4- to 6-membered cycloalkyl ring or a substituted 4- to 6-membered cycloalkenyl ring that comprises substituents R 1 and R 2 that are independently selected from the group consisting of substituted C 1 -C 10 alkyl and substituted C 2 -C 10 alkenyl, and ring A further comprises one or more additional substituents.
  • ring A is a substituted cyclopentyl ring or a substituted cyclopentenyl ring.
  • the one or more additional substituents on ring A are selected from the group consisting of deuterium, hydroxy, amino, oxo, C 1 -C 6 alkyl, and halogen.
  • the one or more additional substituents on ring A are hydroxy or oxo.
  • ring A has two additional substituents that are taken together to form a covalent bond to form a heterocycloalkyl ring.
  • ring A is selected from the consisting of
  • ring A is selected from the group consisting of from the group consisting of
  • ring A is
  • R 1 is substituted C 1 -C 10 alkyl. In other embodiments, R 1 is substituted C 2 -C 10 alkenyl. In some embodiments, R 1 is selected from the group consisting of deuterium, hydroxy, oxo, C 1 -C 6 alkyl, —COOR 3 , and halogen, wherein R 3 is hydrogen or C 1 -C 6 alkyl.
  • R 1 is selected from the group consisting of
  • R 1 is selected from the group consisting of
  • R 1 is
  • R 2 is substituted C 1 -C 10 alkyl. In other embodiments, R 2 is substituted C 2 -C 10 alkenyl. In some embodiments, the substituent on R 2 is selected from the group consisting of deuterium, hydroxy, oxo, C 1 -C 6 alkyl, —COOR 3 , and halogen, wherein R 3 is hydrogen or C 1 -C 6 alkyl.
  • R 2 is selected from the group consisting of
  • R 2 is selected from the group consisting of
  • R 2 is
  • the compound of Formula (I), the pharmaceutically acceptable salt thereof, the solvate thereof, or the stereoisomer thereof is a compound of Formula (Ia), Formula (Ib), Formula (Ic), or Formula (Id), or is a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof:
  • the compound is of Formula (Id).
  • the PGE2 compound that is administered according to the methods of the present invention comprises PGE2.
  • the PGE2 compound that is administered comprises a derivative of PGE2.
  • the derivative is 16,16-dimethyl prostaglandin E2 (dmPGE2).
  • the PGE2 compound that is administered comprises PGE2 and/or dmPGE2.
  • the PGE2 compound that is administered is a compound that attenuates PGE2 catabolism.
  • a compound that attenuates PGE2 catabolism can be a compound, a neutralizing peptide, or a neutralizing antibody that inactivates or blocks 15-hydroxyprostaglandin dehydrogenase (15-PGDH) or inactivates or blocks a prostaglandin transporter, which transports PGE2 inside cells for catabolism by 15-PGDH.
  • the prostaglandin transporter is also known as 2310021C19Rik, MATR1, Matrin F/Q, OATP2A1, PGT, PHOAR2, SLC21A2, solute carrier organic anion transporter family member 2A1, and SLCO2A1.
  • the composition that is administered according to the methods of the present invention may include a stem-cell inducing molecule.
  • the stem-cell inducing molecule is a PGE2 compound as described herein.
  • Other non-limiting examples of stem-cell inducing molecules that may be used herein include oxytocin, beta integrin activating antibody, rapamycin, SetD7 inhibitors, p38 MAPK inhibitors (such as SB202190 and SB203580), neuregulin, nerve growth factor (NGF), Hif2alpha inhibitors, basic fibroblast growth factor (bFGF), fibroblast growth factor 4 (FGF4), epidermal growth factor (EGF), Interleukin-1 ⁇ , Interleukin-13, TNF ⁇ , LIF, IL6, interferon gamma, oncostatin M (OSM), ghrelin, and apelin.
  • oxytocin beta integrin activating antibody
  • rapamycin SetD7 inhibitors
  • p38 MAPK inhibitors such as SB202
  • the myotoxin that is administered according to methods of the present invention is selected from the group consisting of an anesthetic, a divalent cation, venom from snakes, venom from lizards, venom from bees, and a combination thereof.
  • Suitable divalent cations include but are not limited to Ba 2+ , Sr 2+ , Mg 2+ , Ca 2+ , Mn 2+ , Ni 2+ , Co 2+ , salts thereof, and combinations thereof.
  • the snake or lizard venom is selected from the group consisting of notexin, cardiotoxin, bungarotoxin, and a combination thereof.
  • the anesthetic is selected from the group consisting of an amino-amide anesthetic, an amino-ester anesthetic, and a combination thereof.
  • the anesthetic is a mild myotoxin.
  • amino-amide anesthetics include bupivacaine, levobupivacaine, articaine, ropivacaine, butanilicaine, carticaine, dibucaine, etidocaine, lidocaine, mepivacaine, prilocaine, and trimecaine.
  • the composition comprises a combination of amino-amide anesthetics.
  • the anesthetic is an amino-ester anesthetic.
  • the amino-ester anesthetic is an aminobenzoic acid ester anesthetic, a benzoic acid ester anesthetic, or a combination thereof.
  • Non-limiting examples of aminobenzoic acid ester anesthetics include benzocaine, butacaine, butamben, chloroprocaine, dimethocaine, lucaine, meprylcaine, metabutethamine, metabutoxycaine, nitracaine, orthocaine, propoxycaine, procaine, proxymetacaine, risocaine, and tetracaine.
  • Non-limiting examples of benzoic acid anesthetics include amylocaine, cocaine, cyclomethycaine, ⁇ -eucaine, ⁇ -eucaine, hexylcaine, isobucaine, and piperocaine.
  • the composition comprises a combination of one or more aminobenzoic acid ester anesthetics and/or one or more benzoic acid ester anesthetics.
  • anesthetics that may have mild myotoxic effects include benzonatate, diperodon, fomocaine, fotocaine, hydroxyprocaine, oxetacaine, oxybuprocaine, paraethoxycaine, phenacaine, piridocaine, pramocaine, primacaine, procainamide, proparacaine, pyrrocaine, quinisocaine, tolycaine, and tropacocaine.
  • the composition for administration according to methods of the present invention comprises a PGE2 compound that comprises PGE2 and/or dmPGE2 and a myotoxin that is an anesthetic (e.g., bupivacaine).
  • anesthetic e.g., bupivacaine
  • no anesthetic is administered to the subject.
  • a myotoxin that is not an anesthetic is administered to the subject.
  • the methods provided herein can be used to prevent or treat a muscle condition or disease (e.g., a muscle condition or disease associated with muscle damage, injury, or atrophy) in a subject in need thereof.
  • the method can provide prophylactic treatment to a subject who is likely to experience a muscle condition (e.g., muscle damage, injury, or atrophy).
  • the subject can have a condition or disease with possible secondary symptoms that affect muscle.
  • the subject has undergone a surgical or therapeutic procedure or intervention to treat the muscle condition or disease, and the method disclosed herein is used to prevent or inhibit recurrence or relapse.
  • the subject has any one of the conditions or diseases described herein that affects muscle.
  • treatment encompasses administration of compounds and/or cells in an appropriate form prior to the onset of disease symptoms and/or after clinical manifestations, or other manifestations of the condition or disease to reduce disease severity, halt disease progression, or eliminate the disease.
  • prevention of” or “preventing” a disease includes prolonging or delaying the onset of symptoms of the condition or disease, preferably in a subject with increased susceptibility to the condition or disease.
  • treating the subject produces an improvement in muscle strength and/or muscle coordination.
  • the methods provided herein may be useful for promoting muscle regeneration in a subject in need thereof, for increasing muscle mass in a subject in need thereof, or both.
  • Regeneration of muscle includes forming new muscle fibers from muscle stem cells, satellite cells, muscle progenitor cells, and any combination thereof.
  • the methods are also useful for enhancing or augmenting muscle repair, maintenance, or both.
  • the methods provided herein also promote neuromuscular junction establishment and restoration of muscle contractile function and volume.
  • the methods provided herein comprise administering a composition comprising a PGE2 compound and a myotoxin to a muscle or a muscle cell in vivo.
  • the methods provided herein comprise providing to a muscle cell a first composition comprising a PGE2 compound ex vivo, and administering the muscle cell to a muscle in vivo.
  • the first composition may further comprise a myotoxin.
  • the administering the muscle cell to a muscle in vivo further comprises administering a myotoxin to the muscle in vivo.
  • the methods provided herein further comprise administering a senolytic drug.
  • a senolytic drug is a drug that induces clearance of senescent cells that produce a senescence-associated secretory phenotype.
  • a senolytic drug is a drug that targets a pathway involving BCL-2, BCL-XL, MDM2, p53, p21, serpine (PAI-1&2), HSP-90, PI3K ⁇ , AKT, HIF1 alpha, ephrin, or a combination thereof.
  • Examples of a senolytic drug include dasatinib, alvespimycin, geldanamycin, tanespimycin; fisetin, ABT-263, ABT-767, A1331852, and A1155463.
  • administering of a senolytic drug is before, during, after, or a combination, administering a composition comprising a PGE2 compound and a myotoxin.
  • compositions and pharmaceutical compositions of the present invention can be administered to a subject experiencing a muscle condition such as muscle injury, degeneration, damage, atrophy, or any combination thereof.
  • a muscle condition such as muscle injury, degeneration, damage, atrophy, or any combination thereof.
  • the muscle condition is the result of partial or complete denervation.
  • Muscle atrophy can include loss of muscle mass, loss of muscle strength, or both. Muscle atrophy may affect any muscle of a subject.
  • the subject in need of the compositions, methods, and kits provided herein may be exhibiting or experiencing muscle loss due to, e.g., age, inactivity, injury, disease, or any combination thereof.
  • compounds can activate muscle cell proliferation, muscle cell differentiation, fusion of muscle cells, or any combination thereof.
  • the muscle tissue may be regenerated.
  • muscle function e.g., muscle mass, muscle strength, muscle contraction, or any combination thereof
  • muscle weakness and atrophy may be ameliorated.
  • the damaged muscle can be any muscle of the body, including but not limited to, musculi pectoralis complex, latissimus dorsi, teres major and subscapularis, brachioradialis, biceps, brachialis, pronator quadratus, pronator teres, flexor carpi radialis, flexor carpi ulnaris, flexor digitorum superficialis, flexor digitorum profundus, flexor pollicis brevis, opponens pollicis, adductor pollicis (e.g., abductor pollicis brevis, abductor pollicis longus), flexor pollicis brevis, iliopsoas, psoas, rectus abdominis, rectus femoris, gluteus maximus, gluteus minims, medial hamstrings, gastrocnemius, lateral hamstring, quadriceps mechanism
  • Subjects in need of muscle regeneration may have musculoskeletal injuries (e.g., fractures, strains, sprains, acute injuries, overuse injuries, and the like), post-trauma damages to limbs or face, athletic injuries, post-fractures in the aged, soft tissue hand injuries, muscle atrophy (e.g., loss of muscle mass), Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, Fukuyama congenital muscular dystrophy (FCMD), limb-girdle muscular dystrophy (LGMD), congenital muscular dystrophy, facioscapulohumeral muscular dystrophy (FHMD), myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, myotonia congenita, myotonic dystrophy, other muscular dystrophies, muscle wasting disease, such as cachexia due to cancer, end stage renal disease (ESRD), acquired immune deficiency syndrome (AIDS
  • Non-limiting examples of neuromuscular diseases include, but are not limited to, acid maltase deficiency, amyotrophic lateral sclerosis, Andersen-Tawil syndrome, Becker muscular dystrophy, Becker myotonia congenita, Bethlem myopathy, bulbospinal muscular atrophy, carnitine deficiency, carnitine palmityl transferase deficiency, central core disease, centronuclear myopathy, Charcot-Marie-Tooth disease, congenital muscular dystrophy, congenital myasthenic syndromes, congenital myotonic dystrophy, Cori disease, Debrancher enzyme deficiency, Dejerine-Sottas disease, dermatomyositis, distal muscular dystrophy, Duchenne muscular dystrophy, dystrophia myotonica, Emery-Dreifuss muscular dystrophy, endocrine myopathies, Eulenberg disease, facioscapulohumeral muscular dystrophy
  • Muscle atrophy can be caused by or associated with, for example, normal aging (e.g., sarcopenia), genetic abnormalities (e.g., mutations or single nucleotide polymorphisms), poor nourishment, poor circulation, loss of hormonal support, disuse of the muscle due to lack of exercise (e.g., bedrest, immobilization of a limb in a cast, etc.), a surgical procedure (e.g., surgical treatment), trauma (e.g., accidental trauma), injury (e.g., accidental injury), aging, damage to the nerve innervating the muscle, poliomyelitis, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), heart failure, liver disease, diabetes, obesity, metabolic syndrome, demyelinating diseases (e.g., multiple sclerosis, Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica, adren
  • the muscle condition or disease that is prevented or treated is selected from the group consisting of: traumatic injury (e.g., acute muscle trauma, acute nerve trauma), acute muscle injury, acute nerve injury, chronic nerve injury, soft tissue hand injury, carpal tunnel syndrome (CTS), Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, limb girdle muscular dystrophy, amyotrophic lateral sclerosis (ALS), distal muscular dystrophy (DD), inherited myopathies, myotonic muscular dystrophy (MDD), mitochondrial myopathies, myotubular myopathy (MM), myasthenia gravis (MG), congestive heart failure, periodic paralysis, polymyositis, rhabdomyolysis, dermatomyositis, cancer cachexia, AIDS cachexia, cardiac cachexia, stress induced urinary incontinence, sarcopenia, spinal muscular atrophy, fecal sphincter dysfunction, Bell's palsy, rotator cuff injury,
  • the subject has ulnar nerve entrapment (e.g., at the elbow), either with or without muscle wasting.
  • suitable conditions may include muscle disorders that affect small isolated muscles that can be regenerated with localized transplantation of small numbers of cells, including: atrophy and muscle dysfunction in the face or hand after nerve injury or direct trauma that does not recover after reinnervation; extraocular muscle injury causing inability to move the eye and dipoplia seen in Graves' disease, traumatic injury, and progressive external ophthalmoplegia; and urinary and fecal incontinence.
  • the subject has received a traumatic injury.
  • the muscle condition being treated is a traumatic injury.
  • the traumatic injury comprises blunt trauma or a crush injury.
  • the traumatic injury comprises blunt trauma or a crush injury to a limb (e.g., arm, leg, hand, foot, digit).
  • the traumatic injury is accidental.
  • the PGE2 compound e.g., PGE2 receptor agonist
  • the PGE2 compound is administered immediately after the traumatic injury has occurred.
  • a combination of the PGE2 compound (e.g., PGE2 receptor agonist) and the myotoxin is administered immediately after the traumatic injury has occurred.
  • the PGE2 compound (e.g., PGE2 receptor agonist) and the myotoxin are administered simultaneously to the subject.
  • the PGE2 compound or the combination of the PGE2 compound and the myotoxin is administered within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 minutes after occurrence of the traumatic injury.
  • the PGE2 compound or the combination of the PGE2 compound and the myotoxin is administered within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours of occurrence of the traumatic injury.
  • the PGE2 compound (e.g., PGE2 receptor agonist) or the combination of the PGE2 compound and the myotoxin can be administered, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times following occurrence of the traumatic injury.
  • a subject who is treated (e.g., for a muscle condition or disease, or prophylactically) according to methods of the present invention receives a surgical procedure (e.g., surgical treatment).
  • the surgical procedure is for the prevention, reduction, or repair of a nerve injury.
  • the nerve injury e.g., that is surgically treated
  • the nerve injury can be a peripheral nerve injury.
  • a subject who is treated or given prophylactic treatment (e.g., for a muscle condition or disease) according to methods of the present invention undergoes a carpal tunnel release procedure.
  • the surgical procedure comprises cutting a muscle, repairing a muscle, or both.
  • a PGE2 compound e.g., a PGE2 receptor agonist
  • a combination of a PGE2 compound and a myotoxin can be administered in conjunction with a Caesarean section, a hip replacement, or a knee replacement (e.g., a PGE2 compound, or a combination of a PGE2 compound and a myotoxin can be administered at the same time that a Caesarean section, hip replacement, or knee replacement is performed).
  • the methods of the present invention enhance post-operative recovery. Methods of the present invention can also be used to enhance the function of small muscles, the strength of small muscles, or both (e.g., hand, facial, oculopharyngeal muscles).
  • methods of the present invention can be performed, before surgery, during surgery, after surgery, or any combination thereof.
  • a PGE2 compound e.g., a PGE2 receptor agonist
  • no anesthetic is delivered.
  • methods of the present invention may eliminate the need for the administration of marcaine.
  • compositions and pharmaceutical compositions can be administered topically, orally, intraperitoneally, intramuscularly, intra-arterially, intradermally, subcutaneously, intravenously, intracranially, intrathecally, intraspinally, intralesionally, intranasally, intracerebroventricularly, by inhalation and/or by intracardiac injection.
  • the compositions can be administered in accordance with an acute regimen (e.g., single or intermittent dosing) or a chronic regimen (e.g., continuous dosing).
  • the PGE2 compound and the myotoxin can be administered concomitantly or sequentially.
  • the PGE2 compound and the myotoxin can be administered first, followed by the myotoxin, or vice versa.
  • the order of sequential administration alternates or otherwise varies between treatments (e.g., during one treatment, a PGE2 compound is administered first, followed by administration of the myotoxin, then during a subsequent treatment the myotoxin is administered first, followed by the PGE2 compound).
  • administration of the compounds can be separated by some length of time.
  • administration of the compounds is separated by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, or more minutes.
  • administration of the compounds is separated by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or more hours.
  • administration of the compounds is separated by about 1, 2, 3, 4, 5, 6, 7, or more days.
  • a dose of the PGE2 compound (e.g., PGE2 receptor agonist), the myotoxin, or both is determined based upon the size of a target muscle.
  • a dose can comprise about 10 ng of the PGE2 compound (e.g., PGE2 receptor agonist), the myotoxin, or both, when the target muscle is an abductor pollicis brevis muscle (e.g., an abductor pollicis brevis muscle that is of about average size).
  • a dose can comprise about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 25, 40, 45, 50, or more mg of the PGE2 compound (e.g., PGE2 receptor agonist), the myotoxin, or both, per kg of muscle tissue.
  • the PGE2 compound e.g., PGE2 receptor agonist
  • a dose of the PGE2 compound (e.g., PGE2 receptor agonist), the myotoxin, or both is based on the body weight of the subject.
  • a dose of the PGE2 compound (e.g., PGE2 receptor agonist), the myotoxin, or both is about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 25, 40, 45, 50, or more mg per kg of the subject's body weight.
  • the subject is also administered a population of isolated (or isolated and purified) muscle cells that are either autologous or allogeneic to the subject.
  • the cells can be isolated, purified, or both, by any method known to those of skill in the art.
  • the cells can be a homogenous or heterogeneous population of muscle cells.
  • the isolated muscle cells can be administered by injection or transplantation.
  • compositions, the pharmaceutical compositions, or both, described herein e.g., comprising a PGE2 compound and a myotoxin, or comprising a PGE2 receptor agonist and optionally a myotoxin
  • the cells may be administered together or concomitantly.
  • the compositions, the pharmaceutical compositions, or both, and the cells may be administered sequentially.
  • the compositions, the pharmaceutical compositions, or both may be administered before the cells.
  • the cells may be administered before the compositions, the pharmaceutical compositions, or both.
  • the cells can be administered before, during, or after a surgical procedure (e.g., surgical treatment, e.g., for treatment of a nerve injury or a muscle condition or disease).
  • the population of muscle cells administered to the subject can include skeletal muscle cells, smooth muscle cells, cardiac muscle cells, embryonic stem cell-derived muscle cells, induced pluripotent stem cell-derived muscle cells, dedifferentiated muscle cells, or any combinations thereof. Additionally, the muscle cells administered to the subject can be muscle stem cells, satellite cells, myocytes, myoblasts, myotubes, myofibers, or any combination thereof.
  • compositions and/or pharmaceutical compositions described herein can be administered to the subject by topical, oral, intraperitoneal, intramuscular, intra-arterial, intradermal, subcutaneous, intravenous, or intracardiac administration.
  • the compositions and/or pharmaceutical compositions may be administered directly to the dysfunctional, injured, damaged and/or atrophied muscle.
  • the compositions and/or pharmaceutical compositions can be administered in accordance with an acute regimen (e.g., single or intermittent dosing) or a chronic regimen (e.g., continuous dosing).
  • Satellite cells are small mononuclear progenitor cells that can reside within muscle tissue. These cells can be induced to proliferate and differentiate into muscle cells, and in some instances, fuse to muscle fibers. During muscle damage or injury, quiescent satellite cells (e.g., satellite cells that are not differentiating or undergoing cell division at present) and muscle stem cells can be activated to proliferate, and/or migrate out of the muscle stem cell niche. The satellite cells and muscle stem cells can also differentiate into myocytes, myoblasts, or other muscle cell types.
  • Methods and protocols for generating muscle cells from embryonic stem cells are described, e.g., in Hwang et al., PLoS One, 2013, 8(8):e72023; and Darabi et al., Cell Stem Cell, 2012, 10(5):610-9.
  • Methods and protocols for generating muscle cells from induced pluripotent stem cells are described, e.g., in Darabi et al., Cell Stem Cell, 2012, 10(5):610-9; Tan et al., PLoS One, 2011; and Mizuno et al., FASEB J., 2010, 24(7):2245-2253.
  • muscle cells are obtained by biopsy from a muscle such as a mature or adult muscle, e.g., quadriceps, gluteus maximus, biceps, triceps, or any muscle from an individual.
  • the muscle can be a skeletal muscle, smooth muscle, or cardiac muscle.
  • Detailed descriptions of methods of isolating smooth muscle stem cells can be found, e.g., in U.S. Pat. No. 8,747,838, and U.S. Patent App. Publ. No. 20070224167.
  • Methods of isolating muscle cells of interest such as muscle stem cells or satellite cells from muscle tissue are described in detail, for example, in Blanco-Bose et al., Exp. Cell Res., 2001, 26592:212-220.
  • Methods for purifying a population of muscle cells of interest include selecting, isolating or enriching for a cell having a specific cell surface marker or a specific polypeptide that is expressed on the cell surface of the muscle cell of interest.
  • Useful cell surface markers are described in, e.g., Fukada et al., Front. Physiol., 2013, 4:317.
  • Cell sorting methods such as flow cytometry, e.g., fluorescence-activated cell sorting (FACS); magnetic bead cell separation, e.g., magnetic-activated cell sorting (MACS), and other antibody-based cell sorting methods can be performed to isolate or separate the muscle cells of interest from other cell types.
  • FACS fluorescence-activated cell sorting
  • MCS magnetic-activated cell sorting
  • the isolated population of muscle cells of interest can be expanded or multiplied using conventional culture-based methods. Methods for culture muscle cells are found in, e.g., U.S. Pat. No. 5,324,656. In some cases, the cells may be cultured on a scaffold or gel such as a hydrogel.
  • the cells may be stimulated to proliferate by culturing the cells with the PGE2 compound (e.g., PGE2 receptor agonist) and/or myotoxin prior to administering them to the subject.
  • PGE2 compound e.g., PGE2 receptor agonist
  • the cells can be acutely, intermittently or continuously exposed to the compound during in vitro culturing.
  • the population of muscle cells may increase by at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, at least about 500%, at least about 1000%, or more after culturing with the PGE2 compound (e.g., PGE2 receptor agonist) and/or myotoxin.
  • PGE2 compound e.g., PGE2 receptor agonist
  • the methods described herein can be used to increase the number of muscle fibers by at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, at least about 500%, at least about 1000%, or more.
  • the methods can increase the growth of a damaged, injured, atrophied, or degenerated muscle.
  • a target muscle may be subjected to mechanical injury.
  • mechanical injury can comprise cutting, burning, freezing, needle puncture, exercise (e.g., brief or prolonged exercise), a surgical procedure (e.g., surgical treatment), traumatic injury (e.g., accidental trauma or injury), or a combination thereof.
  • the mechanical injury is before, after, or concomitant with administration of a PGE2 compound (e.g., PGE2 receptor agonist).
  • mechanical injury when performed in conjunction with administration of a PGE2 compound (e.g., PGE2 receptor agonist), acts as a regenerative inducer that stimulates muscle cell proliferation, muscle cell growth, muscle cell survival, muscle regeneration, muscle growth, and/or an increase in muscle mass.
  • a PGE2 compound e.g., PGE2 receptor agonist
  • mechanical injury acts as a regenerative inducer when a myotoxin is not administered to the subject.
  • the mechanical injury is before, after, or concomitant with administration of a PGE2 receptor agonist. In some instances, the mechanical injury is before, after, or concomitant with administration of a myotoxin. In some other instances, the mechanical injury is before, after, or concomitant with administration of a combination of a PGE2 compound (e.g., PGE2 receptor agonist) and a myotoxin.
  • a PGE2 compound e.g., PGE2 receptor agonist
  • the methods may comprise the administration of a therapeutic composition comprising a PGE2 compound and/or a myotoxin, as described herein, to the ocular system of a subject in need thereof.
  • the therapeutic composition comprising a PGE2 compound and/or a myotoxin can be administered to a subject in need thereof to treat an ocular disorder or disease.
  • the therapeutic composition comprising a PGE2 compound and/or a myotoxin can be administered to a subject in need thereof to improve an eye function.
  • the therapeutic composition comprising a PGE2 compound and/or a myotoxin can be administered to a subject in need thereof to enhance the effectiveness of an existing approach to treat an ocular disorder or disease, such as cataract surgery or retinal surgery.
  • the eyelids protect the eyes. When the eye blinks, the eyelid spreads moisture over the eyes. Blinking also helps move dirt and other particles off the surface of the eye. When something approaches the eye, the eyelid closes to protect the eye against injuries. Eyelid function may be impaired and result in an ocular disorder or disease. In some cases, the eyelid may droop, resulting in a disorder such as ptosis. In other cases, the eyelid may turn in or out, resulting in disorders such as entropion or ectropion. In other cases, the eyelid may have abnormal blinking or twitching, resulting in disorders such as dry eye syndrome or wet eye syndrome (epiphora).
  • the method comprises administering a therapeutic composition comprising a PGE2 compound and/or a myotoxin to a subject in need thereof to improve an eyelid function.
  • an eyelid function may be improved by inducing muscle regeneration in an eye muscle.
  • the eye muscle may be a muscle that impacts an eyelid function.
  • Non-limiting examples of eye muscles include the levator muscle, Muller's muscle or orbicularis.
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., a PGE2 compound and/or a myotoxin) to an eye muscle.
  • Eyelid drooping is excess sagging of the upper eyelid.
  • the edge of the upper eyelid may be lower than it should, also known as ptosis.
  • there may be excess baggy skin in the upper eyelid also known as dermatochalasis.
  • Eyelid drooping may be due to the weakness of an eyelid muscle.
  • the cause of the weakness of the eyelid muscle may be due to the normal aging process, or a result of an injury or a disease.
  • eyelid drooping may be associated with another disorder such as a tumor around or behind the eye, diabetes, Horner syndrome, Myasthenia gravis, stroke, swelling in the eyelid (e.g., stye).
  • eyelid drooping may be congenital.
  • eyelid drooping may be due to botox administration/exposure.
  • the methods of the disclosure may involve treating eyelid drooping.
  • the methods may comprise administering a therapeutic composition comprising a PGE2 compound and/or a myotoxin to a subject having, suspected of having, or at risk of developing eyelid drooping.
  • eyelid drooping may include ptosis, dermatochalasis, or both.
  • treating eyelid drooping may include treating ptosis, dermatochalasis, or both.
  • the methods may involve treating eyelid drooping caused by weakness of the eye muscle, such as weakness due to the aging process, or as a result of injury or disease.
  • the methods may involve treating eyelid drooping caused by a tumor around or behind the eye, Horner syndrome, Myasthenia gravis, stroke, or swelling in the eye (e.g., stye).
  • the methods involve administering a therapeutic composition of the disclosure to an eyelid muscle of a subject having eyelid drooping.
  • the therapeutic composition may treat eyelid drooping by inducing muscle regeneration of an eyelid muscle of a subject.
  • the eyelid muscle may be the levator muscle, Muller's muscle, orbicularis, the frontalis muscle, or any one of the facial muscles.
  • the methods may involve administering a therapeutic composition of the disclosure to any one of the levator muscle, Muller's muscle, orbicularis, the frontalis muscle, or the facial muscles.
  • the therapeutic composition may be administered in combination with eyelift surgery (e.g., blepharoplasty) to treat eyelid drooping.
  • eyelift surgery e.g., blepharoplasty
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof.
  • the therapeutic composition may be administered without eyelift surgery to treat eyelid drooping.
  • the therapeutic composition (e.g., comprising a PGE2 compound and/or a myotoxin) may be administered by topical administration, intradermal administration, intramuscular administration, or a combination thereof.
  • the therapeutic composition is administered by intramuscular administration.
  • intramuscular administration comprises injection of an eyelid muscle.
  • the eyelid muscle may include any one of the levator muscle, Muller's muscle, the orbicularis muscle, the frontalis muscle, or the facial muscles.
  • an anesthetic may be administered to an eye of a subject prior to injection of the therapeutic composition.
  • the eyelid muscle may be injected with surgical exposure; in other cases, the eyelid muscle may be injected without surgical exposure.
  • a 27-, 28-, 29- or 30-gauge needle may be used to inject the eyelid muscle.
  • the methods of the disclosure may involve injecting an eyelid muscle of a subject in need thereof with a volume of about 0.01 mL to about 0.15 mL of a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin).
  • a therapeutic composition of the disclosure e.g., comprising a PGE2 compound and/or a myotoxin.
  • the eyelid muscle may be injected with at least about 0.01 mL of a therapeutic composition.
  • the eyelid muscle may be injected with at most about 0.15 mL of a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin).
  • the eyelid muscle may be injected with greater than 0.01 mL, greater than 0.02 mL, greater than 0.03 mL, greater than 0.04 mL, greater than 0.05 mL, greater than 0.06 mL, greater than 0.07 mL, greater than 0.08 mL, greater than 0.09 mL, greater than 0.10 mL, greater than 0.11 mL, greater than 0.12 mL, greater than 0.13 mL, or greater than 0.14 mL of a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin).
  • a therapeutic composition of the disclosure e.g., comprising a PGE2 compound and/or a myotoxin.
  • the effectiveness of a therapeutic composition of the disclosure to treat eyelid drooping may be determined by conducting tests before administration, after administration, or both. In some cases, the tests may determine how much the eyelid is drooping before administration, after administration, or both. In some cases, the test may be a slit-lamp examination, a tension test, a visual field test, or a combination thereof. In some embodiments, the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration. In some cases, the dose of the PGE2 compound, the myotoxin, or both, may increase. In other cases, the dose of the PGE2 compound, the myotoxin, or both, may decrease.
  • the dose of the PGE2 compound, the myotoxin, or both may not change.
  • the frequency of administration of a therapeutic composition of the disclosure e.g., comprising a PGE2 compound, a myotoxin, or both
  • the frequency of administration may be adjusted after determining the effectiveness of an administration of the therapeutic composition. In some cases, only a single administration of the therapeutic composition may be needed to treat eyelid drooping. In some cases, two, three, four, five, or more than five administrations of the therapeutic composition may be needed.
  • the frequency of administration may be increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration may be decreased after determining the effectiveness of a prior administration.
  • a subject in need of a therapeutic composition of the disclosure may be identified by a test prior to administration of the therapeutic composition.
  • the test may be a phenylephrine chemical test.
  • a positive reaction to the phenylephrine chemical test may identify the subject as a candidate for regeneration of Muller's muscle.
  • a subject may be treated for eyelid drooping by injecting Muller's muscle with a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound, a myotoxin, or both).
  • methods for treating irregular astigmatism comprising administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound, a myotoxin, or both) to a subject in need thereof.
  • a therapeutic composition of the disclosure e.g., comprising a PGE2 compound, a myotoxin, or both
  • Irregular astigmatism may be due to scarring of the cornea as a result of eyelid dropping.
  • irregular astigmatism may be treated by treating eyelid drooping as described herein.
  • Blinking prevents harmful substances from getting into the eye and may be important in the homeostasis of a healthy ocular tear and corneal epithelial surface.
  • the lacrimal gland produces a lubricating fluid for the eye.
  • the eyelid moves fluid from the lacrimal gland and across the eye.
  • the lacrimal gland produces extra fluid to wash out any impurities.
  • the excess fluid drains through a tear duct and into the nasal cavity.
  • the blinking function of the eye may become impaired, impacting the health of the eye. In some cases, impaired blinking may result in dry eye syndrome, or symptoms similar to dry eye syndrome. In other cases, impaired blinking may result in wet eye syndrome, or symptoms similar to wet eye syndrome.
  • Impaired blinking may be due to many causes including eyelid laxity, lack of eyelid control, and weakness of other eye muscles. Impaired blinking can cause severe damage to the cornea from desiccation and can lead to devastating corneal diseases such as neurotrophic cornea.
  • methods are provided for treating impaired blinking in a subject in need thereof.
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing impaired blinking.
  • the methods may comprise administering a therapeutic composition of the disclosure to a subject having, suspected of having, or at risk of developing dry eye syndrome.
  • the therapeutic composition may be administered to treat dry eye syndrome associated with impaired blinking, with lacrimal gland atrophy, with 7th nerve palsy, or with repeated styes.
  • the methods may comprise administering a therapeutic composition of the disclosure to a subject having, suspected of having, or at risk of developing wet eye syndrome (epiphora or excessive tearing).
  • the therapeutic composition may treat impaired blinking, dry eye syndrome, wet eye syndrome, or a combination thereof, by inducing muscle regeneration in an eye muscle of the subject.
  • the eye muscle comprises a muscle that impacts blinking.
  • the eye muscle may include any one of the orbicularis muscle, the muscle of Riolan, Homer's muscle, the frontalis muscle, or the facial muscles.
  • the facial muscles may include the occipitofrontalis muscle, the temporoparietalis muscle, the procerus muscle, the nasalis muscle, the depressor septi nasi muscle, the orbicularis oculi muscle, the corrugator supercilii muscle, the depressor supercilii muscle, the auricular muscles (anterior, superior and posterior), the orbicularis oris muscle, the depressor anguli oris muscle, the risorius, the zygomaticus major muscle, the zygomaticus minor muscle, the levator labii superioris, the levator labii superioris alaeque nasi muscle, the depressor labii inferioris muscle, the levator anguli oris, the buccinator muscle, or the mentalis.
  • impaired blinking, dry eye syndrome, or wet eye syndrome can be treated by administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound, a myotoxin, or both) to the orbicularis muscle, the muscle of Riolan, Homer's muscle, the frontalis muscle, any one of the facial muscles, or a combination thereof.
  • a therapeutic composition of the disclosure e.g., comprising a PGE2 compound, a myotoxin, or both
  • a therapeutic composition of the disclosure e.g., comprising a PGE2 compound, a myotoxin, or both
  • methods of treating impaired blinking, dry eye syndrome, or wet eye syndrome may include administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound, and/or a myotoxin) to a subject in need thereof by topical administration, intradermal administration, intramuscular administration, or a combination thereof.
  • the therapeutic composition may be administered by intramuscular administration.
  • the intramuscular administration may comprise injection of an eye muscle.
  • the eye muscle may include any one of the orbicularis muscle, the muscle of Riolan, Homer's muscle, the frontalis muscle, or the facial mucles.
  • MuSCs muscle stem cells
  • the methods may comprise administering a therapeutic composition of the disclosure to a muscle that impacts a function of the lacrimal gland to treat impaired blinking associated with lacrimal gland dysfunction, such as lacrimal gland atrophy.
  • an anesthetic may be administered to an eye of the prior to injection of the therapeutic composition.
  • the eyelid muscle may be injected with surgical exposure; in other cases, the eyelid muscle may be injected without surgical exposure.
  • a 27-, 28-, 29- or 30-gauge needle may be used to inject the eyelid muscle.
  • methods of treating impaired blinking, dry eye syndrome, wet eye syndrome, or a combination thereof may include administering (e.g., intramuscular injection) a therapeutic composition of the disclosure to an eye muscle of a subject in need thereof, in a volume of about 0.01 mL to about 0.15 mL.
  • the eye muscle may be injected with at least about 0.01 mL of a therapeutic composition of the disclosure.
  • the eye muscle may be injected with at most about 0.15 mL of a therapeutic composition of the disclosure.
  • the eye muscle may be injected with greater than 0.01 mL, greater than 0.02 mL, greater than 0.03 mL, greater than 0.04 mL, greater than 0.05 mL, greater than 0.06 mL, greater than 0.07 mL, greater than 0.08 mL, greater than 0.09 mL, greater than 0.10 mL, greater than 0.11 mL, greater than 0.12 mL, greater than 0.13 mL, or greater than 0.14 mL of a therapeutic composition of the disclosure.
  • the effectiveness of an administration of a therapeutic composition may be determined by conducting tests before administration, after administration, or both.
  • a fluorescein and Lissamine green staining test, optical coherence tomography of the tear film (OCT), or both may be conducted.
  • OCT optical coherence tomography of the tear film
  • a visual acuity measurement, a slit lamp exam, measurement of tear film break-up time (TBUT), measurement of rate of tear production (Schirmer test), measurement of concentration of tears (osmolality), or a combination thereof may be conducted.
  • the test may involve measuring levels of inflammatory or growth factor molecules including, without limitation, MMP-9, lactoferrin, and NGF-1.
  • a dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound, the myotoxin, or both may increase.
  • the dose of the PGE2 compound, the myotoxin, or both may decrease.
  • the dose of the PGE2 compound, the myotoxin, or both may not change.
  • the frequency of administration of a therapeutic composition of the disclosure e.g., comprising a PGE2 compound and/or a myotoxin
  • the frequency of administration may be increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration may be decreased after determining the effectiveness of a prior administration.
  • the eyelid protects the eye from foreign objects.
  • the eyelid does not lie properly on the eye.
  • entropion is the turning in of an edge of an eyelid. In some cases, it causes the lashes of the eye to rub against the eye. This can result in excessive tearing, eye discomfort, eye pain, eye irritation, eye redness, and in some extreme cases, cornea damage and decreased vision.
  • causes of entropion may include weakening of eye muscles, especially the muscles in the lower part of the eye.
  • Ectropion is the turning out of the eyelid so that the inner surface is exposed.
  • ectropian may cause dry, painful eyes, excessive tearing of the eye (epiphora), chronic conjunctivitis, keratitis, eye redness, or a combination thereof.
  • ectropion may be due to weakening of the eyelid due to the aging process, facial palsy, and the like.
  • methods are provided for the treatment of entropion, ectropion, or both.
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing entropion or ectropion.
  • the methods of treating entropion or ectropion may involve administering a therapeutic composition of the disclosure to an eye muscle of a subject in need thereof.
  • the eyelid muscle may be the orbicularis, the frontalis muscles, or any of the facial muscles.
  • the facial muscles may include the occipitofrontalis muscle, the temporoparietalis muscle, the procerus muscle, the nasalis muscle, the depressor septi nasi muscle, the orbicularis oculi muscle, the corrugator supercilii muscle, the depressor supercilii muscle, the auricular muscles (anterior, superior and posterior), the orbicularis oris muscle, the depressor anguli oris muscle, the risorius, the zygomaticus major muscle, the zygomaticus minor muscle, the levator labii superioris, the levator labii superioris alaeque nasi muscle, the depressor labii inferioris muscle, the levator anguli oris, the buccinator muscle, or the mentalis.
  • the therapeutic composition may be administered in combination with eyelid surgery (e.g., lateral tarsal strip procedure).
  • eyelid surgery e.g., lateral tarsal strip procedure
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof.
  • the therapeutic composition may be administered without eye surgery.
  • the methods provided herein may include administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject in need thereof by topical administration, intradermal administration, intramuscular administration, or a combination thereof.
  • the therapeutic composition may be administered by intramuscular administration.
  • the intramuscular administration comprises injection of an eye muscle.
  • the eye muscle may comprise any of the orbicularis muscle, the frontalis muscle, or the facial muscles.
  • an anesthetic may be administered to an eye of a subject in need prior to injection.
  • the eye muscle may be injected with surgical exposure; in other cases, the eye muscle may be injected without surgical exposure.
  • a 27-, 28-, 29- or 30-gauge needle may be used to inject the eye muscle.
  • methods of treating ectropion, entropion, or both may include administering (e.g., intramuscular injection) a therapeutic composition of the disclosure to an eye muscle of a subject in need thereof, in a volume of about 0.01 mL to about 0.15 mL.
  • the eye muscle may be injected with at least about 0.01 mL of a therapeutic composition of the disclosure.
  • the eye muscle may be injected with at most about 0.15 mL of a therapeutic composition of the disclosure.
  • the eye muscle is injected with greater than 0.01 mL, greater than 0.02 mL, greater than 0.03 mL, greater than 0.04 mL, greater than 0.05 mL, greater than 0.06 mL, greater than 0.07 mL, greater than 0.08 mL, greater than 0.09 mL, greater than 0.10 mL, greater than 0.11 mL, greater than 0.12 mL, greater than 0.13 mL, or greater than 0.14 mL of a therapeutic composition of the disclosure.
  • the effectiveness of an administration of a therapeutic composition of the disclosure may be determined by conducting tests before administration, after administration, or both.
  • the tests may include an examination of the eye, the eyelid, or a combination thereof.
  • the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound, the myotoxin, or both may be increased.
  • the dose of the PGE2 compound, the myotoxin, or both may be decreased.
  • the dose of the PGE2 compound, the myotoxin, or both may not change.
  • the frequency of administration of a therapeutic composition of the disclosure may be adjusted after determining the effectiveness of an administration of the therapeutic composition (e.g., to treat ectropion, entropion, or both).
  • an administration of the therapeutic composition e.g., to treat ectropion, entropion, or both.
  • only a single administration of the therapeutic composition may be needed to treat entropion or ectropion.
  • two, three, four, five, or more than five administrations of the therapeutic composition may be needed to treat entropion or ectropion.
  • the frequency of administration may be increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration may be decreased after determining the effectiveness of a prior administration.
  • the extraocular muscles comprise six muscles that control movement of the eye (lateral rectus, medial rectus, superior rectus, inferior rectus, superior oblique, and inferior oblique) and one muscle (levator palpebrae) that controls eyelid elevation. Damage or injury to, weakening of, or improper innervation of any one of these extraocular muscles can result in an ocular disorder or disease, and reduced visual function.
  • a therapeutic composition of the disclosure e.g., comprising a PGE2 compound and/or a myotoxin.
  • the therapeutic composition may be administered to at least one extraocular muscle, e.g., lateral rectus, medial rectus, superior rectus, inferior rectus, superior oblique, inferior oblique, or levator palpebrae.
  • the methods may comprise administering a therapeutic composition of the disclosure to an extraocular muscle of a subject in need thereof to induce muscle regeneration.
  • Strabismus is an ocular disorder in which both eyes do not line up in the same direction. As a result, the eyes do not look at the same object at the same time.
  • the condition is more commonly known as “crossed eyes”.
  • Six different extraocular muscles (lateral rectus, medial rectus, superior rectus, inferior rectus, superior oblique and inferior oblique) surround each eye and work together to allow both eyes to focus on the same object. In a patient having strabismus, these muscles do not work together. As a result, one eye looks at one object and the other eye turns in a different direction to focus on another object. In many cases, the cause of strabismus is unknown.
  • eye misalignment is observed at birth or shortly afterwards (congenital strabismus).
  • disorders associated with strabismus in children may include, without limitation, Apery Syndrome, Cerebral Palsy, Congenital Rubella, Hemangioma, Incontinentia Pigmenti Syndrome, Noonan Syndrome, Prader-Willi Syndrome, Retinopathy of Prematurity, Retinoblastoma, Traumatic Brain Injury and Trisomy 18. Strabismus can develop in adults and may be due to many different causes including, without limitation, botulism, diabetes, Graves Disease, Guillain-Barre Syndrome, injury to the eye, shellfish poisoning, stroke, traumatic brain injury and vision loss from an eye disease or injury.
  • methods are provided for treating strabismus or congenital strabismus.
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing strabismus or congenital strabismus.
  • the therapeutic composition may treat strabismus or congenital strabismus by inducing muscle regeneration in at least one of the extraocular muscles, e.g., lateral rectus, medial rectus, superior rectus, inferior rectus, superior oblique, and inferior oblique.
  • the methods may comprise administering a therapeutic composition of the disclosure to any of the lateral rectus muscle, the medial rectus muscle, the superior rectus muscle, the inferior rectus muscle, the superior oblique muscle, and the inferior oblique muscle.
  • each eye muscle may have a width of about 5 mm to about 7 mm, a length of about 10 mm, and a thickness of less than or equal to 1 mm.
  • a therapeutic composition of the disclosure may be administered in combination with eye muscle surgery to treat strabismus or congenital strabismus.
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof.
  • the therapeutic composition may be administered without eye muscle surgery to treat strabismus or congenital strabismus.
  • a therapeutic composition of the disclosure may be administered by injection of an extraocular muscle (e.g., lateral rectus, medial rectus, superior rectus, inferior rectus, superior oblique, and inferior oblique) for the treatment of strabismus or congenital strabismus.
  • an extraocular muscle e.g., lateral rectus, medial rectus, superior rectus, inferior rectus, superior oblique, and inferior oblique
  • a therapeutic composition of the disclosure may be administered via slow drug release in a drug releasing depot, by gene therapy methods that may include a cell matrix depot that produces a composition of the disclosure (e.g., a PGE2 compound, a myotoxin), or a polymeric implant placed near or adjacent to the muscles.
  • a local anesthetic, an ocular decongestant, or both may be administered to an eye of a subject in need thereof prior to injection of the extraocular muscle.
  • the extraocular muscle may be injected with surgical exposure; in other cases, the extraocular muscle may be injected without surgical exposure.
  • the extraocular muscle may be injected with electromyographic guidance; in other embodiments, the extraocular muscle may be injected without electromyographic guidance.
  • a 27-, 28-, 29- or 30-gauge needle may be used to inject the extraocular muscle.
  • one or more extraocular muscles can be injected as needed.
  • extraocular muscles in both eyes can be injected to correct the misalignment.
  • methods of treating strabismus may include administering (e.g., intramuscular injection) a therapeutic composition of the disclosure to an extraocular eye muscle of a subject in need thereof, in a volume of about 0.05 mL to about 0.15 mL.
  • the extraocular muscle may be injected with at least about 0.05 mL of the therapeutic composition.
  • the extraocular muscle may be injected with at most about 0.15 mL of the therapeutic composition.
  • the extraocular muscle may be injected with greater than 0.05 mL, greater than 0.06 mL, greater than 0.07 mL, greater than 0.08 mL, greater than 0.09 mL, greater than 0.10 mL, greater than 0.11 mL, greater than 0.12 mL, greater than 0.13 mL, or greater than 0.14 mL of the therapeutic composition.
  • the effectiveness of an administration of a therapeutic composition of the disclosure may be determined by conducting tests before administration, after administration, or both. In some cases, the tests may determine how much the eyes are out of alignment. In some embodiments, a corneal light reflex test, a cover/uncover test, a retinal exam, an ophthalmic exam, visual acuity, or a combination thereof, may be conducted. In some cases, the effectiveness of an administration of the therapeutic composition can be determined by changes in the alignment of the eyes before administration and after administration. In some embodiments, the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound, the myotoxin, or both may be increased. In other cases, the dose of the PGE2 compound, the myotoxin, or both may be decreased. In some cases, the dose of the PGE2 compound, the myotoxin, or both, may not be changed.
  • the frequency of administration of a therapeutic composition of the disclosure may be adjusted after determining the effectiveness of an administration of the therapeutic composition (e.g., to treat strabismus). In some cases, only a single administration of the therapeutic composition may be needed to treat strabismus. In some cases, two, three, four, five, or more than five administrations of the therapeutic composition may be needed. In some cases, the frequency of administration may be increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration may be decreased after determining the effectiveness of a prior administration.
  • Nystagmus or eye tremor
  • the movement may be from side to side (horizontal nystagmus); up and down (vertical nystagmus), or rotary (rotary or torsional nystagmus).
  • the movement may be in one eye. In other cases, the movement may be in both eyes.
  • nystagmus may be present at birth (Infantile Nystagmus Syndrome (INS)).
  • INS Infantile Nystagmus Syndrome
  • nystagmus may be caused by a congenital disease of the eye.
  • nystagmus may be acquired through a variety of causes including intake of certain drugs or medications (e.g., phenytoin), excessive alcohol, a sedating medicine that can impair a function of the labyrinth, head injury, an inner ear disorder (e.g., labyrinthis or Meniere disease), stroke, and thiamine or vitamin B12 deficiency.
  • drugs or medications e.g., phenytoin
  • excessive alcohol e.g., alcohol
  • a sedating medicine that can impair a function of the labyrinth
  • head injury e.g., head injury
  • an inner ear disorder e.g., labyrinthis or Meniere disease
  • stroke thiamine or vitamin B12 deficiency
  • thiamine or vitamin B12 deficiency thiamine or vitamin B12 deficiency
  • eye tremors may be secondary to other disorders such as Parkinson's disease.
  • nystagmus is horizontal nystagmus, vertical nystagmus, rotary or torsional nystagmus, or any combination thereof.
  • nystagmus is Infantile Nystagmus Syndrome.
  • the methods comprise a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing nystagmus.
  • the therapeutic composition may treat nystagmus by inducing muscle regeneration in at least one of the extraocular muscles, e.g., lateral rectus, medial rectus, superior rectus, inferior rectus, superior oblique, and inferior oblique.
  • the therapeutic composition may be administered to at least one of the extraocular muscles, e.g., lateral rectus, medial rectus, superior rectus, inferior rectus, superior oblique, and inferior oblique, for the treatment of nystagmus.
  • the iris Located between the cornea and the lens, the iris comprises a sphincter muscle (sphincter pupillae) and dilator muscles (dilator pupillae).
  • the round, central opening of the iris is called the pupil.
  • the iris modulates the size of the pupil to control how much light comes into the eye. Impairment of the iris can result in impaired visual function.
  • methods are provided for treating impaired visual function.
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin), to a subject having, suspected of having, or at risk of developing impaired visual function.
  • the therapeutic composition may treat impaired visual function by inducing muscle regeneration of an iris muscle.
  • the iris muscle may be the sphincter muscle, the dilator muscle, or both.
  • the therapeutic composition may be administered topically, intradermally, or intraocularly to a subject in need thereof.
  • the therapeutic composition may be administered by intramuscular administration to a muscle of the iris (e.g., the sphincter muscle, the dilator muscle).
  • the effectiveness of the treatment may be determined by observing changes in light sensitivity before administration, after administration, or both.
  • the ciliary body is a circular structure that contains the ciliary muscle.
  • the ciliary muscle changes the shape of the lens when the eye focuses on a near object in a process called accommodation.
  • Presbyopia is a condition in which the lens of the eye loses its ability to focus, making it hard to see objects up close.
  • Presbyopia is thought to be a natural part of the aging process.
  • One approach to treating presbyopia may be to induce muscle regeneration of the ciliary muscle.
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing presbyopia.
  • the therapeutic composition may treat presbyopia by inducing muscle regeneration of the ciliary muscle.
  • the effectiveness of the treatment can be determined by performing a reading test before administration, after administration, or both.
  • methods are provided for treating myopia, or to modulate regression of myopia.
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing myopia, or to a subject to modulate regression of myopia.
  • the therapeutic composition may be administered to an eye muscle, such as the ciliary muscle, a muscle in the sclera, a muscle around the sclera, or an intraocular muscle.
  • Oculopharyngeal muscular dystrophy is a genetic disorder characterized by slowly progressing muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat. Onset is typically during adulthood, most often between 40 and 60 years of age. Symptoms may include, without limitation: eyelid drooping (ptosis), arm and leg weakness, and difficulty swallowing (dysphagia).
  • myopathy slowly progressing muscle disease
  • Symptoms may include, without limitation: eyelid drooping (ptosis), arm and leg weakness, and difficulty swallowing (dysphagia).
  • methods are provided for treating oculopharyngeal muscular dystrophy.
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing oculopharyngeal muscular dystrophy.
  • treating oculopharyngeal muscular dystrophy may involve administering the therapeutic composition to the muscles of the upper eyelid, the muscles of the throat, or both.
  • the therapeutic composition can be administered to a subject in need thereof to treat a musculoskeletal disorder.
  • the musculoskeletal disorder is a muscle disorder.
  • the therapeutic composition can be administered to a subject in need thereof to improve a function of the musculoskeletal system.
  • the therapeutic composition can be administered to a subject in need thereof to augment effectiveness of an existing treatment of a disorder or disease of the musculoskeletal system such as carpometacarpal arthroplasty.
  • Impaired function of the musculoskeletal system may be due to different factors.
  • the muscle disorder may be due to aging.
  • sarcopenia is the degenerative loss of skeletal muscle mass, varying from 0.5% to 1% muscle loss per year after the age of 50, and is associated with aging.
  • the muscle disorder may be due to disuse of the affected muscle.
  • disuse may be due to immobilization (e.g., a splint, a cast).
  • disuse may be due to pain (e.g., arthritis).
  • the muscle disorder may be muscle atrophy as a result of denervation. Diseases that affect lower motor neurons may impair innervation of myofibers resulting in muscle atrophy.
  • the muscle disorder may be due to metabolic reasons, such as glucocorticoid-induced muscle atrophy.
  • excess alcohol intake can result in alcoholic myopathy.
  • chronic diabetes mellitus can damage the nerves that innervate the hands and feet, resulting in diabetic amyotrophy.
  • Other causes of impaired muscle function may include trauma, and muscle-related degenerative diseases.
  • Provided herein are methods of treating a muscle disorder due to any of the causes described herein.
  • the methods comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin).
  • methods are provided for treating impaired hand function.
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., a PGE2 compound and/or a myotoxin) to a subject in need thereof.
  • a therapeutic composition of the disclosure e.g., a PGE2 compound and/or a myotoxin
  • the subject is greater than 50 years old, greater than 55 years old, greater than 60 years old, greater than 65 years, or greater than 70 years old.
  • the impaired hand function may be a result of aging.
  • the therapeutic composition may treat the impaired hand function by inducing muscle regeneration in a hand muscle of the subject.
  • the hand muscle may be an intrinsic muscle.
  • An intrinsic muscle may include any of the following, without limitation: the three thenar muscles, the three hypothenar muscles, the interossei muscles, the lumbrical muscles, the palmaris brevis, and the adductor pollicis.
  • the hand muscle is an extrinsic muscle.
  • An extrinsic muscle may include any of the following, without limitation: abductor pollicis longus, extensor pollicis brevis, flexor pollicis longus, flexor carpi radialis, flexor digitorum profundus, four flexor digitorum superficialis, flexor carpi ulnaris, extensor carpi radialis longus, extensor carpi radialis brevis, extensor indicis, extensor digitorum communis, extensor digiti minimi, and extensor carpi ulnaris.
  • the therapeutic composition may be administered in combination with hand surgery (e.g., closed reduction and fixation surgery, tendon repair, nerve repair, surgical drainage and/or debridement, or joint replacement).
  • hand surgery e.g., closed reduction and fixation surgery, tendon repair, nerve repair, surgical drainage and/or debridement, or joint replacement.
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof.
  • the therapeutic composition may be administered without hand surgery.
  • a therapeutic composition of the disclosure may be administered by topical administration, intradermal administration, intramuscular administration, or a combination thereof.
  • the therapeutic composition may be administered by intramuscular administration.
  • the intramuscular administration may comprise injection of a hand muscle.
  • the hand muscle may include any one of the following: thenar muscle, a hypothenar muscle, an interossei muscle, a lumbrical muscle, palmaris brevis, adductor pollicis abductor pollicis longus, flexor pollicis longus, flexor carpi radialis, flexor digitorum profundus, four flexor digitorum superficialis, flexor carpi ulnaris, extensor pollicis brevis, extensor carpi radialis longus, extensor carpi radialis brevis, extensor indicis, extensor digitorum communis, extensor digiti minimi, or extensor carpi ulnaris.
  • an anesthetic may be administered to a hand of a subject prior to injection of a therapeutic composition.
  • the hand muscle may be injected with surgical exposure; in other cases, the hand muscle may be injected without surgical exposure.
  • a 20-, 21-, 22-, 23-, 24- or 25-gauge needle may be used to inject the hand muscle.
  • methods of treating impaired hand function may include administering (e.g., intramuscular injection) a therapeutic composition of the disclosure to a hand muscle of a subject in need thereof, in a volume of about 0.01 mL to about 0.15 mL.
  • the hand muscle is injected with at least about 0.01 mL of the therapeutic composition.
  • the hand muscle is injected with at most about 0.15 mL of the therapeutic composition.
  • the hand muscle is injected with greater than 0.01 mL, greater than 0.02 mL, greater than 0.03 mL, greater than 0.04 mL, greater than 0.05 mL, greater than 0.06 mL, greater than 0.07 mL, greater than 0.08 mL, greater than 0.09 mL, greater than 0.10 mL, greater than 0.11 mL, greater than 0.12 mL, greater than 0.13 mL, or greater than 0.14 mL of the therapeutic composition.
  • the effectiveness of an administration of a therapeutic composition of the disclosure may be determined by conducting tests before administration, after administration, or both.
  • the test may measure a hand function before administration, after administration, or both.
  • the test may be a maximum pinch force test, a steadiness pinch force test, a pegboard test, a two-point discrimination test, a precision pinch steadiness test, a handgrip force test, or a combination thereof.
  • the dose of a therapeutic composition of the disclosure may be adjusted after determining the effectiveness of a prior administration (e.g., to treat impaired hand function).
  • the dose of the PGE2 compound, the myotoxin, or both may be increased.
  • the dose of the PGE2 compound, the myotoxin, or both may be decreased.
  • the dose of the PGE2 compound, the myotoxin, or both may not be changed.
  • the frequency of administration of a therapeutic composition of the disclosure may be adjusted after determining the effectiveness of an administration of the therapeutic composition.
  • a therapeutic composition of the disclosure e.g., comprising a PGE2 compound and/or a myotoxin
  • the frequency of administration may be increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration may be decreased after determining the effectiveness of a prior administration.
  • a subject in need thereof may be identified by a test prior to administration of the therapeutic composition.
  • the test may be a maximum pinch force test, a steadiness pinch force test, a pegboard test, a two-point discrimination test, a precision pinch steadiness test, a handgrip force test, or a combination thereof.
  • Compression peripheral nerve injuries are a category of nerve injury caused by constriction of the nerve.
  • Carpal tunnel syndrome is the most common peripheral compression neuropathy, resulting from median nerve compression at the wrist. Symptoms of carpal tunnel syndrome may include sensory impairments (e.g., numbness and paresthesias) and motor deficits in the abductor pollicis brevis (APB), opponens pollicis, and the superficial belly of the flexor pollicis brevis, which are the intrinsic median-innervated thenar muscles. Prolonged compression of the median nerve potentially disturbs motor function of the thenar muscles, and in patients with severe carpal tunnel syndrome, atrophy of the thenar muscles may result.
  • methods are provided for the treatment of impaired thumb function.
  • the methods comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing impaired thumb function.
  • the impaired thumb function is due to thenar atrophy.
  • the therapeutic composition may treat impaired thumb function by inducing muscle regeneration in a hand muscle of a subject.
  • the therapeutic composition in administered to a hand muscle of the subject for the treatment of impaired thumb function.
  • the hand muscle is the abductor pollicis brevis (APB), the opponens pollicis, or flexor pollicis brevis.
  • the hand muscle is the abductor pollicis brevis.
  • a therapeutic composition of the disclosure may administered in combination with hand surgery to treat impaired thumb function.
  • the hand surgery may be carpel tunnel syndrome surgery.
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof. In other embodiments, the therapeutic composition may be administered without hand surgery.
  • a therapeutic composition of the disclosure may be administered by topical administration, intradermal administration, intramuscular administration, or a combination thereof for the treatment of impaired thumb function.
  • the therapeutic composition may be administered by intramuscular administration.
  • the intramuscular administration comprises injection of a hand muscle.
  • the hand muscle may comprise a thenar muscle.
  • the hand muscle may comprise the abductor pollicis brevis (APB), the opponens pollicis, or flexor pollicis brevis.
  • the hand muscle may be the abductor pollicis brevis.
  • an anesthetic may be administered to a hand of a subject in need thereof prior to injection of a therapeutic composition of the disclosure.
  • the hand muscle may be injected with surgical exposure; in other cases, the hand muscle may be injected without surgical exposure.
  • a 20-, 21-, 22-, 23-, 24- or 25-gauge needle may be used to inject the hand muscle.
  • methods of treating impaired thumb function may include administering (e.g., intramuscular injection) a therapeutic composition of the disclosure to a hand muscle of a subject in need thereof, in a volume of about 0.01 mL to about 0.15 mL.
  • the hand muscle may be injected with at least about 0.01 mL of the therapeutic composition.
  • the hand muscle may be injected with at most about 0.15 mL of the therapeutic composition.
  • the hand muscle may be injected with greater than 0.01 mL, greater than 0.02 mL, greater than 0.03 mL, greater than 0.04 mL, greater than 0.05 mL, greater than 0.06 mL, greater than 0.07 mL, greater than 0.08 mL, greater than 0.09 mL, greater than 0.10 mL, greater than 0.11 mL, greater than 0.12 mL, greater than 0.13 mL, or greater than 0.14 mL of the therapeutic composition.
  • the effectiveness of an administration of a therapeutic composition of the disclosure may be determined by conducting tests before administration, after administration, or both.
  • the test may measure a hand function before administration, after administration, or both.
  • the test may be a tip pinch strength test, a Moberg pickup test, or both.
  • the test may be a patient-centric overall quality of life measure such as the Canadian Occupational Performance Measure (COPM).
  • COPM Canadian Occupational Performance Measure
  • the dose of a therapeutic composition of the disclosure may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound, the myotoxin, or both may be increased.
  • the dose of the PGE2 compound, the myotoxin, or both may be decreased.
  • the dose of the PGE2 compound, the myotoxin, or both may not be changed.
  • the frequency of administration of a therapeutic composition of the disclosure may be adjusted after determining the effectiveness of an administration of the therapeutic composition.
  • a therapeutic composition of the disclosure e.g., comprising a PGE2 compound and/or a myotoxin
  • the frequency of administration may be increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration may be decreased after determining the effectiveness of a prior administration.
  • a subject having, suspected of having, or at risk of having impaired thumb function may be identified by a test prior to administration of a therapeutic composition of the disclosure.
  • the test may be a tip pinch strength test, a Moberg pickup test, or both.
  • methods are provided for the treatment of muscle impairment caused by compression peripheral nerve injuries.
  • the methods comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing a compression peripheral nerve injury.
  • a therapeutic composition of the disclosure e.g., comprising a PGE2 compound and/or a myotoxin
  • cubital tunnel syndrome results from ulnar nerve entrapment at the elbow and is the second most common entrapment of the upper limb.
  • Ulnar nerve compression results in pain or paraesthesia in the fourth and fifth finger.
  • muscle atrophy is a common result of ulnar nerve compression.
  • thoracic outlet syndrome results from compression of the nerves between the shoulder and neck, known as the brachial plexus. This can cause pain, weakness, numbness, tingling, a cold sensation, or sometimes a more general type of discomfort in one or both upper limbs.
  • the common symptoms are pain, numbness, and tingling that radiates below the shoulder down towards the hand and usually into the pinky and ring finger. This condition also can lead to muscle atrophy of the intrinsic muscles of the hand.
  • the plantar fascia is the thick tissue on the bottom of the foot. It connects the heel bone to the toes and creates the arch of the foot. When this tissue becomes swollen or inflamed, it is called plantar fasciitis. Plantar fasciitis is one of the most common causes of heel pain and has been estimated to affect about two million people in the US, resulting in more than one million visits to both primary care physicians and foot specialists. Plantar fasciitis affects both sedentary and athletic people and is thought to result from chronic overload either from lifestyle or exercise. Current literature suggests that plantar fasciitis is more correctly termed fasciosis because of the chronicity of the disease and the evidence of degeneration rather than inflammation.
  • Muscle weakness may be a potential cause of chronic plantar fasciitis.
  • PIFM plantar intrinsic foot muscles
  • TP tibialis posterior
  • the forefoot muscles include flexor hallucis brevis medialis, flexor hallucis brevis lateralis, adductor hallucis transverse, adductor hallucis oblique and the plantar interossei.
  • Patients with abductor digiti minimi atrophy also have a significantly greater frequency of Achilles tendinosis, calcaneal edema, calcaneal spur, plantar fasciitis, and posterior tibialis tendon dysfunction than those without. Additionally, strengthening a weakened or atrophied flexor digitorum brevis could also help stabilize the medial longitudinal arch.
  • methods are provided for the treatment of impaired foot function.
  • the methods comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing impaired foot function.
  • the impaired foot function is due to plantar fasciitis.
  • the therapeutic composition may be suitable to treat plantar fasciitis.
  • the therapeutic composition may treat the impaired foot function by inducing muscle generation in a foot muscle of a subject in need thereof.
  • the foot muscle is a plantar intrinsic foot muscle, flexor hallucis medialis, flexor hallucis brevis lateralis, adductor hallucis transverse, adductor hallucis oblique, dorsal and plantar interossei, abductor digiti minimi, and flexor digitorum brevis.
  • a therapeutic composition of the disclosure may be administered in combination with foot surgery.
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof.
  • the therapeutic composition may be administered without foot surgery.
  • the therapeutic composition may be administered in combination with another treatment.
  • the another treatment comprises a nonsteroidal anti-inflammatory medication, stretching, a night splint, custom orthotics, a corticosteroid injection, a platelet-rich plasma injection, extracorporeal shock wave therapy, fasciotomy, or a combination thereof.
  • a therapeutic composition of the disclosure may be administered by topical administration, intradermal administration, intramuscular administration, or a combination.
  • the therapeutic composition may be administered by intramuscular administration.
  • the intramuscular administration may comprise injection of a foot muscle.
  • the foot muscle may comprise plantar intrinsic foot muscle, flexor hallucis medialis, flexor hallucis brevis lateralis, adductor hallucis transverse, adductor hallucis oblique, dorsal and plantar interossei, abductor digiti minimi, and flexor digitorum brevis.
  • an anesthetic may be administered to a foot to a subject in need thereof prior to injection of a therapeutic composition of the disclosure.
  • the foot muscle may be injected with surgical exposure; in other cases, the foot muscle may be injected without surgical exposure.
  • a 20-, 21-, 22-, 23-, 24- or 25-gauge needle may be used to inject the foot muscle.
  • methods of treating impaired foot function may include administering (e.g., intramuscular injection) a therapeutic composition of the disclosure to a foot muscle of a subject in need thereof, in a volume of about 0.01 mL to about 0.15 mL.
  • the foot muscle may be injected with at least about 0.01 mL of the therapeutic composition.
  • the foot muscle may be injected with at most about 0.15 mL of the therapeutic composition.
  • the foot muscle may be injected with greater than 0.01 mL, greater than 0.02 mL, greater than 0.03 mL, greater than 0.04 mL, greater than 0.05 mL, greater than 0.06 mL, greater than 0.07 mL, greater than 0.08 mL, greater than 0.09 mL, greater than 0.10 mL, greater than 0.11 mL, greater than 0.12 mL, greater than 0.13 mL, or greater than 0.14 mL of the therapeutic composition.
  • the effectiveness of an administration of a therapeutic composition of the disclosure may be determined by conducting tests before administration, after administration, or both.
  • the tests may measure a foot function before administration, after administration, or both.
  • the test may be a physical exam to determine pain on the bottom of a foot, pain along the sole of a foot, flat feet, high arches, foot swelling, foot redness, stiffness or tightness of the arch in the bottom of a foot, or a combination thereof.
  • the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound, the myotoxin, or both may be increased.
  • the dose of the PGE2 compound, the myotoxin, or both may be decreased.
  • the dose of the PGE2 compound, the myotoxin, or both may not be changed.
  • the frequency of administration of a therapeutic composition of the disclosure to treat impaired foot may be adjusted after determining the effectiveness of an administration of the therapeutic composition. In some cases, only a single administration of the therapeutic composition may be needed to treat impaired foot function. In some cases, two, three, four, five, or more than five administrations of the therapeutic composition may be needed to treat impaired foot function. In some cases, the frequency of administration is increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration is decreased after determining the effectiveness of a prior administration.
  • a subject in need of treatment for impaired foot function may be identified by a test prior to administration of the therapeutic composition.
  • the test may be a physical exam to determine pain on the bottom of a foot, pain along the sole of a foot, flat feet, high arches, foot swelling, foot redness, stiffness or tightness of the arch in the bottom of a foot, or a combination thereof.
  • Foot drop also known as drop foot
  • foot drop foot is a term for difficulty lifting the front part of the foot.
  • the front of the foot may drag on the ground during walking. Foot drop impairs ambulation and can result in falls.
  • Foot drop is caused by weakness or paralysis of one or more of the muscles involved in lifting the front part of the foot.
  • compression of a nerve in a leg that controls the muscles involved in lifting the foot, the peroneal nerve is a common cause of foot drop. This nerve may also be injured during hip or knee replacement surgery.
  • a nerve root injury, “pinched nerve”, in the spine can also cause foot drop.
  • Diabetes may also make a subject more susceptible to nerve disorders, which are associated with foot drop.
  • Various forms of muscular dystrophy that cause progressive muscle weakness.
  • disorders that affect the spinal cord or brain such as amyotrophic lateral sclerosis (ALS), multiple sclerosis or stroke, may cause foot drop.
  • ALS amyotrophic lateral sclerosis
  • Described herein are methods of treating foot drop comprising administering a therapeutic composition comprising a PGE2 compound and a myotoxin to a subject in need thereof.
  • the therapeutic composition treats the impaired foot function by inducing muscle generation in a foot or lower leg muscle of a subject in need thereof.
  • the foot or lower leg muscle is the anterior tibialis muscle, fibularis tertius, extensor digitorum longus, extensor hallucis longus, or a combination thereof.
  • the therapeutic composition is administered in combination with surgery (e.g., nerve surgery).
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof.
  • the therapeutic composition is administered without foot or lower leg surgery.
  • the therapeutic composition is administered in combination with another treatment.
  • the another treatment comprises braces or splints, physical therapy, nerve stimulation, nerve surgery, or a combination thereof.
  • the therapeutic composition comprising a PGE2 compound and a myotoxin is administered by topical administration, intradermal administration, intramuscular administration, or a combination.
  • the therapeutic composition is administered by intramuscular administration.
  • the intramuscular administration comprises injection of a foot or lower leg muscle.
  • the foot or lower leg muscle may comprise the anterior tibialis muscle, fibularis tertius, extensor digitorum longus, extensor hallucis longus.
  • an anesthetic may be administered to a foot or lower leg of a subject in need prior to injection.
  • the foot or lower leg muscle is injected with surgical exposure; in other cases, the foot or lower leg muscle is injected without surgical exposure.
  • a 20-, 21-, 22-, 23-, 24- or 25-gauge needle is used to inject the foot or lower leg muscle.
  • a foot or lower leg muscle of a subject in need is injected with a volume of about 0.01 mL to about 0.15 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the foot or lower leg muscle is injected with at least about 0.01 mL of therapeutic composition.
  • the foot or lower leg muscle is injected with at most about 0.15 mL of therapeutic composition.
  • the foot or lower leg muscle is injected with greater than 0.01 mL, greater than 0.02 mL, greater than 0.03 mL, greater than 0.04 mL, greater than 0.05 mL, greater than 0.06 mL, greater than 0.07 mL, greater than 0.08 mL, greater than 0.09 mL, greater than 0.10 mL, greater than 0.11 mL, greater than 0.12 mL, greater than 0.13 mL, or greater than 0.14 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the effectiveness of an administration of the therapeutic composition may be determined by conducting tests before administration, after administration, or a combination thereof.
  • the tests may measure a foot or lower leg function before and/or after administration.
  • the test may be a physical exam to observe gait, to determine weakness of leg muscles, to determine numbness of shin, foot, and/or toes, or a combination thereof.
  • the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound and/or the myotoxin may increase.
  • the dose of the PGE2 compound and/or the myotoxin may decrease.
  • the dose of the PGE2 compound and/or the myotoxin may stay the same.
  • the frequency of administration of the therapeutic composition comprising a PGE2 compound and/or the myotoxin may be adjusted after determining the effectiveness of an administration of the therapeutic composition.
  • a single administration of the therapeutic composition is needed to treat impaired foot or lower leg function.
  • two or more, three or more, four or more, five or more administrations of the therapeutic composition are needed.
  • the frequency of administration is increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration is decreased after determining the effectiveness of a prior administration.
  • Diabetes is the most common cause of neuropathy in US and neuropathies are the most common complication of diabetes mellitus. Atrophy of the small muscles of the foot is common in diabetes and is related to peripheral motor neuropathy. In long-term diabetic patients, muscle weakness and atrophy in the lower leg muscles, including the foot muscles, is common in neuropathic patients compared to non-neuropathic patients. Volume of the intrinsic foot muscles has been shown to be lower in neuropathic diabetic patients compared to non-neuropathic diabetic patients and non-diabetic controls. Atrophy of the intrinsic muscles of the foot can lead to fixed claw and hammer toe deformities, which are common in neuropathic diabetic patients. Additionally, the intrinsic muscles of the foot stabilize the arches of the foot. High arches are common with the atrophy of plantar intrinsic muscles like Abductor Hallucis, Flexor Hallucis Brevis and Adductor Hallucis.
  • methods are provided for the treatment of diabetic neuropathy or associated disorders.
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing a diabetic neuropathy or an associated disorder.
  • the disorder associated with a diabetic neuropathy may include, without limitation, atrophy of the small muscles of the foot, muscle weakness and atrophy of the lower leg muscles, and atrophy of the intrinsic muscles of the foot.
  • the methods comprise administering the therapeutic composition to the small muscles of the foot, to the lower leg muscles, or to the intrinsic muscles of the foot.
  • Loss of skeletal muscle mass occurs frequently in clinical settings following limb immobilization, bed rest, spinal cord injury and partial/complete peripheral nerve damage, resulting in significant loss of muscle mass and force production.
  • the extent of muscle atrophy under disuse conditions is variable and can be dependent on a variety of factors including age, the physiological function and fiber type composition of the muscle, and the degree of unloading and inactivity. Disuse-induced atrophy will likely affect every person in his or her lifetime, and can be debilitating especially in the elderly.
  • Described herein are methods of treating disuse-induced muscle atrophy comprising administering a therapeutic composition comprising a PGE2 compound and a myotoxin to a subject in need thereof.
  • the affected muscle has experienced unloading, inactivity, or a combination, for greater than 1 day, greater than 5 days, greater than 10 days, greater than 50 days, or greater than 100 days.
  • the therapeutic composition treats disuse-induced atrophy by inducing muscle generation in a muscle of a subject in need thereof, wherein the muscle has experienced unloading and/or inactivity of a prolonged period of time.
  • the muscle is a skeletal muscle.
  • the therapeutic composition comprising a PGE2 compound and a myotoxin is administered by intramuscular administration. In some cases, the intramuscular administration comprises injection of the affected muscle.
  • disuse-induced muscle atrophy is due to a distal radius fracture, also known as Colles fracture.
  • a Colles fracture results in a backward and outward position of the hand in relation to the wrist. It is common in the elderly. Loss of muscle mass can occur due to immobilization.
  • Described herein are methods of treating muscle atrophy due to a distal radius fracture comprising administering a therapeutic composition comprising a PGE2 compound and a myotoxin to a subject in need thereof.
  • the therapeutic composition treats the muscle atrophy by inducing muscle generation in a muscle of a subject in need thereof.
  • the muscle is the flexor carpi radialis, flexor pollicis longus, flexor digitorum superficialis, flexor digitorum profundus, flexor carpi ulnaris, extensor carpi radialis brevis/longus, extensor pollicis longus, extensor digitiorum communis, extensor carpi ulnaris or a combination thereof.
  • the therapeutic composition is administered in combination with surgery (e.g., wrist arthroscopy). In those embodiments, the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof. In other embodiments, the therapeutic composition is administered without surgery.
  • the therapeutic composition is administered in combination with another treatment.
  • the another treatment comprises braces or splints, physical therapy, nerve stimulation, nerve surgery, or a combination thereof.
  • the therapeutic composition comprising a PGE2 compound and a myotoxin is administered by topical administration, intradermal administration, intramuscular administration, or a combination. In some cases, the therapeutic composition is administered by intramuscular administration. In some cases, the intramuscular administration comprises injection of a hand or lower arm muscle.
  • the hand or lower arm muscle may comprise the flexor carpi radialis, flexor pollicis longus, flexor digitorum superficialis, flexor digitorum profundus, flexor carpi ulnaris, extensor carpi radialis brevis/longus, extensor pollicis longus, extensor digitiorum communis, extensor carpi ulnaris, or a combination thereof.
  • an anesthetic may be administered to a hand or lower arm of a subject in need prior to injection.
  • the hand or lower arm muscle is injected with surgical exposure; in other cases, the hand or lower arm muscle is injected without surgical exposure.
  • a 20-, 21-, 22-, 23-, 24- or 25-gauge needle is used to inject the hand or lower arm leg muscle.
  • a hand or lower arm muscle of a subject in need is injected with a volume of about 0.01 mL to about 0.15 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the hand or lower arm muscle is injected with at least about 0.01 mL of therapeutic composition.
  • the hand or lower arm muscle is injected with at most about 0.15 mL of therapeutic composition.
  • the hand or lower arm muscle is injected with greater than 0.01 mL, greater than 0.02 mL, greater than 0.03 mL, greater than 0.04 mL, greater than 0.05 mL, greater than 0.06 mL, greater than 0.07 mL, greater than 0.08 mL, greater than 0.09 mL, greater than 0.10 mL, greater than 0.11 mL, greater than 0.12 mL, greater than 0.13 mL, or greater than 0.14 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the effectiveness of an administration of the therapeutic composition may be determined by conducting tests before administration, after administration, or a combination thereof.
  • the tests may measure a hand or lower arm function before and/or after administration.
  • the test may include range of motion of wrist, grip strength, patient reported outcomes such as the Disability of Arm Shoulder and Hand or a combination thereof.
  • the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound and/or the myotoxin may increase.
  • the dose of the PGE2 compound and/or the myotoxin may decrease.
  • the dose of the PGE2 compound and/or the myotoxin may stay the same.
  • the frequency of administration of the therapeutic composition comprising a PGE2 compound and/or the myotoxin may be adjusted after determining the effectiveness of an administration of the therapeutic composition.
  • a single administration of the therapeutic composition is needed to treat impaired hand or lower arm function.
  • two or more, three or more, four or more, five or more administrations of the therapeutic composition are needed.
  • the frequency of administration is increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration is decreased after determining the effectiveness of a prior administration.
  • disuse-induced muscle atrophy is due to a hip fracture.
  • a hip fracture may be due to major or minor trauma. In elderly people with bones weakened by osteoporosis, relatively little trauma, even walking, may result in a hip fracture. Loss of muscle mass can occur due to joint immobilization, and bed rest. Loss of muscle can be induced by a combination of unloading and inactivity. Weakness of the hip muscle is an often-occurring condition after displaced fractures of the proximal femur in older patients. Described herein are methods of treating muscle atrophy due to a hip fracture comprising administering a therapeutic composition comprising a PGE2 compound and a myotoxin to a subject in need thereof.
  • the therapeutic composition treats the muscle atrophy by inducing muscle generation in a hip muscle of a subject in need thereof.
  • the hip muscle is iliacus, psoas major, gluteus maximus, gluteus maximus, gluteus minimus, tensor fasciae latae, superior gemellus, inferior gemellus, obturator internus, obturator externus, quadratus femoris, piriformis, adductor magnus, adductor longus, adductor brevis, adductor minimus, pectineus, rectus femoris, vastus lateralis, vastus medialis, vastus intermedius, quadriceps femoris, Sartorius, biceps femoris, semitendinosus, semimembranosus, psoas minor, iliopsoas, gracilis, or a combination thereof.
  • the therapeutic composition is administered in combination with surgery (e.g., joint arthroplasty).
  • surgery e.g., joint arthroplasty
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof.
  • the therapeutic composition is administered without surgery.
  • the therapeutic composition is administered in combination with another treatment regimen.
  • the another treatment regimen comprises braces or splints, physical therapy, nerve stimulation, nerve surgery, or a combination thereof.
  • the therapeutic composition comprising a PGE2 compound and a myotoxin is administered by topical administration, intradermal administration, intramuscular administration, or a combination. In some cases, the therapeutic composition is administered by intramuscular administration. In some cases, the intramuscular administration comprises injection of a hip muscle.
  • the hip muscle is iliacus, psoas major, gluteus maximus, gluteus maximus, gluteus minimus, tensor fasciae latae, superior gemellus, inferior gemellus, obturator internus, obturator externus, quadratus femoris, piriformis, adductor magnus, adductor longus, adductor brevis, adductor minimus, pectineus, rectus femoris, vastus lateralis, vastus medialis, vastus intermedius, quadriceps femoris, Sartorius, biceps femoris, semitendinosus, semimembranosus, psoas minor, iliopsoas, gracilis, or a combination thereof.
  • an anesthetic may be administered to a hip of a subject in need prior to injection.
  • the hip muscle is injected with surgical exposure; in other cases, the hip muscle is injected without surgical exposure.
  • a 20-, 21-, 22-, 23-, 24- or 25-gauge needle is used to inject the hip muscle.
  • a hip muscle of a subject in need is injected with a volume of about 0.5 mL to about 5 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the hip muscle is injected with at least about 0.5 mL of therapeutic composition.
  • the hip muscle is injected with at most about 4 mL of therapeutic composition.
  • the hip muscle is injected with greater than 0.5 mL, greater than 1.0 mL, greater than 1.5 mL, greater than 2.0 mL, greater than 2.5 mL, greater than 3.0 mL, greater than 3.5 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the effectiveness of an administration of the therapeutic composition may be determined by conducting tests before administration, after administration, or a combination thereof.
  • the tests may measure a hip-related function before and/or after administration.
  • the test may be strength testing of hip and knee muscles as well as functional tests such as the get up and go test or a combination thereof.
  • the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound and/or the myotoxin may increase.
  • the dose of the PGE2 compound and/or the myotoxin may decrease.
  • the dose of the PGE2 compound and/or the myotoxin may stay the same.
  • the frequency of administration of the therapeutic composition comprising a PGE2 compound and/or the myotoxin may be adjusted after determining the effectiveness of an administration of the therapeutic composition.
  • a single administration of the therapeutic composition is needed to treat impaired hand or lower arm function.
  • two or more, three or more, four or more, five or more administrations of the therapeutic composition are needed.
  • the frequency of administration is increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration is decreased after determining the effectiveness of a prior administration.
  • disuse-induced muscle atrophy is due to a rotator cuff injury.
  • a rotator cuff injury may be due to an acute rotator cuff tear.
  • a rotator cuff injury may be due to degenerative and/or chronic rotator cuff tear.
  • a degenerative and/or chronic rotator cuff tear may be due to repetitive stress, lack of blood supply, bone spurs, or a combination thereof. People over 40 years old are at a greater risk for a rotator cuff tear. Loss of muscle mass can occur due to lack of tension on muscle as well as joint stiffness. Loss of muscle can be induced by a combination of unloading and inactivity.
  • Described herein are methods of treating muscle atrophy due to a rotator cuff injury comprising administering a therapeutic composition comprising a PGE2 compound and a myotoxin to a subject in need thereof.
  • the therapeutic composition treats the muscle atrophy by inducing muscle generation in a rotator cuff muscle of a subject in need thereof.
  • the rotator cuff muscle is supraspinatus, infraspinatus, subscapularis, teres minor, or a combination thereof.
  • the therapeutic composition is administered in combination with surgery (e.g., rotator cuff arthroscopy).
  • surgery e.g., rotator cuff arthroscopy
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof.
  • the therapeutic composition is administered without surgery.
  • the therapeutic composition is administered in combination with another treatment regimen.
  • the another treatment regimen comprises braces or splints, physical therapy, nerve stimulation, nerve surgery, or a combination thereof.
  • the therapeutic composition comprising a PGE2 compound and a myotoxin is administered by topical administration, intradermal administration, intramuscular administration, or a combination. In some cases, the therapeutic composition is administered by intramuscular administration. In some cases, the intramuscular administration comprises injection of a rotator cuff muscle. In some cases, the rotator cuff muscle is supraspinatus, infraspinatus, subscapularis, teres minor, or a combination thereof.
  • an anesthetic may be administered to a rotator cuff muscle of a subject in need prior to injection.
  • the rotator cuff muscle is injected with surgical exposure; in other cases, the rotator cuff muscle is injected without surgical exposure.
  • a 20-, 21-, 22-, 23-, 24- or 25-gauge needle is used to inject the rotator cuff muscle.
  • a rotator cuff muscle of a subject in need is injected with a volume of about 0.5 mL to about 5 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the rotator cuff muscle is injected with at least about 0.5 mL of therapeutic composition.
  • the rotator cuff muscle is injected with at most about 4 mL of therapeutic composition.
  • the rotator cuff muscle is injected with greater than 0.5 mL, greater than 1.0 mL, greater than 1.5 mL, greater than 2.0 mL, greater than 2.5 mL, greater than 3.0 mL, greater than 3.5 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the effectiveness of an administration of the therapeutic composition may be determined by conducting tests before administration, after administration, or a combination thereof.
  • the tests may measure a rotator cuff-related function before and/or after administration.
  • the test may be strength testing of shoulder abduction, external rotation and forward flexion, full and empty can test, drop arm test, and The Quality of Life Outcome Measure for Rotator Cuff or a combination thereof.
  • the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound and/or the myotoxin may increase.
  • the dose of the PGE2 compound and/or the myotoxin may decrease.
  • the dose of the PGE2 compound and/or the myotoxin may stay the same.
  • the frequency of administration of the therapeutic composition comprising a PGE2 compound and/or the myotoxin may be adjusted after determining the effectiveness of an administration of the therapeutic composition.
  • a single administration of the therapeutic composition is needed to treat impaired hand or lower arm function.
  • two or more, three or more, four or more, five or more administrations of the therapeutic composition are needed.
  • the frequency of administration is increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration is decreased after determining the effectiveness of a prior administration.
  • Pelvic floor disorders arise from dysfunction of the pelvic floor muscles.
  • the pelvic floor muscles are often damaged by childbirth and pelvic surgery.
  • Pelvic floor disorders also arise from other trauma, aging, obesity, neurological diseases, and other injuries.
  • the most common pelvic floor disorders are due, at least in part, to decreased function of the pelvic floor muscles. These disorders include stress urinary incontinence, overactive bladder/urinary urgency incontinence, mixed urinary incontinence, pelvic organ prolapse, and fecal incontinence.
  • Pelvic floor disorders comprise a wide variety of conditions in both men and women, although women are more commonly affected.
  • the pelvic floor provides anatomic support for the pelvic organs (bladder, prostate, rectum, uterus vagina) and is integral to the proper function of the urinary system, to sexual and reproductive function, and to colorectal function.
  • the pelvic floor is comprised of the pelvic floor muscles as well as the relevant connective tissue (ligaments, tendons, and overlying fascia).
  • the pelvic floor muscles include the levator ani and the coccygeus.
  • the levator ani has three parts: the pubococcygeus, the iliococcygeus and the puborectalis.
  • Strengthening or improving function of the pelvic floor muscles may treat these types of pelvic floor disorders.
  • strengthening or improving function of the pelvic floor muscles may prevent pelvic floor disorders from developing in patients identified as high risk (e.g., after complicated delivery, after certain types of pelvic surgery).
  • This application may also be used in combination with existing treatments for pelvic floor disorders (e.g., muscle training/biofeedback, neuromodulation, pharmacotherapy, surgery) in order to improve treatment outcomes.
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing a pelvic floor disorder.
  • the pelvic floor disorder is selected from the group consisting of stress urinary incontinence, overactive bladder/urinary urgency incontinence, mixed urinary incontinence, pelvic organ prolapse, and fecal incontinence.
  • the methods may comprise administering a therapeutic composition of the disclosure to the pelvic floor muscles of a subject in need thereof.
  • the pelvic floor muscles comprise the levator ani, the coccygeus, or both.
  • the levator ani includes the pubococcygeus, the iliococcygeus, and the puborectalis.
  • a therapeutic composition comprising a prostaglandin E2 (PGE2) compound and a myotoxin, as described elsewhere herein, the genitourinary system.
  • the therapeutic composition can be administered to improve a function of the genitourinary system.
  • the therapeutic composition can be administered to enhance the effectiveness of an existing approach to treat a disease or disorder of the genitourinary system.
  • the disease or disorder of the genitourinary system can be a urological disorder, gynecological disorder, a colorectal disorder, or a combination thereof.
  • the pelvic floor muscles support the bladder and the urethra. Most adults can hold over 400 mL of urine in the bladder. Urine flows from the bladder through the urethra to the outside. Around the opening of the bladder is the sphincter muscle. It squeezes to prevent urine from leaking through the urethra. Impairment of any of these muscles can result a urological disorder such as stress incontinence. Moreover, strengthening of any of these muscles can be targeted to treat urological disorders such overactive bladder disorder and underactive bladder disorder.
  • Stress urinary incontinence occurs when the bladder leaks urine during physical activity or exertion such as coughing, lifting of heavy objects, exercise, or change in positions. It occurs when any of the muscles that control the ability to hold urine in the bladder is weak or impaired in function. When any one of the muscles, such as the skeletal external urethral muscle, the pubic urethral muscle, becomes weak, urine can pass when pressure is place on the bladder. Weakened muscles may be caused by childbirth, injury to the urethra area, medications, surgery in the pelvic area such as prostate surgery, progressive atrophy and diminished contractility of the skeletal muscles, nerve damage. Current treatments include surgical interventions and injection of “bulking agents”.
  • Described herein are methods of treating stress urinary incontinence (SUI) comprising administering a therapeutic composition comprising a PGE2 compound and a myotoxin to a subject in need thereof.
  • the therapeutic composition treats SUI by inducing muscle regeneration a muscle of a subject in need thereof.
  • the muscle is the skeletal external urethral muscle, the pubic urethral muscle, or the external urethral sphincter muscle.
  • the therapeutic composition is administered in combination with surgery (e.g., prostate surgery). In those embodiments, the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof. In other embodiments, the therapeutic composition is administered without surgery.
  • surgery e.g., prostate surgery.
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof. In other embodiments, the therapeutic composition is administered without surgery.
  • the therapeutic composition comprising a PGE2 compound and a myotoxin is administered by intramuscular administration.
  • the intramuscular administration comprises injection of the skeletal external urethral muscle, the pubic urethral muscle, and the external urethral sphincter muscle.
  • an anesthetic may be administered prior to injection.
  • the muscle is injected with surgical exposure; in other cases, the muscle is injected without surgical exposure.
  • an 18-, 19-, 20-, 21-, 22- or 23-gauge needle is used to inject the muscle.
  • a muscle of a subject in need is injected with a volume of about 2 mL or less of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the muscle is injected with at least about 2 mL of therapeutic composition.
  • the muscle is injected with less than 2 mL, less than 1.8 mL, less than 1.6 mL, less than 1.4 mL, less than 1.2 mL, less than 1 mL, less than 0.8 mL, less than 0.6 mL, less than 0.4 mL or less than 0.2 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the effectiveness of an administration of the therapeutic composition may be determined by conducting tests before administration, after administration, or a combination thereof.
  • the test may be cystoscopy, a pad weight tests, a voiding diary, pelvic or abdominal ultrasound, post-void residual (PVR), urinalysis, urinary stress test, urodynamic studies such as leak point pressure, x-rays with contrast dye, or a combination thereof.
  • the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration. In some cases, the dose of the PGE2 compound and/or the myotoxin may increase. In other cases, the dose of the PGE2 compound and/or the myotoxin may decrease.
  • the dose of the PGE2 compound and/or the myotoxin may stay the same.
  • the frequency of administration of the therapeutic composition comprising a PGE2 compound and/or the myotoxin may be adjusted after determining the effectiveness of an administration of the therapeutic composition. In some cases, a single administration of the therapeutic composition is needed. In some cases, two or more, three or more, four or more, five or more administrations of the therapeutic composition are needed. In some cases, the frequency of administration is increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration is decreased after determining the effectiveness of a prior administration.
  • Overactive bladder is a condition in which the bladder squeezes urine out at the wrong time.
  • a person suffering from an overactive bladder may urinate eight or more times a day or two or more times at night; may have a sudden and strong need to urinate immediately; or leak urine after a sudden, strong urge to urinate.
  • overactive bladder Several conditions may contribute to signs and symptoms of overactive bladder including neurological disorders (e.g., stroke, multiple sclerosis), diabetes, diuretics, urinary tract infections, tumors, bladder stones, enlarged prostate, constipation, excess consumption of caffeine or alcohol, declining cognitive function due to aging, and incomplete bladder emptying.
  • Strengthening and improving function of the external urethral sphincter muscle can impact positive and negative reflex actions between the bladder and the urethra.
  • improved contractile action of the urethral sphincter muscle can signal the bladder to inhibit flow of urine.
  • Described herein are methods of treating overactive bladder (OAB) comprising administering a therapeutic composition comprising a PGE2 compound and a myotoxin to a subject in need thereof.
  • the therapeutic composition treats OAB by inducing muscle regeneration a muscle of a subject in need thereof.
  • the muscle is the skeletal external urethral muscle.
  • the therapeutic composition is administered in combination with surgery (e.g., prostate surgery). In those embodiments, the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof. In other embodiments, the therapeutic composition is administered without surgery.
  • surgery e.g., prostate surgery.
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof. In other embodiments, the therapeutic composition is administered without surgery.
  • the therapeutic composition comprising a PGE2 compound and a myotoxin is administered by intramuscular administration.
  • the intramuscular administration comprises injection of the skeletal external urethral muscle.
  • an anesthetic may be administered prior to injection.
  • the muscle is injected with surgical exposure; in other cases, the muscle is injected without surgical exposure.
  • an 18-, 19-, 20-, 21-, 22- or 23-gauge needle is used to inject the muscle.
  • a muscle of a subject in need is injected with a volume of about 2 mL or less of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the muscle is injected with at least about 2 mL of therapeutic composition.
  • the muscle is injected with less than 2 mL, less than 1.8 mL, less than 1.6 mL, less than 1.4 mL, less than 1.2 mL, less than 1 mL, less than 0.8 mL, less than 0.6 mL, less than 0.4 mL or less than 0.2 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the effectiveness of an administration of the therapeutic composition may be determined by conducting tests before administration, after administration, or a combination thereof.
  • the test may be post-void residual (PVR) test, urine flow rate test, bladder pressure test, or a combination thereof.
  • the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound and/or the myotoxin may increase.
  • the dose of the PGE2 compound and/or the myotoxin may decrease.
  • the dose of the PGE2 compound and/or the myotoxin may stay the same.
  • the frequency of administration of the therapeutic composition comprising a PGE2 compound and/or the myotoxin may be adjusted after determining the effectiveness of an administration of the therapeutic composition. In some cases, a single administration of the therapeutic composition is needed. In some cases, two or more, three or more, four or more, five or more administrations of the therapeutic composition are needed. In some cases, the frequency of administration is increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration is decreased after determining the effectiveness of a prior administration.
  • OASIS Obstetrical anal Sphincter Injury
  • Obstetrical anal sphincter injury is damage to the anal sphincter during childbirth, and can lead to significant comorbidities, including anal incontinence, rectovaginal fistula and pain. They are more commonly associated with force deliveries than vacuum-assisted vaginal deliveries. They are also associated with an increased risk of postpartum urinary retention. Surgical repair of the anal sphincter may not completely restore muscle function.
  • Described herein are methods of treating obstetrical anal sphincter injury comprising administering a therapeutic composition comprising a PGE2 compound and a myotoxin to a subject in need thereof.
  • the therapeutic composition treats OAB by inducing muscle regeneration of an anal muscle of a subject in need thereof.
  • the anal muscle is the external anal sphincter muscle, or the inner anal sphincter muscle.
  • the therapeutic composition is administered in combination with surgery (e.g., external anal sphincter repair, internal anal sphincter repair).
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof.
  • the therapeutic composition is administered without surgery.
  • the therapeutic composition comprising a PGE2 compound and a myotoxin is administered by intramuscular administration.
  • the intramuscular administration comprises injection of the skeletal external anal sphincter muscle.
  • an anesthetic may be administered prior to injection.
  • the muscle is injected with surgical exposure; in other cases, the muscle is injected without surgical exposure.
  • an 18-, 19-, 20-, 21-, 22- or 23-gauge needle is used to inject the muscle.
  • an anal sphincter muscle of a subject in need is injected with a volume of about 2 mL or less of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the muscle is injected with at least about 2 mL of therapeutic composition.
  • the muscle is injected with less than 2 mL, less than 1.8 mL, less than 1.6 mL, less than 1.4 mL, less than 1.2 mL, less than 1 mL, less than 0.8 mL, less than 0.6 mL, less than 0.4 mL or less than 0.2 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the effectiveness of an administration of the therapeutic composition may be determined by conducting tests before administration, after administration, or a combination thereof.
  • the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound and/or the myotoxin may increase.
  • the dose of the PGE2 compound and/or the myotoxin may decrease.
  • the dose of the PGE2 compound and/or the myotoxin may stay the same.
  • the frequency of administration of the therapeutic composition comprising a PGE2 compound and/or the myotoxin may be adjusted after determining the effectiveness of an administration of the therapeutic composition. In some cases, a single administration of the therapeutic composition is needed.
  • the frequency of administration is increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration is decreased after determining the effectiveness of a prior administration.
  • Fecal incontinence also known as bowel incontinence or encopresis, is the inability to control bowel movement, causing stool/feces to leak unexpectedly from the rectum. It ranges from an occasional leakage of stool while passing gas, to a complete loss of bowel control. Causes include diarrhea, constipation, muscle damage or never damage. In some cases, muscle damage is due to childbirth, or is associated with aging.
  • Described herein are methods of treating fecal incontinence comprising administering a therapeutic composition comprising a PGE2 compound and a myotoxin to a subject in need thereof.
  • the therapeutic composition treats fetal incontinence by inducing muscle regeneration of an anal muscle of a subject in need thereof.
  • the anal muscle is the external anal sphincter muscle, or the inner anal sphincter muscle.
  • the therapeutic composition is administered in combination with surgery (e.g., external anal sphincter repair, internal anal sphincter repair).
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof.
  • the therapeutic composition is administered without surgery.
  • the therapeutic composition comprising a PGE2 compound and a myotoxin is administered by intramuscular administration.
  • the intramuscular administration comprises injection of the skeletal external anal sphincter muscle.
  • an anesthetic may be administered prior to injection.
  • the muscle is injected with surgical exposure; in other cases, the muscle is injected without surgical exposure.
  • an 18-, 19-, 20-, 21-, 22- or 23-gauge needle is used to inject the muscle.
  • an anal sphincter muscle of a subject in need is injected with a volume of about 2 mL or less of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the muscle is injected with at least about 2 mL of therapeutic composition.
  • the muscle is injected with less than 2 mL, less than 1.8 mL, less than 1.6 mL, less than 1.4 mL, less than 1.2 mL, less than 1 mL, less than 0.8 mL, less than 0.6 mL, less than 0.4 mL or less than 0.2 mL of therapeutic composition comprising a PGE2 compound and a myotoxin.
  • the effectiveness of an administration of the therapeutic composition may be determined by conducting tests before administration, after administration, or a combination thereof.
  • the dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound and/or the myotoxin may increase.
  • the dose of the PGE2 compound and/or the myotoxin may decrease.
  • the dose of the PGE2 compound and/or the myotoxin may stay the same.
  • the frequency of administration of the therapeutic composition comprising a PGE2 compound and/or the myotoxin may be adjusted after determining the effectiveness of an administration of the therapeutic composition. In some cases, a single administration of the therapeutic composition is needed.
  • the frequency of administration is increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration is decreased after determining the effectiveness of a prior administration.
  • GSD gastroesophageal reflux disease
  • Esophageal symptoms e.g., heartburn
  • extraesophageal symptoms e.g., oral, pharyngeal, laryngeal, and pulmonary disorders
  • Other GERD symptoms may include epigastric fullness, pressure or pain, dyspepsia, nausea, bloating, belching, chronic cough, bronchospasm, wheezing, hoarseness, and asthma.
  • the antireflux barrier includes two sphincters—the lower esophageal sphincter (LES) and the diaphragmatic sphincter at the gastroesophageal junction.
  • the two sphincters maintain tonic closure and augmented reflex closure of the sphincter mechanism.
  • the LES is composed of smooth muscles, and it maintains tonic contraction owing to myogenic as well as neurogenic factors.
  • the diaphragmatic sphincter is composed of striated muscles that also exhibit tone and contracts due to the excitatory nerves.
  • the mammalian diaphragm is primarily a respiratory muscle. However, it consists of two separate muscles: the crural and the costal diaphragms.
  • the costal diaphragm is a respiratory muscle, while the crural diaphragm has two functions: respiratory and gastrointestinal.
  • the crural diaphragm is composed of skeletal muscle. Contraction of the diaphragmatic sphincter provides a powerful sphincter mechanism at the lower end of the esophagus contributing to both tonic (sustained) and phasic pressure increases at the level of the LES.
  • a crural myotomy study has demonstrated that there was a significant increase in spontaneous acid reflux. After removal of the crural diaphragm, intrinsic esophageal muscle cannot fully compensate for the loss of the crural muscle.
  • the diaphragmatic hiatus is the site of minimum GEJ opening aperture, and hiatal hernia has shown excess reflux indicating that the crural diaphragm has a crucial barrier role.
  • a study has also shown that patients with esophagitis may have a thinner crural diaphragm and a deficient GEJ activity during forced inhalation.
  • the anatomical changes and functional failure of the crural diaphragm is esophagitis patients supports the possibility of a skeletal muscle deficiency in GERD.
  • GERD GERD
  • Surgical therapy may include laparoscopic fundoplication or bariatric surgery.
  • Complications from anti-reflux surgery may include dysphagia of sufficient severity to require esophageal dilation in about 6% of patients treated with fundoplication surgery as well as a significant increase in flatulence and the inability to belch (gas bloat syndrome).
  • methods are provided for treating gastroesophageal reflux disease (GERD).
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing GERD.
  • a therapeutic composition of the disclosure e.g., a PGE2 compound and/or a myotoxin
  • the therapeutic composition may treat GERD by inducing muscle regeneration in the crural diaphragm.
  • a therapeutic composition of the disclosure may be administered in combination with a surgical procedure to treat GERD.
  • the therapeutic composition can be administered before surgery, during surgery, after surgery, or any combination thereof.
  • the crural diaphragm may be accessed laparoscopically and injected with a therapeutic composition of the disclosure.
  • the location of the crural diaphragm may be identified by locating the esophagus and the diaphragm hiatus, and then injecting the diaphragm adjacent to the esophagus with a therapeutic composition provided herein.
  • the injections may be performed circumferentially around the esophagus.
  • At least one, two, three, four, five, six, seven, eight, nine, ten, or more than ten circumferential injections around the esophagus may be performed.
  • a 27-, 28-, 29- or 30-gauge needle may be used to inject the crural diaphragm.
  • methods of treating GERD may include administering (e.g., intramuscular injection) a therapeutic composition of the disclosure to the crural diaphragm of a subject in need thereof, in a volume of about 0.05 mL to about 0.15 mL.
  • the crural diaphragm may be injected with at least about 0.05 mL of the therapeutic composition.
  • the crural diaphragm may be injected with at most about 0.15 mL of the therapeutic composition.
  • the crural diaphragm may be injected with greater than 0.05 mL, greater than 0.06 mL, greater than 0.07 mL, greater than 0.08 mL, greater than 0.09 mL, greater than 0.10 mL, greater than 0.11 mL, greater than 0.12 mL, greater than 0.13 mL, or greater than 0.14 mL of the therapeutic composition.
  • the effectiveness of an administration of a therapeutic composition of the disclosure may be determined by conducting tests before administration, after administration, or both.
  • the test may include the Heartburn Specific Quality of Life (HBQQL) questionnaire, the GERD Health-Related Quality of Life (GERD-HRQL) questionnaire, or both.
  • the test may include monitoring an increase in thickness of the crural diaphragm using endoscopic ultrasound.
  • Obstructive sleep apnea is characterized by repetitive episodes of complete or partial obstructions of the upper airway during sleep.
  • the upper airway is divided into three regions: the nasopharynx, the oropharynx, and the hypopharynx.
  • the oropharynx is subdivided into the retropalatal region (the posterior margin of the hard palate to the caudal margin of the soft palate) and the retroglossal region (the caudal margin of the soft palate to the base of the epiglottis).
  • the majority of patients with OSA have upper airway narrowing in the retropalatal region, the retroglossal region, or both.
  • the skeletal muscles surrounding the pharyngeal airway are phasically activated during inspiration, which may help to dilate the airway and stiffen the airway walls.
  • the pharyngeal muscles help regulate the position of the soft palate, tongue, hyoid apparatus, and posterolateral pharyngeal walls. Contraction of specific muscles within the palatal muscles opens the airway in the retropalatal region. Pharyngeal muscles can have different effects when activated in concert as opposed to when activated individually. Coactivation of the muscles in the anterior pharyngeal wall such as the geniohyoid and sternohyoid act on the hyoid bone to move it ventrally.
  • the tensor palatine moves the soft palate ventrally.
  • the genioglossus acts to displace the tongue ventrally.
  • the extrinsic muscles of the tongue consist of the genioglossus, hyoglossus, and syloglossus and are important for the protrusion and retraction of the tongue.
  • the genioglossus is the primary protruder muscle of the tongue with its contraction playing a seminal role in keeping the pharyngeal airway open, mainly by widening the oropharynx in the anterior-poasterior dimension.
  • the primary goal of the pharyngeal muscles is to keep the airway open allowing for the flow of air in and out of the lung.
  • OSA is characterized by increased collapsibility of the upper airway during sleep, which results in reduced airflow (hypopnea) or blocked airflow (apnea) resulting in intermittent hypoxia.
  • the upper airway may collapse because dilator muscles may be unable to sustain patency during portions of the respiratory cycle.
  • the genioglossus is the major upper airway dilator muscle.
  • the genioglossus muscles have been shown to be structurally and functionally abnormal.
  • One potential mechanism by which these upper airway dilating muscles fail is by fatigue. Fatigue is the loss in the muscle capacity for developing force resulting from muscle activity under load, and which is reversible by rest.
  • the upper airway dilating muscles are subjected to repeated bursts of forceful contraction at the end of each obstructive apnea, which may occur several hundred times each night. The frequency and duration of obstructive apneas are greater in the latter part of the night in OSA potentially implicating genioglossus fatigue as a contributing factor.
  • skeletal muscle fiber phenotype can under a shift from oxidative slow-twitch, fatigue resistant Type I, to glycolytic fast-twitch Type II fibers, which generate increased force but are more prone to fatigue.
  • Fast-twitch muscle fibers fatigue more rapidly than slow-twitch fibers.
  • An increase in fast-twitch fibers would be expected to increase the fatigueability of the upper airway muscles, leaving the airway susceptible to collapse and leading to a cycle of increasingly severe episodes as the level of fatigue increases following repeated activation during the night.
  • the genioglossus is only one of many muscles that act in concert to prevent flow limitation in the pharynx, it may substantially improve pharyngeal patency when activated adequately to obtain optimal anterior displacement of the tongue.
  • the reduction in tension and strength of the upper airway muscles may be one of the key factors in the etiology of OSA. These muscles may include the genioglossus and the tensor palatine. In some cases, improving the strength of these muscles may improve the patency of the upper airway, and reducing the symptoms of OSA. In addition, other upper airway muscles that may contribute to upper airway patency may include the geniohyoid muscles. Targeting these muscles, either individually or in combination, may improve upper airway patency to treat OSA. Although a number of factors may contribute to OSA, upper airway collapsibility and anatomy is fundamentally important in OSA pathogenesis. Accordingly, OSA patients with upper airway pharyngeal muscle weakness may be potential targets for this therapy.
  • Continuous positive airway pressure is the standard treatment for moderate-to-severe OSA.
  • the nasal mask required for CPAP during sleep leads to poor acceptance and compliance rates.
  • Oral appliance (OA) therapy is also widely used for the treatment of moderate and severe OSA. These consist of a maxillary and mandibular splint which hold the lower jaw forward during sleep.
  • OA Oral appliance
  • Upper airway stimulation augments neural drive of the pharyngeal muscle by unilaterally stimulating the hypoglossal nerve. The main limitations of this approach are the risky surgical procedure to implant the device, a high upfront cost and variable response.
  • OSA has various pathophysiologic causes including an anatomically compromised or collapsible upper airway, inadequate responsiveness of the upper airway dilator muscles during sleep (minimal increase in EMG activity to negative pharyngeal pressure), waking up prematurely to airway narrowing (a low respiratory arousal threshold), or having an oversensitive ventilatory control system.
  • effective treatments may require treating a primary cause of OSA or treating a combination of causes.
  • methods are provided for treating obstructive sleep apnea (OSA).
  • the methods may comprise administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject having, suspected of having, or at risk of developing OSA.
  • the methods may comprise administering a therapeutic composition of the disclosure to a subject having, suspected of having, or at risk of developing hypopnea.
  • the methods may comprise administering a therapeutic composition of the disclosure to a subject having, suspected of having, or at risk of developing apnea.
  • the methods may comprise administering a therapeutic composition of the disclosure to a subject to complement or enhance the efficacy of an additional therapy or intervention to treat OSA.
  • the therapeutic composition may treat obstructive sleep apnea, hypopnea, apnea, or a combination thereof, by inducing muscle regeneration in a muscle of the upper airway of a subject.
  • the upper airway muscle comprises the genioglossus.
  • the upper airway muscle comprises the tensor palatine.
  • the upper airway muscle comprises the geniohyoid muscles.
  • OSA, hypopnea, or apnea can be treated by administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to the upper airway muscle (e.g., the genioglossus, the tensor palatine, the geniohyoid muscles, or any combination thereof).
  • a therapeutic composition of the disclosure e.g., comprising a PGE2 compound and/or a myotoxin
  • the upper airway muscle e.g., the genioglossus, the tensor palatine, the geniohyoid muscles, or any combination thereof.
  • methods of treating OSA, hypopnea, or apnea may include administering a therapeutic composition of the disclosure (e.g., comprising a PGE2 compound and/or a myotoxin) to a subject in need thereof by topical administration, intradermal administration, intramuscular administration, or a combination thereof.
  • the therapeutic composition may be administered by intramuscular administration.
  • the intramuscular administration may comprise injection of an upper airway muscle.
  • the upper airway muscle may include the genioglossus, the tensor palatine, the geniohyoid muscles, or a combination thereof.
  • an anesthetic may be administered to the upper airway prior to injection of the therapeutic composition.
  • the upper airway muscle may be injected with surgical exposure; in other cases, the upper airway muscle may be injected without surgical exposure.
  • surgical procedures to alter the anatomy of the upper airway may be enhanced by increasing the strength of upper airway muscles (e.g., by administering a therapeutic composition of the disclosure to the upper airway muscles).
  • a 27-, 28-, 29- or 30-gauge needle may be used to inject the upper airway muscle.
  • methods of treating OSA, hypopnea, apnea, or a combination thereof may include administering (e.g., intramuscular injection) a therapeutic composition of the disclosure to an upper airway muscle of a subject in need thereof, in a volume of about 0.01 mL to about 0.15 mL.
  • the upper airway muscle may be injected with at least about 0.01 mL of a therapeutic composition of the disclosure.
  • the upper airway muscle may be injected with at most about 0.15 mL of a therapeutic composition of the disclosure.
  • the upper airway muscle may be injected with greater than 0.01 mL, greater than 0.02 mL, greater than 0.03 mL, greater than 0.04 mL, greater than 0.05 mL, greater than 0.06 mL, greater than 0.07 mL, greater than 0.08 mL, greater than 0.09 mL, greater than 0.10 mL, greater than 0.11 mL, greater than 0.12 mL, greater than 0.13 mL, or greater than 0.14 mL of a therapeutic composition of the disclosure.
  • the effectiveness of an administration of a therapeutic composition may be determined by conducting tests before administration, after administration, or both.
  • the test may assess clinical benefits for an OSA patient using the apnea/hypopnea index (AHI) and the level of daytime sleepiness associated with OSA, estimated by the Epworth Sleepiness Scale (ESS).
  • the test may include polysomnographic parameters (e.g., AI, HI, RERArl, Arl, LSat), Sleep Related Quality of Life (FOSQ), and Reaction Time Testing (PVT).
  • a dose of the therapeutic composition may be adjusted after determining the effectiveness of a prior administration.
  • the dose of the PGE2 compound, the myotoxin, or both may be increased.
  • the dose of the PGE2 compound, the myotoxin, or both may be decreased.
  • the dose of the PGE2 compound, the myotoxin, or both may not be changed.
  • the frequency of administration of a therapeutic composition of the disclosure e.g., comprising a PGE2 compound and/or a myotoxin
  • the frequency of administration may be increased after determining the effectiveness of a prior administration. In other cases, the frequency of administration may be decreased after determining the effectiveness of a prior administration.
  • kits for promoting muscle regeneration and/or increasing muscle mass in a subject in need thereof, or for preventing or treating a muscle condition in a subject in need thereof comprises a composition described herein that comprises a combination of a PGE2 compound (e.g., PGE2 receptor agonist) and a myotoxin.
  • the kit comprises a pharmaceutical composition described herein.
  • the kit typically contains containers which may be formed from a variety of materials such as glass or plastic, and can include for example, bottles, vials, syringes, and test tubes.
  • a label typically accompanies the kit, and includes any writing or recorded material, which may be electronic or computer readable form providing instructions or other information for use of the kit contents.
  • Kits of the present invention may be suitable for treating any number of muscle conditions, including but not limited to muscle conditions that are associated with muscle damage, injury, or atrophy.
  • the kits may also be useful for promoting muscle regeneration in a subject in need thereof and/or increasing muscle mass.
  • suitable conditions for prevention or treatment with kits of the present invention include traumatic injury (e.g., acute muscle trauma, acute nerve trauma), acute muscle injury, acute nerve injury, chronic nerve injury, soft tissue hand injury, carpal tunnel syndrome (CTS), Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, limb girdle muscular dystrophy, amyotrophic lateral sclerosis (ALS), distal muscular dystrophy (DD), inherited myopathies, myotonic muscular dystrophy (MDD), mitochondrial myopathies, myotubular myopathy (MM), myasthenia gravis (MG), congestive heart failure, periodic paralysis, polymyositis, rhabdomyolysis, dermatomyositis, cancer cachexia,
  • kits of the present invention may include muscle disorders that affect small isolated muscles that can be regenerated with localized transplantation of small numbers of cells, including: atrophy and muscle dysfunction in the face or hand after nerve injury or direct trauma that does not recover after reinnervation; extraocular muscle injury causing inability to move the eye and dipoplia seen in Graves' disease; traumatic injury; progressive external ophthalmoplegia; and urinary and fecal incontinence.
  • the kit further comprises isolated muscle cells.
  • the kit further comprises instructions for use (e.g., to the kit user).
  • the kit further comprises one or more reagents and/or one or more devices (e.g., a delivery device) that are used, for example, to administer a composition and/or pharmaceutical composition of the present invention, to administer isolated muscle cells (e.g., to a subject in need thereof), or a combination thereof.
  • This example illustrates that PGE2 signaling is required for muscle stem cell function during regeneration.
  • MuSCs also known as satellite cells
  • MuSCs also known as satellite cells
  • a transient inflammatory and fibroadipogenic response plays a crucial role in muscle regeneration
  • An analysis of our transcriptome database revealed that the Ptger4 receptor for PGE2, a natural and potent lipid mediator during acute inflammation, was expressed at high levels on freshly isolated MuSCs.
  • Ptger4 receptor for PGE2 a natural and potent lipid mediator during acute inflammation
  • PGE2 is known to signal through four G-protein coupled receptors (Ptger 1-4; EP1-4), but the expression of these receptors in MuSCs has not previously been described.
  • An analysis of the transcript levels of the different receptors (Ptger1-4) revealed that the only receptors upregulated after PGE2 treatment of MuSCs are Ptger1 and Ptger4 ( FIG. 6E ).
  • PGE2 stimulated MuSCs had elevated intracellular cAMP confirming that PGE2 signals through EP4 to promote proliferation and a stem cell transcriptional state ( FIGS. 6F-6H ).
  • ONO-AE3-208 proliferation induced by PGE2 was blunted ( FIG. 2D ).
  • FIG. 4A Following acute treatment with PGE2, young MuSC regenerative capacity was enhanced by an order of magnitude when assessed by BLI ( FIG. 4A ).
  • FIG. 4B Following transplantation of 4-fold greater numbers of cultured MuSCs that lacked the EP4 receptor due to conditional ablation ( FIG. 4B ), the BLI signal that was initially detected progressively declined to levels below the threshold of significance ( FIG. 4B ).
  • FIGS. 10A-10B when notexin injury was performed in the mouse model of muscle stem cell specific deletion of EP4 (Pax7 CreERT2 ;EP4 fl/fl ) ( FIGS. 10A-10B ), muscle regeneration was impaired as observed by the elevated number of embryonic myosin heavy chain (eMHC) positive fibers ( FIGS. 10C-10D ). This was accompanied by the reduction in cross-sectional area of the mouse fibers in the Pax7 CreERT 2 ;EP4 fl/f group, assessed at the end of the regeneration time point (day 21) ( FIG. 10E ). A significant reduction in force output (tetanus) was also detected at day 14 post-injury ( FIGS. 10F-10G ). Thus, PGE2 signaling via the EP4 receptor is required for MuSC regeneration in vivo.
  • eMHC embryonic myosin heavy chain
  • dmPGE2 enhanced regeneration could lead to increased muscle strength after a natural injury induced by downhill treadmill-running.
  • damage was caused by a daily 10 min run on a downhill treadmill 20 degree decline.
  • aged mice in the treatment group ran for 5 days in succession and were injected daily with dmPGE2 after exercise.
  • aged mice in the treatment group ran for 5 consecutive days but received no additional treatment ( FIG. 5L ).
  • the specific twitch and tetanic force were compared for dmPGE2 treated and untreated gastrocnemius mouse muscles (GA) and both were significantly increased ( FIGS. 5M-5P ).
  • G gastrocnemius mouse muscles
  • mice We performed all experiments and protocols in compliance with the institutional guidelines of Stanford University and Administrative Panel on Laboratory Animal Care (APLAC). We obtained wild-type aged C57BL/6 (18-20 mo) mice from the US National Institute on Aging (NIA) for aged muscle studies and young wild-type C57BL/6 mice from Jackson Laboratory. Double-transgenic GFP/luc mice were generated as described previously 1 . Briefly, mice expressing a firefly luciferase (luc) transgene under the regulation of the ubiquitous Actb promoter were maintained in the FVB strain. Mice expressing a green fluorescent protein (GFP) transgene under the regulation of the ubiquitous UBC promoter were maintained in the C57BL/6 strain.
  • luc firefly luciferase
  • GFP green fluorescent protein
  • EP4 flox/flox mice were a kind gift from K. Andreasson (Stanford University) 2 .
  • Double-transgenic Pax7 CreERT 2 ;Rosa26-LSL-Luc were generated by crossing Pax7 CreERT2 mice obtained from Jackson Laboratory (Stock #017763) 3 and Rosa26-LSL-Luc obtained from Jackson Laboratory (Stock #005125) 4 .
  • Muscle stem cell isolation We isolated and enriched muscle stem cells as previously described 1,5,6 . Briefly, a gentle collagenase digestion and mincing by the MACs Dissociator enabled numerous single fibers to be dissociated, followed by dispase digestion to release mononucleated cells from their niches. Subsequently, the cell mixture was depleted for hematopoietic lineage expressing and non-muscle cells (CD45 ⁇ /CD11b ⁇ /CD31 ⁇ ) using a magnetic bead column (Miltenyi). The remaining cell mixture was then subjected to FACS analysis to sort for MuSCs co-expressing CD34 and ⁇ 7-integrin markers. We generated and analyzed flow cytometry scatter plots using FlowJo v10.0. For each sort, we pooled together MuSCs (5,000 each) from at least three independent donor female mice.
  • Muscle stem cell transplantation We transplanted 250 MuSCs ( FIGS. 4A, 4C , and 4 D) or 1,000 MuSCs ( FIG. 4B ) immediately following FACS isolation or after collection from cell culture directly into the tibialis anterior (TA) muscles of recipient mice as previously described 1,5,6 .
  • TA tibialis anterior
  • Cultured cells were treated as indicated (vehicle or PGE2 treated 10 ng/ml) and collected from hydrogel cultures by incubation with 0.5% trypsin in PBS for 2 min at 37° C. and counted using a hemocytometer.
  • For fresh MuSCs transplantation we coinjected sorted cells with 13 nmol of 16,16-Dimethyl Prostaglandin E2 (dmPGE2) (Tocris, catalog #4027) or vehicle control (PBS).
  • One month after transplant we injected 10 ⁇ l of notexin (10 ⁇ g ml ⁇ 1 ; Latoxan, France) to injure recipient muscles and to activate MuSCs in vivo.
  • ROI region-of-interest
  • Muscle injury We used an injury model entailing intramuscular injection of 10 ⁇ l of notexin (10 ⁇ g ml ⁇ 1 ; Latoxan) or cardiotoxin (10 ⁇ M; Latoxan) into the TA muscle.
  • notexin 10 ⁇ g ml ⁇ 1 ; Latoxan
  • cardiotoxin 10 ⁇ M; Latoxan
  • an incision was made in the skin overlying the TA muscle and a copper probe, chilled in liquid nitrogen, was applied to the TA muscle for three 10 s intervals, allowing the muscle to thaw between each application of the cryoprobe.
  • dmPGE2 16,16-Dimethyl Prostaglandin E2
  • PBS vehicle control
  • mice For Pax7 CreERT2 ; Rosa26-LSL-Luc mice experiments, we treated mice with five consecutive daily intraperitoneal injections of tamoxifen to activate luciferase expression under the control of the Pax? promoter. A week after the last tamoxifen injection, mice were subjected to intramuscular injection of 10 ⁇ l of cardiotoxin (10 ⁇ M; Latoxan), which we designated as day 0 of the assay. Three days later either 13 nmol dmPGE2 (13 nmol) or vehicle control (PBS) was injected into the TA muscle. The contralateral TA was used as an internal control. Bioluminescence was assayed at days 3, 7, 10 and 14 post-injury.
  • Tissue histology We collected and prepared recipient TA muscle tissues for histology as previously described 5,6 . We incubated transverse sections with anti-LAMININ (Millipore, clone A5, catalog #05-206, 1:200), and anti-PAX7 (Santa Cruz Biotechnology, catalog #sc-81648, 1:50) primary antibodies and then with AlexaFluor secondary Antibodies (Jackson ImmunoResearch Laboratories, 1:200). We counterstained nuclei with DAPI (Invitrogen).
  • PAX7 quantification we examined serial sections spanning a depth of at least 2 mm of the TA. For fiber area at least 10 fields of LAMININ-stained myofiber cross-sections encompassing over 400 myofibers were captured for each mouse as above. Data analyses were blinded. The researchers performing the imaging acquisition and scoring were unaware of treatment condition given to sample groups analyzed.
  • Hydrogel fabrication We fabricated polyethylene glycol (PEG) hydrogels from PEG precursors, synthesized as described previously 6 . Briefly, we produced hydrogels by using the published formulation to achieve 12-kPa (Young's modulus) stiffness hydrogels in 1 mm thickness which is the optimal condition for culturing MuSCs and maintaining stem cell fate in culture 6 .
  • PEG polyethylene glycol
  • Muscle stem cell culture, treatment and lentiviral infection Following isolation, we resuspended MuSCs in myogenic cell culture medium containing DMEM/F10 (50:50), 15% FBS, 2.5 ng ml ⁇ 1 fibroblast growth factor-2 (FGF-2 also known as bFGF) and 1% penicillin-streptomycin.
  • FGF-2 also known as bFGF
  • penicillin-streptomycin We seeded MuSC suspensions at a density of 500 cells per cm 2 surface area. We maintained cell cultures at 37° C. in 5% CO 2 and changed medium daily.
  • MuSC culture assays and transplantations were performed after 1 week of culture unless noted otherwise.
  • For aged MuSCs transplant studies we infected MuSCs with lentivirus encoding elongation factor-1 ⁇ promoter-driven luc-IRES-GFP (GFP/luc virus) for 24 h in culture as described previously 3 .
  • For EP4 f/f MuSCs studies we isolated MuSCs as described above (Muscle stem cell isolation), and infected all cells with the GFP/luc virus and a subset of them was coinfected with a lentivirus encoding pLM-CMV-R-Cre (mCherry/Cre virus) for 24 h in culture.
  • pLM-CMV-R-Cre was a gift from Michel Sadelain (Addgene plasmid #27546) 7 .
  • EP4 f/f MuSCs were plated on hydrogels post-infection and treated for 24 hr with vehicle (DMSO) or 10 ng/ml PGE2, and proliferation was assayed 3 days later.
  • MuSCs are freshly isolated from the mice by FACS and put in culture for a maximum time period of one week, therefore mycoplasma contamination is not assessed.
  • Proliferation assays To assay proliferation, we used three different assays (hemocytometer, VisionBlue, and EdU). For each, we seeded MuSCs on flat hydrogels (hemocytometer and VisionBlue) or collagen-coated plates (EdU assay) at a density of 500 cells per cm 2 surface area. For hemocytometer cell number count, we collected cells at indicated timepoints by incubation with 0.5% trypsin in PBS for 5 min at 37° C. and quantified them using a hemocytometer at least 3 times. Additionally, we used the VisionBlue Quick Cell Viability Fluorometric Assay Kit (BioVision, catalog #K303) as a readout for cell growth in culture.
  • time-lapse microscopy we monitored cell proliferation for those wells with single cells beginning 12 hr (day 0) to two days after seeding and recorded images every 3 min at 10 ⁇ magnification using a PALM/AxioObserver Z1 system (Carl Zeiss MicroImaging) with a custom environmental control chamber and motorized stage. We changed medium every other day in between the acquisition time intervals.
  • Viable and dead cells were distinguished in time-lapse sequences based on phase-contrast boundary and motility maintenance or loss, respectively.
  • the proliferation rate in the treated condition during the second 24 hour interval is 5.38% per hour.
  • Table 1 shows that the rates of proliferation and death in the two conditions are similar in the first time interval, and that the difference in cell numbers at the end of the experiment is due to differences in both the division rates and the death rates during the second time interval.
  • the modeled cell counts in the two time intervals are given by
  • c ⁇ ( t ) ⁇ c 0 ⁇ exp ⁇ ( ( p 24 - d 24 ) ⁇ t ) 0 ⁇ t ⁇ 24 c ⁇ ( 24 ) ⁇ exp ⁇ ( ( p 48 - d 48 ) ⁇ ( t - 24 ) ) 24 ⁇ t ⁇ 48
  • c 0 is the number of cells at the onset.
  • the modeled curves are plotted together with the actual cell counts in FIG. 8F .
  • the data analysis was blinded.
  • the researchers performing the imaging acquisition and scoring were unaware of the treatment condition given to sample groups analyzed.
  • RNA from MuSCs using the RNeasy Micro Kit (Qiagen). For muscle samples, we snap froze the tissue in liquid nitrogen, homogenized the tissues using a mortar and pestle, followed by syringe and needle trituration, and then isolated RNA using Trizol (Invitrogen). We reverse-transcribed cDNA from total mRNA from each sample using the SensiFASTTM cDNA Synthesis Kit (Bioline). We subjected cDNA to RT-PCR using SYBR Green PCR Master Mix (Applied Biosystems) or TaqMan Assays (Applied Biosystems) in an ABI 7900HT Real-Time PCR System (Applied Biosystems). We cycled samples at 95° C.
  • Gapdh forward 5′-TTCACCACCATGGAGAAGGC-3′, reverse 5′-CCCTTTTGGCTCCACCCT-3; Hpgd, forward 5′-TCCAGTGTGATGTGGCTGAC-3′, reverse 5′-ATTGTTCACGCCTGCATTGT-3; Ptges, forward 5′-GCTGTCATCACAGGCCAGA-3′, reverse 5′-CTCCACATCTGGGTCACTCC-3; Ptges 2, forward 5′-CTCCTACAGGAAAGTGCCCA-3′, reverse 5′-ACCAGGTAGGTCTTGAGGGC-3′; Ptger1 , forward 5′ GTGGTGTCGTGCATCTGCT-3′, reverse, 5′ CCGCTGCAGGGA
  • TaqMan Assays were used to quantify Pax7, Myogenin, Slco2a1 (PGT), Ptger3 and Ptger4 in samples according to the manufacturer instructions with the TaqMan Universal PCR Master Mix reagent kit (Applied Biosystems). Transcript levels were expressed relative to Gapdh levels.
  • SYBR Green qPCR Gapdh qPCR was used to normalize input cDNA samples.
  • FAM multiplex qPCR enabled target signals (FAM) to be normalized individually by their internal Gapdh signals (VIC).
  • PGE2 ELISA Muscle was harvested, rinsed in ice-cold PBS containing indomethacin (5.6 ⁇ g/ml), and snap frozen in liquid nitrogen. Frozen samples were pulverized in liquid nitrogen. The powder was transferred to an Eppendorf tube with 500 ⁇ l of lysate buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 4 mM CaCl, 1.5% Triton X-100, protease inhibitors and micrococcal nuclease), and then homogenized using a tissue homogenizer.
  • lysate buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 4 mM CaCl, 1.5% Triton X-100, protease inhibitors and micrococcal nuclease
  • the PGE2 level of the supernatant was measured using a PGE2 ELISA Kit (R&D Systems, catalog #KGE004B) and expressed relative to total protein measured by BCA assay (BioRad) and expressed as ng of PGE2. Each sample was assayed in duplicate and in each of two independent experiments.
  • cAMP activity assay MuSCs were treated with DMSO (vehicle) or PGE2 (10 ng/ml) for 1 h and cyclic AMP levels measured according to the cAMP-Glo Assay protocol optimized by the manufacturer (Promega). Each sample was assayed in triplicate and in two independent experiments.
  • Calibration Curve preparation Analyte stock solutions (5 mg/mL) were prepared in DMSO. These stock solutions were serially diluted with acetonitrile/water (1:1 v/v) to obtain a series of standard working solutions, which were used to generate the calibration curve. Calibration curves were prepared by spiking 10 uL of each standard working solution into 200 ⁇ L of homogenization buffer (acetone/water 1:1 v/v; 0.005% BHT to prevent oxidation) followed by addition of 10 uL internal standard solution (3000 ng/mL each PGF2 ⁇ -D9 and PGE2-D4). A calibration curve was prepared fresh with each set of samples.
  • Calibration curve ranges: for PGE2 and 13,14-dihydro 15-keto PGE2, from 0.05 ng/mL to 500 ng/mL; for PGD2 and PGF2 ⁇ , from 0.1 ng/mL to 500 ng/mL; and for 15-keto PGE2, from 0.025 ng/mL to 500 ng/mL.
  • Extraction procedure The extraction procedure was modified from that of Prasain et al. 11 and included acetone protein precipitation followed by 2-step liquid-liquid extraction; the latter step enhances LC-MS/MS sensitivity. Butylated hydroxytoluene (BHT) and evaporation under nitrogen (N2) gas were used to prevent oxidation.
  • BHT Butylated hydroxytoluene
  • N2 evaporation under nitrogen
  • Solid tissues were harvested, weighed, and snap-frozen with liquid nitrogen. Muscle tissue was combined with homogenization beads and 200 ⁇ L homogenization buffer in a polypropylene tube and processed in a FastPrep 24 homogenizer (MP Biomedicals) for 40 seconds at a speed of 6 m/s. After homogenization, 10 ⁇ L internal standard solution (3000 ng/mL) was added to tissue homogenate followed by sonication and shaking for 10 minutes. Samples were centrifuged and the supernatant was transferred to a clean eppendorf tube. 200 ⁇ L hexane was added to the sample, followed by shaking for 15 minutes, then centrifugation. Samples were frozen at ⁇ 80° C. for 40 minutes.
  • MP Biomedicals FastPrep 24 homogenizer
  • the hexane layer was poured off from the frozen lower aqueous layer, and discarded. After thawing, 25 ⁇ L of 1N formic acid was added to the bottom aqueous layer, and the samples were vortexed. For the second extraction, 200 ⁇ L chloroform was added to the aqueous phase. Samples were shaken for 15 minutes to ensure full extraction. Centrifugation was performed to separate the layers. The lower chloroform layer was transferred to a new eppendorf tube and evaporated to dryness under nitrogen at 40° C. The dry residue was reconstituted in 100 ⁇ L acetonitrile/10 mM ammonium acetate (2:8 v/v) and analyzed by LC-MS/MS.
  • LC-MS/MS Since many prostaglandins are positional isomers with identical masses and have similar fragmentation patterns, chromatographic separation is critical. Two SRM transitions—one quantifier and one qualifier—were carefully selected for each analyte. Distinctive qualifier ion intensity ratios and retention times were essential to authenticate the target analytes. All analyses were carried out by negative electrospray LC-MS/MS using an LC-20AD XR prominence liquid chromatograph and 8030 triple quadrupole mass spectrometer (Shimadzu). HPLC conditions: Acquity UPLC BEH C18 2.1 ⁇ 100 mm, 1.7 um particle size column was operated at 50° C. with a flow rate of 0.25 mL/min.
  • SRM Selected reaction monitoring
  • the mass transitions were as follows: PGD2: m/z 351.10 ⁇ m/z 315.15 (quantifier) and m/z 351.10 ⁇ m/z 233.05 (qualifier); PGE2: m/z 351.10 ⁇ m/z 271.25 (quantifier) and m/z 351.10 ⁇ m/z 315.20 (qualifier); PGF2 ⁇ : m/z 353.10 ⁇ m/z 309.20 (quantifier) and m/z 353.10 ⁇ m/z 193.20 (qualifier); 15 keto-PGE2: m/z 349.30 ⁇ m/z 331.20 (quantifier) and m/z 349.30 ⁇ m/z 113.00 (qualifier); 13, 14-dihydro 15-keto PGE2: m/z 351.20 ⁇ m/z 333.30 (quantifier) and m/z 351.20 ⁇ m/z 113.05 (qualifier); PGE2-D4:
  • Quantitative analysis was done using LabSolutions LCMS (Shimadzu).
  • An internal standard method was used for quantification: PGE2-D4 was used as an internal standard for quantification of PGE2, 15-keto PGE2, and 13, 14-dihydro 15-keto PGE2.
  • PGF2 ⁇ -D9 was the internal standard for quantification of PGD2 and PGF2 ⁇ . Calibration curves were linear (R>0.99) over the concentration range using a weighting factor of 1/X 2 where X is the concentration. The back-calculated standard concentrations were ⁇ 15% from nominal values, and ⁇ 20% at the lower limit of quantitation (LLOQ).
  • mice Aged mice (18 mo.) were subjected to downhill treadmill run for 2 consecutive weeks. During week 1, mice ran daily for 5 days and rested on days 6 and 7. Two hours after each treadmill run during week 1, each (lateral and medial) gastrocnemius (GA) muscle from both legs of each mouse was injected with a dose of either PBS (vehicle control) or 13 nM dmPGE2 (experimental group). During week 2, mice were subjected to 5 days treadmill run only. The treadmill run was performed using the Exer3/6 (Columbus Instruments). Mice ran for 10 minutes on the treadmill at 20 degrees downhill, starting at a speed of 7 meters/min.
  • PBS vehicle control
  • 13 nM dmPGE2 experimental group
  • the lower limb was immobilized below the knee by a metal clamp without compromising the blood supply to the leg.
  • the mouse was under inhaled anesthetic (2% isofluorane) during the entire force measuring procedure and body temperature was maintained by a heat lamp.
  • the GA muscles were stimulated via the proximal sciatic nerve using a bipolar electrical stimulation cuff delivering a constant current of 2 mA (square pulse width 0.1 ms). GA muscles were stimulated with a single 0.1-ms pulse for twitch force measurements, and a train of 150 Hz for 0.3 s pulses for tetanic force measurements.
  • ⁇ pennation angle of the fiber and ⁇ is muscle density (0.001056 g/mm 3 ).
  • Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nature biotechnology 29, 73-78, doi:10.1038/nbt.1717 (2011); Chenouard, N. et al. Objective comparison of particle tracking methods. Nature methods 11, 281-289, doi:10.1038/nmeth.2808 (2014); Magnusson, K. E., Jalden, J., Gilbert, P. M. & Blau, H. M. Global linking of cell tracks using the Viterbi algorithm. IEEE transactions on medical imaging 34, 911-929, doi:10.1109/TMI.2014.2370951 (2015); Maska, M. et al. A benchmark for comparison of cell tracking algorithms.
  • This example shows an increase in specific twitch force of gastrocnemius muscles in aged mice injected with PGE2.
  • the aged mice (18 months old) were subject to treadmill run to exhaustion daily for 10 days.
  • the treadmill run was performed using the Exer3/6 (Columbus Instruments). Mice ran on the treadmill at 20 degrees downhill, starting at a speed of 10 meters/min. After 3 min, the speed was increased 1 meter/min to a final speed of 20 meters/min. Exhaustion was defined as the inability of the animal to remain on the treadmill despite electrical prodding.
  • 2 h after each treadmill run both gastrocnemius muscles of each mouse were injected with either PBS (control group) or 3 nM PGE2 (experimental group).
  • the force measurement was performed 4 weeks after the last treadmill run using a 300C-LR force transducer (Aurora Scientific) with a single 0.1 ms pulse at predetermined supramaximal stimulation intensity.
  • FIGS. 5M-5N Representative raw muscle force traces of single gastrocnemius muscles are provided in FIGS. 5M-5N .
  • the muscle force and synchronization pulses were recorded via a PCI-6251 acquisition card (National Instruments) and analyzed using Matlab.
  • FIGS. 5O-5P show the specific muscle force values that were calculated by normalizing the force measurements with the muscle physiological cross-sectional area.
  • FIGS. 5Q and 5R show twitch force and tetanic force data, respectively, from a separate experiment in which mice were treated with PGE2 or vehicle only.
  • PGE2 tetanic force data
  • FIGS. 5Q and 5R show twitch force and tetanic force data, respectively, from a separate experiment in which mice were treated with PGE2 or vehicle only.
  • isometric force in aged (18-22 mo) mice injected with PGE2 and subjected to downhill treadmill exercise.
  • aged mice ran daily (at 20 degrees downhill and 14 meter/min maximum speed for 10min) for 5 days and rested on days 6 and 7.
  • This eccentric exercise regime leads to MuSC expansion due to a cycle of muscle degeneration and regeneration.
  • mice were subjected to 5 days treadmill run only. Force measurements (twitch and tetanic) were performed on the TA muscles at week 5 using our previously published protocols.
  • the PGE2 treated group exhibited a significant increase in force compared to the control group.
  • Prostaglandin E2 is Essential for Efficacious Skeletal Muscle Stem Cell Function, Augmenting Regeneration and Strength
  • PGE2 Prostaglandin E2
  • the PGE2 EP4 interaction causes MuSC expansion by triggering a cyclic AMP/phosphoCREB pathway that activates the proliferation-inducing transcription factor, Nurr1.
  • a cyclic AMP/phosphoCREB pathway that activates the proliferation-inducing transcription factor, Nurr1.
  • Our findings reveal that loss of PGE2 signaling to MuSCs during recovery from injury impedes muscle repair and strength. Through such gain or loss of function experiments, we found that PGE2 signaling acts as a rheostat for muscle stem cell function. Decreased PGE2 signaling due to NSAIDs or increased PGE2 due to exogenous delivery dictates MuSC function which determines the outcome of regeneration. The markedly enhanced and accelerated repair of damaged muscles following intramuscular delivery of PGE2 suggests a new indication for this therapeutic agent.
  • PGE2 Prostaglandin E2
  • MuSCs muscle stem cells
  • EP4 is the receptor that mediates PGE2 signaling in MuSCs and genetically engineered mice that lack EP4 in MuSCs have impaired regeneration.
  • Non-steroidal anti-inflammatory drugs commonly used to treat pain after muscle injury, inhibit PGE2 synthesis, hinder muscle regeneration, and lead to weakened muscles.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • Satellite cells also known as muscle stem cells (MuSCs) are crucial to muscle regeneration. They reside in a quiescent state in niches juxtaposed to myofibers in muscle tissues, poised to respond to damage and repair skeletal muscles throughout life (1-4). Muscle injury precipitates an inflammatory response that is marked by the sequential infiltration of multiple cell types including neutrophils, monocytes, macrophages, T-cells and fibroadipocytes, and is accompanied by muscle stem cell activation. During this inflammatory phase, concurrent waves of cytokine and growth factor release, including CC-chemokine ligand 2 (CCL2), IL-10, IL-1 ⁇ , tumor necrosis factor- ⁇ (TNF ⁇ ), transforming growth factor- ⁇ 1 (TGF ⁇ 1) (3, 5-10).
  • CCL2 CC-chemokine ligand 2
  • IL-10 IL-1 ⁇
  • TGF ⁇ tumor necrosis factor- ⁇ 1
  • prostaglandins potent lipid mediators of inflammation
  • PGH2 prostaglandin H2
  • PGD2 prostaglandin subtypes
  • TXA2 thromboxane
  • mice treated with non-steroidal anti-inflammatory drugs which block the production of prostaglandins through inhibition of COX1 and COX2, exhibited regeneration deficits (20, 21).
  • NSAIDs non-steroidal anti-inflammatory drugs
  • NSAIDS lead to an attenuation of exercise-induced expansion of human satellite cells in biopsies (20).
  • glucocorticoids which reduce prostaglandin synthesis by suppressing phospholipase A2, COX-2 and mPGES-1 expression, adversely affect the recovery of muscle strength in polymyositis patients (22).
  • the target of NSAIDs and glucocorticoids are the COX enzymes, this effect could entail a number of prostaglandin subtypes in addition to PGE2 and therefore have pleiotropic effects.
  • PGE2 in response to injury, PGE2 is transiently induced in muscle tissues.
  • PGE2 acts directly on MuSCs, the building blocks of muscle regeneration, we generated mice in which the PGE2 receptor, EP4, could be conditionally ablated in MuSCs.
  • transgenic reporter mice that enabled specific tracking of MuSC contribution to regeneration dynamically and sensitively over time by bioluminescence imaging after PGE2 delivery.
  • PGE2 signaling acts as a rheostat for muscle stem cell function.
  • BLI bioluminescence imaging
  • FIGS. 13A, 19A, and 19B Histological analysis reveals GFP+MuSC engraftment in the niche and GFP + fibers resulting from fusion over the time course ( FIGS. 13A, 19A, and 19B ). Moreover, following engraftment, a secondary injury elicited a spike in BLI signals of PGE2-treated MuSCs relative to controls, suggesting enhanced stem cell repopulation ( FIG. 13A ). Notably PGE2 is known to have a relatively short half-life in vivo (31). Thus these experiments demonstrate that transient exposure of MuSCs to PGE2 at the time of co-delivery to injured muscle suffices to significantly enhance muscle regeneration.
  • EP4 receptor mediates PGE2 signaling to promote MuSC proliferation and engraftment PGE2 is known to signal through four G-protein coupled receptors (Ptger1-4; EP1-4) (6, 11), but the expression of these receptors in MuSCs has not previously been reported.
  • PGE2 treated MuSCs showed elevated downstream intracellular cyclic AMP (cAMP) levels ( FIG. 14B ), a response associated to EP4 signaling (11), and in the presence of an EP4 antagonist, ONO-AE3-208, the increased proliferation response induced by PGE2 was blunted ( FIG.
  • cAMP cyclic AMP
  • Transcription factor Nurr1 is a downstream mediator of PGE2/EP4 signaling in MuSCs: To perform an unbiased search for mediators of signaling downstream of PGE2 that mediate the enhanced effect of MuSC functions, we performed an RNA-seq analysis comparing isolated MuSCs treated with vehicle (control) or PGE2 for 24 h ( FIG. 21A ). Bioinformatics analyses using Ingenuity Pathway Analysis (IPA) and Metacore software packages revealed that in addition to regulators of PGE2 metabolism, PGE2 treatment of MuSCs led to an increase in molecular and cellular functions consistent with stem cell expansion, including cAMP signaling, and cell cycle regulation ( FIGS. 21B and 21C ).
  • IPA Ingenuity Pathway Analysis
  • Metacore software packages revealed that in addition to regulators of PGE2 metabolism, PGE2 treatment of MuSCs led to an increase in molecular and cellular functions consistent with stem cell expansion, including cAMP signaling, and cell cycle regulation ( FIGS. 21B and 21C ).
  • FIG. 15A Among the top 200 differentially expressed genes with a non-adjusted p-value ⁇ 0.05, only 11 transcription factors were identified ( FIG. 15A ).
  • Nurr1 was among the few that were differentially expressed.
  • Nurr1 had also previously been shown to mediate PGE2 signaling through cAMP and phospho-CREB to induce cell proliferation in colorectal cancer and neuronal cells (32, 33).
  • PGE2 has been implicated as an immunomodulator that acts on neutrophils, mast cells, and macrophages that are crucial to the early inflammatory response after injury. The ensuing cytokine storm is thought to induce muscle stem cell function in regeneration (3, 6, 7, 11). Studies in whole body COX2 KO mice, in which all prostaglandin synthesis was ablated, supported this conclusion (15, 19). Myoblasts have been proposed as the cell type responsive to PGE2 in culture (14, 16-18, 34, 35), but these cells perform poorly in regeneration (24) and cannot account for the observed effects. Moreover, other studies implicating PGE2 in regeneration all suffered from pleiotropic effects on a multiplicity of cell types.
  • MuSCs are crucial to development and regeneration (1-3, 24, 36-38) and their numbers dramatically increase in response to insults that damage the muscles in mice and humans (5, 20, 39-42). Injections of MuSCs into injured muscles leads to their exponential increase, whereas injection of their myoblast derivatives results in a decline in numbers, revealing a remarkable distinction in regenerative capacity of these two cell types (24).
  • the major effect of PGE2 during muscle regeneration is on MuSCs and that this effect is direct and mediated by the EP4 receptor.
  • EP4 is robustly expressed on MuSCs and progressively diminishes to negligible levels on differentiating myoblasts suggesting that the most responsive myogenic cell type to PGE2 is the MuSC.
  • Nurr1 has been associated in intestinal epithelial cells with induction of proliferation and regeneration by directly blocking the cell cycle inhibitor p21 (Waf1/Cip1) in intestinal epithelial cells (43), its role in the expansion of stem cells, and particularly muscle stem cells, has not previously been described.
  • the finding that further substantiates that Nurr1 mediates the onset of MuSC proliferation in vivo is that its levels transiently peak in muscle tissues three days post injury, concomitant with the observed surge in PGE2.
  • PGE2 levels act as a rheostat that controls the efficacy of regeneration. Augmentation of the innate pro-inflammatory PGE2 response to injury leads to accelerated MuSC expansion and muscle regeneration. By contrast, NSAID administration at the time of injury to control pain, a common practice, abrogates that effect, suggesting that PGE2 signaling during this early temporal window is crucial to its beneficial effects. Most striking is our finding that a single PGE2 treatment suffices to rapidly and robustly invoke a muscle stem cell response to enhance regeneration of damaged muscle and restore strength.
  • Double-transgenic Pax7 CreERT 2;EP4 f/f were generated by crossing Pax7 CreERT2 mice obtained from Jackson Laboratory (Stock #017763) (48) and EP4 f/f mice.
  • Double-transgenic Pax7 CreERT2 ;Rosa26-LSL-Luc were generated by crossing Pax7 CreERT2 mice and Rosa26-LSL-Luc obtained from Jackson Laboratory (Stock #005125) (49).
  • We validated these genotypes by appropriate PCR-based strategies. All mice from transgenic and wild-type strains were of young age (2-4 months). All experiments were conducted using age and gender-matched controls, and littermates randomly assigned to experimental groups.
  • dmPGE2 16,16-Dimethyl Prostaglandin E2 (dmPGE2) (13 nmol, Tocris, catalog #4027), Indomethacin (35 ⁇ g, Sigma, catalog #17378) or vehicle control (PBS) was injected into the TA muscle.
  • the contralateral TA was used as an internal control, except for the force measurement experiments where each mouse had both legs injured with the same condition and independent mice were used for each condition.
  • mice For Pax7 CreERT2 ;Rosa26-LSL-Luc mice experiments, we treated mice with five consecutive daily intraperitoneal injections of tamoxifen to activate luciferase expression under the control of the Pax7 promoter. A week after the last tamoxifen injection, mice were subjected to intramuscular injection of 10 ⁇ l of cardiotoxin (10 ⁇ M; Latoxan), which we designated as day 0 of the assay. Three days later either 13 nmol dmPGE2 or vehicle control (PBS) was injected into the TA muscle. The contralateral TA was used as an internal control. Bioluminescence was assayed at days 3, 7, 10 and 14 post-injury.
  • mice For Pax7 CreERT2 ; Ep4 flox/flox mice experiments, we treated mice with five consecutive daily intraperitoneal injections of tamoxifen to excise the EP4 allele in Pax7 expressing cells. A week after the last tamoxifen injection, mice were subjected to intramuscular injection of 10 ⁇ l of notexin (10 ⁇ g ml ⁇ 1 ; Latoxan), which we designated as day 0 of the assay. As control mice, Pax7 +/+ ; EP4 flox/+ littermates of the same sex were used.
  • mice hind-limb muscles were isolated and dissociated using the gentleMACS Octo Dissociator with a modified manufacturer protocol (Miltenyi Biotech).
  • Dissociated muscle was digested with 0.2% collagenase (Roche) for 60 min, followed by collagenase/dispase (0.04 U ml ⁇ 1 ; Roche) digestion for 30 minutes.
  • Mononucleated cells were liberated by syringe dissociation with an 18 G needle.
  • mice muscle stem cells For mouse muscle stem cells, single cell suspension were incubated with biotinylated antibodies against CD11 b (1:800), CD45 (1:500), Scal (1:200) and CD31 (1:200), followed by incubation with streptavidin magnetic beads (Miltenyi Biotech), streptavidin-APC-Cy7, integrin- ⁇ 7 -PE (1:500) and CD34-eFluor660 (1:67). The cell mixture was depleted for hematopoietic lineage expressing and non-muscle cells on a magnetic based selection column (Miltenyi) for biotin-positive cells.
  • MuSCs Following isolation, we resuspended MuSCs in myogenic cell culture medium containing DMEM/F10 (50:50), 20% FBS, 2.5 ng ml ⁇ 1 lfibroblast growth factor-2 (FGF-2 also known as bFGF) and 1% penicillin-streptomycin.
  • FGF-2 also known as bFGF
  • penicillin-streptomycin We seeded MuSC suspensions at a density of 500 cells per cm 2 surface area. We maintained cell cultures at 37° C. in 5% CO 2 and changed medium every other day.
  • MuSCs were cultured on hydrogels and vehicle (DMSO) or 10 ng/ml PGE2 (Cayman Chemical) was added to the cultures with every media change (every two days). Proliferation (see below) was assayed 7 days later. We performed all MuSC culture assays and transplantations after 1 week of culture unless noted otherwise.
  • MuSCs For EP4 f/f MuSCs studies, we isolated MuSCs as described above (Muscle stem cell isolation), and infected all cells with lentivirus encoding EF1 ⁇ -luc-IRES-GFP (GFP/luc virus) for 24 h in culture as described previously (26) and a subset of them was coinfected with a lentivirus encoding pLM-CMV-R-Cre (mCherry/Cre virus) for 24 h in culture.
  • pLM-CMV-R-Cre was a gift from Michel Sadelain (Addgene plasmid #27546) (50).
  • EP4 f/f MuSCs 1,000 cells
  • young (2-4 mo) 18-gy irradiated TAs of NSG recipient mice were transplanted EP4 f/f MuSCs (1,000 cells) into young (2-4 mo) 18-gy irradiated TAs of NSG recipient mice.
  • EP4 f/f MuSCs were plated on hydrogels post-infection and treated for 24 hr with vehicle (DMSO) or 10 ng/ml PGE2, and proliferation was assayed 3 days later. Cells were assayed for GFP and/or mCherry expression 48 h post-infection using an inverted fluorescence microscope (Carl Zeiss Microimaging).
  • MuSCs isolated from Pax7 CreERT2 ; EP4 flox/flox or control Pax7 +/+ ; EP4 flox/+ littermates.
  • MuSCs were plated on collagen-coated plates and treated with 1 ⁇ M 4-hydroxy tamoxifen or vehicle (95% Ethanol) during 48 h and then either passed onto hydrogels to assess proliferation 7 days later or treated with PGE2 or vehicle and collected for analysis.
  • MuSCs are freshly isolated from the mice by FACS and put in culture for a maximum time period of one week, therefore mycoplasma contamination is not assessed.
  • time-lapse microscopy we monitored cell proliferation for those wells with single cells for 38 h days after seeding and recorded images every 3 min at 10 ⁇ magnification using a PALM/AxioObserver Z1 system (Carl Zeiss MicroImaging) with a custom environmental control chamber and motorized stage.
  • PALM/AxioObserver Z1 system Carl Zeiss MicroImaging
  • Viable and dead cells were distinguished in time-lapse sequences based on phase-contrast boundary and motility maintenance or loss, respectively.
  • the proportion of live cells in each generation (G1-G6) at all timepoints is shown as cell number normalized to a starting population of 100 single MuSCs.
  • the data analysis was blinded. The researchers performing the imaging acquisition and scoring were unaware of the treatment condition given to sample groups analyzed.
  • lentiviruses containing pLKO.1-scramble shRNA (shSCR) and pLKO.1-Nurr1 shRNA (Mission shRNA, TRCN0000026029, Sigma) were produced in 293T cells using the packaging plasmids pLP1, pLP2 and pLP/VSVG (Invitrogen), by cotransfecting all plasmids using FuGENE-6 (Promega) according to the manufacturer's protocol. Cells were plated the day prior to infection, and supernatants were collected every 12 hours for two days from 293T cells.
  • Freshly sorted MuSCs were seeded on collagen-coated plates for 24 hrs and were then infected with the lentiviruses. 48 hrs after, cells were passed onto hydrogels and treated with PGE2 or vehicle (DMSO) for 24 hrs. Proliferation was assayed 7 days later.
  • RNA from MuSCs using the RNeasy Micro Kit (Qiagen). For muscle samples, we snap froze the tissue in liquid nitrogen, homogenized the tissues using a mortar and pestle, followed by syringe and needle trituration, and then isolated RNA using Trizol (Invitrogen).
  • Trizol Invitrogen
  • SensiFASTTM cDNA Synthesis Kit Bioline.
  • Gapdh forward 5′-TTCACCACCATGGAGAAGGC-3′, reverse 5′-CCCTTTTGGCTCCACCCT-3; Ptges, forward 5′-GCTGTCATCACAGGCCAGA-3′, reverse 5′-CTCCACATCTGGGTCACTCC-3; Ptges2, forward 5′-CTCCTACAGGAAAGTGCCCA-3′, reverse 5′-ACCAGGTAGGTCTTGAGGGC-3′; Ptger1, forward 5′ GTGGTGTCGTGCATCTGCT-3′, reverse, 5′ CCGCTGCAGGGAGTTAGAGT-3′, and Ptger2, forward 5′-ACCTTCGCCATATGCTCCTT-3′, reverse 5′-GGACCGGTGGCCTAAGTATG-3′.
  • TaqMan Assays were used to quantify Pax7, Myogenin, Nurr1 , Ptger3 and Ptger4 in samples according to the manufacturer instructions with the TaqMan Universal PCR Master Mix reagent kit (Applied Biosystems). Transcript levels were expressed relative to Gapdh levels.
  • SYBR Green qPCR Gapdh qPCR was used to normalize input cDNA samples.
  • multiplex qPCR enabled target signals (FAM) to be normalized individually by their internal Gapdh signals (VIC).
  • Muscle was harvested, rinsed in ice-cold PBS containing indomethacin (5.6 ⁇ g/ml), and snap frozen in liquid nitrogen. Frozen samples were pulverized in liquid nitrogen. The powder was transferred to an Eppendorf tube with 500 ⁇ l of lysate buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 4 mM CaCl, 1.5% Triton X-100, protease inhibitors and micrococcal nuclease), and then homogenized using a tissue homogenizer.
  • lysate buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 4 mM CaCl, 1.5% Triton X-100, protease inhibitors and micrococcal nuclease
  • the PGE2 level of the supernatant was measured using a PGE2 ELISA Kit (R&D Systems, catalog #KGE004B) and expressed relative to total protein measured by BCA assay (BioRad) and expressed as ng of PGE2. Each sample was assayed in duplicate and in each of two independent experiments.
  • muscle fibers from the extensor digitorum longus were isolated as previously described (53). Fibers were cultured in stripped serum medium in the presence or absence of indomethacin (1 ⁇ M, Sigma) for 24 hours. Conditioned medium was collected and measured using the PGE2 ELISA Kit (R&D Systems, catalog #KGE004B) and expressed relative to the collected volume (ml). Each sample was assayed in triplicate and in two independent experiments.
  • MuSCs were treated with DMSO (vehicle) or PGE2 (10 ng/ml) for 1 h and cyclic AMP levels measured according to the cAMP-Glo Assay protocol optimized by the manufacturer (Promega). Each sample was assayed in triplicate and in two independent experiments.
  • mice were injured as described in the Muscle injury section. Force measurements were on the TA muscles at day 14 post-injury based on protocols published previously (26, 54). Briefly, mice were anesthetized with 2-5% vaporized Isoflurane mixed with O 2 . Mice were positioned under a heat lamp in order to maintain the body and muscle temperature at 30° C. The distal tendon of the TA muscle was dissected and tied to a 300C-LR force transducer (Aurora Scientific) by surgical suture. Knees of the animals were secured to a fixed steel post and their feet were taped to the platform to prevent movement from the contraction of other muscle groups.
  • ⁇ pennation angle of the fiber and ⁇ is muscle density (0.001056 g/mm 3 ).
  • RNA sequencing ⁇ 7-integrin + CD34 + muscle stem cells were isolated as described above, seeded on collagen-coated plates, treated a day later with PGE2 or vehicle (DMSO) and processed after 24 hours of treatment.
  • RNA was isolated using Qiagen RNAEasy Micro kit from 5,000-10,000 cells, and cDNA generated and amplified using NuGEN Ovation RNA-Seq System v2 kit. Libraries were constructed from cDNA with the TruSEQ RNA Library Preparation Kit v2 (Illumina), and sequenced to 30-40 ⁇ 106 1 ⁇ 75 bp reads per sample on a HiSEQ 2500 from the Stanford Functional Genomics Facility, purchased using an NIH S10 Shared Instrument Grant (S10OD018220).
  • RNA sequences were aligned against the Mus musculus genome using STAR (56).
  • RSEM 57 was used for calling transcripts and calculating transcripts per million (TPM) values, as well as total counts.
  • TPM transcripts per million
  • a counts matrix containing the number of counts for each gene and each sample was obtained. This matrix was analyzed by DESeq to calculate statistical analysis of significance (58) of genes between samples.
  • Muscle injury We used an injury model entailing intramuscular injection of 10 ⁇ l of notexin (10 ⁇ g ml ⁇ 1 ; Latoxan, catalog #L8104) or cardiotoxin (10 ⁇ M; Latoxan, catalog #L8102) into the Tibilais anterior (TA) muscle.
  • TA Tibilais anterior
  • an incision was made in the skin overlying the TA muscle and a copper probe, chilled in liquid nitrogen, was applied to the TA muscle for three 10 s intervals, allowing the muscle to thaw between each application of the cryoprobe.
  • dmPGE2 16,16-Dimethyl Prostaglandin E2 (dmPGE2) (13 nmol, Tocris, catalog #4027), Indomethacin (35 ⁇ g, Sigma, catalog #17378) or vehicle control (PBS) was injected into the TA muscle.
  • the contralateral TA was used as an internal control, except for the force measurement experiments where each mouse had both legs injured with the same condition and independent mice were used for each condition.
  • mice For Pax7 CreERT2 ;Rosa26-LSL-Luc mice experiments, we treated mice with five consecutive daily intraperitoneal injections of tamoxifen to activate luciferase expression under the control of the Pax7 promoter. A week after the last tamoxifen injection, mice were subjected to intramuscular injection of 10 ⁇ l of cardiotoxin (10 ⁇ M; Latoxan), which we designated as day 0 of the assay. Three days later either 13 nmol dmPGE2 or vehicle control (PBS) was injected into the TA muscle. The contralateral TA was used as an internal control. Bioluminescence was assayed at days 3, 7, 10 and 14 post-injury.
  • mice For Pax7 CreERT2 ; Ep4 flox/flox mice experiments, we treated mice with five consecutive daily intraperitoneal injections of tamoxifen to excise the EP4 allele in Pax7 expressing cells. A week after the last tamoxifen injection, mice were subjected to intramuscular injection of 10 ⁇ l of notexin (10 ⁇ g ml ⁇ 1 ; Latoxan), which we designated as day 0 of the assay. As control mice, Pax7 +/+ ; EP4 flox/+ littermates of the same sex were used.
  • Fluorescence activated cell sorting for mouse muscle stem cells For muscle stem cell isolation, mouse hind-limb muscles were dissociated using the gentleMACS Octo Dissociator with a modified manufacturer protocol (Miltenyi Biotech). Dissociated muscle was digested with 0.2% collagenase (Roche) for 60 min, followed by collagenase/dispase (0.04 U ml ⁇ 1 ; Roche) digestion for 30 minutes. Mononucleated cells were liberated by syringe dissociation with an 18 G needle.
  • mice muscle stem cells For mouse muscle stem cells, single cell suspension were incubated with biotinylated antibodies against CD11 b (1:800), CD45 (1:500), Scal (1:200) and CD31 (1:200), followed by incubation with streptavidin magnetic beads (Miltenyi Biotech), streptavidin-APC-Cy7, integrin- ⁇ 7 -PE (1:500) and CD34-eFluor660 (1:67). The cell mixture was depleted for hematopoietic lineage expressing and non-muscle cells on a magnetic based selection column (Miltenyi) for biotin-positive cells.
  • Muscle stem cell transplantation For wild-type MuSC studies, we transplanted cells from GFP/luc mice (2-4 mo of age) into hindlimb-irradiated NSG mice. For EP4 flox/flox MuSCs studies, we transplanted cells from EP4 flox/flox mice (2-4 mo) that were transduced with a luc-IRES-GFP lentivirus (GFP/luc virus) and a subgroup received either a mCherry/Cre lentivirus or a mock infection on day 2 of culture for a period of 24 hr before transplantation, as previously described (26) (see “Muscle stem cell culture, treatment and lentiviral infection” section for details).
  • GFP/luc mice luc-IRES-GFP lentivirus
  • ROI region-of-interest
  • Hydrogel fabrication We produced hydrogels by using the published formulation to achieve 12-kPa (Young's modulus) stiffness hydrogels in 1 mm thickness, which is the optimal condition for culturing MuSCs and maintaining stem cell fate in culture (27).
  • 12-kPa Young's modulus stiffness hydrogels in 1 mm thickness
  • Viable and dead cells were distinguished in time-lapse sequences based on phase-contrast boundary and motility maintenance or loss, respectively.
  • the proportion of live cells in each generation (G1-G6) at all timepoints is shown as cell number normalized to a starting population of 100 single MuSCs.
  • the data analysis was blinded. The researchers performing the imaging acquisition and scoring were unaware of the treatment condition given to sample groups analyzed.
  • Proliferation assays To assay proliferation, we used three different assays (hemocytometer, VisionBlue, and EdU). For each, we seeded MuSCs on flat hydrogels (hemocytometer and VisionBlue) or collagen-coated plates (EdU assay) at a density of 500 cells per cm 2 surface area. For hemocytometer cell number count, we collected cells at indicated timepoints by incubation with 0.5% trypsin in PBS for 5 min at 37° C. and quantified them using a hemocytometer at least 3 times. Additionally, we used the VisionBlue Quick Cell Viability Fluorometric Assay Kit (BioVision, catalog #K303) as a readout for cell growth in culture.
  • PGE2 ELISA Muscle was harvested, rinsed in ice-cold PBS containing indomethacin (5.6 ⁇ g/ml), and snap frozen in liquid nitrogen. Frozen samples were pulverized in liquid nitrogen. The powder was transferred to an Eppendorf tube with 500 ⁇ l of lysate buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 4 mM CaCl, 1.5% Triton X-100, protease inhibitors and micrococcal nuclease), and then homogenized using a tissue homogenizer.
  • lysate buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 4 mM CaCl, 1.5% Triton X-100, protease inhibitors and micrococcal nuclease
  • the PGE2 level of the supernatant was measured using a PGE2 ELISA Kit (R&D Systems, catalog #KGE004B) and expressed relative to total protein measured by BCA assay (BioRad) and expressed as ng of PGE2. Each sample was assayed in duplicate and in each of two independent experiments.
  • muscle fibers from the extensor digitorum longus were isolated as previously described (53). Fibers were cultured in stripped serum medium in the presence or absence of indomethacin (1 ⁇ M, Sigma) for 24 hours. Conditioned medium was collected and measured using the PGE2 ELISA Kit (R&D Systems, catalog #KGE004B) and expressed relative to the collected volume (ml). Each sample was assayed in triplicate and in two independent experiments.
  • mice were first anesthetized with 2-5% vaporized Isoflurane mixed with O 2 . Mice were positioned under a heat lamp in order to maintain the body and muscle temperature at 30° C. The distal tendon of the TA muscle was dissected and tied to a 300C-LR force transducer (Aurora Scientific) by surgical suture. Knees of the animals were secured to a fixed steel post and their feet were taped to the platform to prevent movement from the contraction of other muscle groups. Electrical stimulations were applied across two needle electrodes, placed through the skin just above the knee and beneath the TA muscle to stimulate the tibial nerve.
  • ⁇ pennation angle of the fiber and ⁇ is muscle density (0.001056 g/mm 3 ).
  • This example describes the use of a double-transgenic mouse model and bioluminescent imaging to examine the effects of compositions of the present invention on muscle regeneration and to establish an optimal dose of PGE2 or a PGE2 derivative (16,16-dimethyl prostaglandin E2) for use in conjunction with bupivacaine.
  • Double-transgenic Pax7 creERT2 ;Rosa26-LSL-Luc mice were generated by crossing Pax7 CreERT2 mice and Rosa26-LSL-Luc mice obtained from Jackson Laboratory (Stock #005125). These genotypes were validated by appropriate PCR-based strategies. All mice from transgenic and wild-type strains were of young age (2-4 months). All experiments were conducted using age and gender-matched controls. As depicted in the experimental scheme shown in FIG. 23A , mice were treated with five consecutive daily intraperitoneal injections of tamoxifen to activate luciferase expression under the control of the Pax7 promoter.
  • TA tibialis anterior muscles
  • TA tibialis anterior muscles
  • BPV bupivacaine
  • dmPGE2 10,16-dimethyl prostaglandin E2
  • the contralateral TA received 50 ⁇ L of a mixture containing 0.5% bupivacaine (BPV) and DMSO vehicle as baseline sham control. Bioluminescence was assayed at days 3, 7, 10 and 14 post-injury.
  • ROI region-of-interest
  • a bioluminescence signal was calculated in radiance (p s ⁇ 1 cm ⁇ 2 sr ⁇ 1 ) value of 10 4 to define a positive threshold signal over background.
  • BLI imaging was performed bi-weekly for 2 weeks after coinjection of BPV with dmPGE2 or vehicle.
  • FIG. 23B shows examples of BLI signals, which were higher in muscles that were treated with a combination of BPV and dmPGE2 than muscles that were treated with BPV alone.
  • the BLI images were obtained two weeks after injection.
  • the log fold change in BLI two weeks after injection was significantly higher (p ⁇ 0.05) in the BPV/dmPGE2 group compared to the BPV/vehicle group, indicating that muscle regeneration was more pronounced when a combination of BPV and dmPGE2 was used. No detectable change was noted in the negative control (DMSO vehicle only) and dmPGE2 only groups.
  • the bupivacaine component serves two purposes: it provides anesthesia for the injection and also stimulates muscle stem cell function in regeneration.
  • the dosages to be tested comprise ranges that have been used previously in patients for each drug alone.
  • the total PGE2-bupivacaine dosage is delivered in four injections in order to maximize muscle stem cell activation due to the needle and the mildly myotoxic anesthetic.
  • the Pax7-Luciferase transgenic mouse model is used, which provides a bioluminescence readout for increased endogenous stem cell function non-invasively over time.
  • a model of sciatica nerve transection is employed, which is a well-tolerated, validated, and reproducible model of denervation-induced skeletal muscle atrophy in rodents.
  • This technique leads to a loss of muscle mass mimicking the atrophic abductor pollicis brevis (APB) muscles seen in patients with CTS.
  • APB abductor pollicis brevis
  • a bolus of PGE2-bupivacaine is delivered into four randomized groups of mice to test the range of three PGE2 dosages that are compared to a control untreated group.
  • histology is especially useful in analyses of the atrophied muscle cohort, to determine the degree of denervation and early muscle damage response induced by a combination of PGET2 and bupivacaine injection and subsequent muscle regeneration and re-innervation, which may be attributed to restoration of muscle functions at the treatment endpoint.
  • a bioluminescence imaging (BLI) assay is employed as a convenient non-invasive method to quickly assess MuSC expansion in vivo, and provide a sensitive measure of regeneration potential, by using a muscle stem cell reporter mouse model (i.e., Pax7 CreERT2 ; Rosa26-LSL-Luc) after inducing nerve transection induced atrophy and GA injection of a combination of PGE2 and bupivacaine.
  • the PGE-bupivacaine total dosage in each case is delivered in 4 injections to maximize exposure of the entire muscle and enhance muscle stem cell activation and regeneration due to the needle and the mild myotoxin anesthetic.
  • BLI affords extraordinary sensitivity due to its high signal-to-noise ratio, as excitation light used in fluorescence imaging (which generates background noise) is not required.
  • the BLI signal emitted from the luciferin catalytic reaction by the luciferase expressed in the expanded endogenous muscle stem cells is directly recorded by a cooled charge-coupled device (CCD) camera.
  • CCD charge-coupled device
  • Muscle regeneration is induced by using bupivacaine as a myotoxin.
  • Bupivacaine has been found to be efficacious in muscle injury/regeneration models in prior studies of muscle stem cells.
  • a combined formulation of a fixed dose of bupivacaine is tested with a range of PGE2 concentrations, all of which are below the maximum FDA approved dose of PGE2 (see, NCT00602095).
  • An FDA-approved GMP-grade PGE2 is used, which can be obtained, for example, from Pfizer Pharmaceuticals, UK.
  • the formulation comprising PGE2 and bupivacaine is delivered to the induced atrophied gastrocnemius (GA) muscles of both legs, as the mixed fast and slow fiber type composition and size of the GA mouse muscles (135 ⁇ 22.6 mg) more closely approximates the human ABP muscle (261 ⁇ 119 mg) than the tibialis anterior muscles studied previously.
  • the mouse GA muscle also has a similar fiber length/muscle length ratio (45.5% ⁇ 4.5%) to the human APB muscle (69% ⁇ 9%). Previous studies have shown that transplanted MuSCs can restore strength to injured GA muscles of dystrophic mice.
  • Mouse hindlimb muscle atrophy is induced using the established sciatic nerve transection model to mimic the atrophic APB muscles seen in patients with CTS .
  • This model causes a period of denervation of the posterior hindlimb muscles (i.e., after nerve transection) which results in atrophy, and is followed by reinnervation of the muscle (after the nerve axons have regenerated back to their motor endplates).
  • mice are treated with five consecutive daily intraperitoneal injections of tamoxifen to activate luciferase expression. A week after the last tamoxifen injection, mice are subjected to sciatic nerve transection. After two weeks, a time point when muscle atrophy is evident, intramuscular injection of 50 ⁇ L of the PGE2-bupivacaine mixture is performed. Previous reports have shown that the proposed maximum dose of PGE2 20 ⁇ g (or 4 mg/kg) can be administered to rodents without deleterious effects.
  • PGE2 doses from 5, 10, and 20 ⁇ g are delivered to the GA. Delivery entails four 12.5 ⁇ L injections, two into each GA muscle per leg (0.5 cc total). As controls, GA muscles are injected with vehicle alone (i.e., PBS), 0.5% Bupivacaine alone, or PGE2 alone (5, 10, or 20 ⁇ g). In vivo MuSC activity is assessed by bioluminescence imaging (BLI) every 2 days for 2 weeks post-injury, and biweekly afterward for 3 months. The optimal PGE2-bupivacaine dose is the lowest effective dose with a saturating effect on muscle regeneration, as assessed by BLI.
  • BLI bioluminescence imaging
  • Endogenous MuSC populations are believed to be initially activated and then rapidly proliferate, yielding an exponential increase in BLI signal that peaks and then plateaus when regeneration reaches homeostasis.
  • 6 mice per condition total 48 mice are analyzed, to achieve 95% statistical power, based on a two-sided alpha of 0.05 and a standard deviation of 6.24 ⁇ 10 5 p/s/cm 2 /sr in BLI intensity (based upon prior data).
  • the experiments described in this section determine the formulation, or optimal dose of PGE2, that enhances expansion of endogenous MuSC numbers in regeneration.
  • the optimal dose is then used in experiments described in the following section of this example.
  • bioluminescence and TOMATO assays track expansion of endogenous stem cells, they do not distinguish stem cells, subsets which include progenitors, and differentiating myoblasts.
  • histological analysis and immunostaining is performed with antibodies to myogenic transcription factors that mark stem cells (e.g., Pax7), progenitors (e.g., Myf5) and differentiated cells (e.g., MyoD) at the end of each experiment.
  • MuSCs myofibers and self-renewal to yield stem cells in niches in the satellite cell position along the myofiber.
  • Myofibers are identified by immunostaining with antibodies to laminin and myosin heavy chain (MHC). Based on previous work, it is expected that soon after PGE2 treatment there will be a boost the proportion of stem cells relative to more differentiated cells in the GA muscle.
  • the “reinnervation ratio” is scored as the frequency of reinnervated neuromuscular junctions (NMJs). This ratio derives from the total NMJs labeled by neurofilament and synaptic vessel protein (SV2) immunoreactivity (new NMJs) as a function of the frequency of neuromuscular junctions labeled by ⁇ -bungarotoxin and Schwann cell GAP-43 immunoreactivity (total NMJs).
  • NMJs neurofilament and synaptic vessel protein
  • FACS analysis of dissociated wildtype muscle tissue is performed to determine the ratio of muscle stem cells (Pax7 + ) to activated (Pax7 + /Myf5 + ) and committed (MyoD + /Myogenin + ) myogenic cells. This is critical for establishing that PGE2 is enhancing stem cell activity.
  • a non-parametric t-test e.g., Mann-Whitney test is used to assess the statistical significance of all proposed animal experiments.
  • This example illustrates a study which can be used to evaluate muscle function improvement in mice using multiple technologies.
  • a novel handheld microendoscope built by the Delp laboratory at Stanford ( FIG. 25 ) is employed that allows measurement of the contractile dynamics from a single motor unit in mice or humans. Force generation dynamics are calculated based on the time course of sarcomere displacement.
  • in vivo force measurements are made using an independent technique developed by the Blau and Delp labs at Stanford to evaluate strength and assesses twitch and tetanic muscle force. Additionally, increases in muscle volume are measured by ultrasound to determine the extent of injured muscle recovery of muscle mass. These measurements assess the efficacy of the PGE2-bupivacaine formulation in promoting muscle regeneration in the atrophic GA mouse model.
  • Histological assessment of the fiber sizes and extent of reinnervation is performed to cross-validate the outcomes based on endoscopy and ultrasound studies.
  • the microendoscopy and ultrasound assessment methodologies can be directly translated and applied to evaluate the human hand muscles of patients to assess baseline function and post-intervention recovery.
  • mice are assessed using ultrasound, microendoscopy, and force assays to evaluate increases in muscle volume, architecture, and strength.
  • force assays to evaluate increases in muscle volume, architecture, and strength.
  • non-invasive measurements of the contractile dynamics of a single motor unit are performed. Force generation is calculated based on the time course of sarcomere displacement. In some instances, this assay is conducted weekly over an 8-week time-course. The aim is to assess the functional improvement of muscles that have received a combination of PGE2 and bupivacaine treatment compared to a control group. The volume of the treated muscles is also evaluated by ultrasound analysis.
  • Sarcomere length is also assessed using minimally invasive optical microendoscopy in order to observe second-harmonic frequencies of light generated in the muscle fibers in mice after treatment.
  • Striated skeletal muscles are comprised of sarcomeres, the basic contractile units.
  • Useful instruments for performing these measurements include a laser-scanning microscope, adapted to allow the addition of a microendoscope for deep-tissue imaging, and an ultrashort-pulsed titanium-sapphire laser to generate second-harmonic signals.
  • This minimally invasive technology can be readily translated to the clinic for assessing parameters of muscle function and can used to evaluate the efficacy of PGE2-bupivacaine treated abductor pollicis brevis (APB) in patients (see, Example 7 below).
  • Ultrasound imaging is a non-invasive method that can be used to assess muscle regeneration based on muscle volume. Furthermore, ultrasound is a fast and noninvasive method, allowing repeated measurements to be made over time to evaluate the effects of compositions and methods of the present invention on muscle mass. Ultrasound imaging of the muscle is based on the different acoustical impedance produced when the ultrasound beam encounters tissue. Atrophy and increased muscle mass due to regeneration can be readily quantified by measuring muscle thickness, as the sonographic appearance of muscle is quite distinct from the surrounding fat, fibrous tissue, nerves, blood vessels and bone.
  • Atrophy due to CTS causes structural muscle changes that can be visualized with ultrasound. Atrophy can be objectified by measuring muscle thickness (i.e., the muscles become whiter on the ultrasound image). Ultrasound is more sensitive in detecting fasciculations compared to electromyography (EMG) and clinical observations, because ultrasound can visualize a large muscle area and deeper muscles, especially in the hand. With improving resolution and frame, smaller scale spontaneous muscle activity such as fibrillations can be detected by ultrasound.
  • EMG electromyography
  • This example illustrates a clinical trial designed to determine the benefit of compositions and methods of the present invention for the treatment of patients with severe carpal tunnel syndrome (CTS).
  • CTS severe carpal tunnel syndrome
  • the intervention for this trial tests the therapeutic strategy by injecting a PGE2-bupivacaine formulation into denervated abductor pollicis brevis (APB) muscles 2 months post carpal tunnel release.
  • the following outcomes are assessed: 1) upper extremity function using the upper limb PROMIS assessment; 2) patient outcomes as assessed by a self-evaluation questionnaire standardized by The Canadian Occupational Performance; 3) Moberg pickup test ; 4) ultrasound volume measurements; 5) functional strength using pinch strength using the “digital Pinch Dynamometer” device; and 6) determination of muscle mass by ultrasound and muscle architecture by microendoscopy.
  • the study is a randomized placebo-controlled trial to assess whether intramuscular PGE2 administration improves muscle recovery after denervation. This clinical trial that will yield two deliverables: (1) It will reveal if PGE2 improves denervated muscle regenerative capacity; (2) it will also test if PGE2 improves muscle function after denervation/re-innervation.
  • Exclusion criteria subjects having one or more of the following are excluded from participating in the trial:
  • Surgery is an open carpal tunnel release. These procedures are performed under local anesthetic with 1% lidocaine with epinephrine. This procedure uses a longitudinal incision on the palmar aspect of the hand. The patients are wrapped in light gauze without splint immobilization and return 12 days for suture removal. At the 12-day visit the patients are taught scar massage and only follow up again if they are having difficulties.
  • PGE2 dinoprostone
  • Dinoprostone has been used for many years in pregnant women as a drug for induction of labor. This study repurposes this clinically available medication.
  • the most common side effects in humans are largely pregnancy related: uterine rupture, and amniotic embolism.
  • Other side effects reported include anaphylaxis, pyrexia, chest pain, arrhythmias, nausea as well as others.
  • the half-life of the drug is less than 5 minutes.
  • This medication is diluted with bupivacaine to the optimal dose as directed by one or more preceding animal trials for optimal dosage.
  • Matching placebo injections that are identical in appearance are mixed within a pharmacy.
  • the randomization i.e., assignment of subjects to treatment or control groups
  • This program utilizes a “biased-coin” methodology that progressively alters the probability of randomization assignment to correct any imbalances in the groups of previously randomized subjects. This “biased-coin” approach reduces the likelihood of significant imbalances between treatment groups in all strata while maintaining unpredictability in every treatment assignment. Randomization is done in a 1:1 ratio of treatment to placebo.
  • APB strength is assessed using tip pinch strength using dynamometry. Tip pinch is a recommended measure for assessing APB strength in CTS. Tip pinch is also the first pinch/grip test that shows improvement after carpal tunnel release. For inclusion in the trial, the APB strength needs to be 15% less than normative data or 3.84 kg in women and 5.78 kg in men.
  • Persistent weakness is defined by using a force measure of the APB with the patient having 15% less force than the contralateral side. Patients with continued pain greater than 3 at the surgical site are then excluded. Pain greater than three is moderate pain and may interfere with force generation. Previous work suggests (minocycline trial) that 6% will still have moderate pain at 3 months.
  • Pre-operative Data Acquisition After recruitment participants complete a baseline assessment. This is accomplished prior to the carpal tunnel release. This assessment includes the measures listed below:
  • Demographic data Ethnic origin, race, age, gender and medical comorbidities.
  • Nerve conduction studies are operator dependent and values can vary between sites. This assessment eliminates this problem by using values that are abnormal for that test for that testing site instead of a precise value.
  • the PROMIS Upper Extremity instrument is a computer adaptive test, which draws items from the PROMIS item Bank (v1.0: PF) that has a collection of calibrated questions that define and quantify a particular symptom or functional problem. It uses an item selection algorithm that enables the assessment program to choose a respondent's next item based on the response given to the respondent's current item, thereby avoiding the presentation of redundant, irrelevant, or otherwise poorly targeted items.
  • PROMIS scores are reported as T-scores, with a mean of 50 and a SD of 10; higher scores represent higher levels of PF. This test has been evaluated and showed to have a reliability >0.95 for a representative US sample.
  • COPM Canadian Occupational Performance Measure
  • Moberg pickup test In this test, the thumb, index finger, and middle finger are used to pick up 12 different objects, one at a time, at random. The patient puts them in an open box as quickly as possible. The time (in seconds) required to complete the task is measured and recorded as the end point. The is performed twice until all objects are picked up, or until 30 seconds has been spent unsuccessfully attempting to pick up an identified object. The test is repeated with and without a blindfold. The same procedure will be done for the uninjured hand. This will be scored as an index between the injured hand and the other hand. This test provides information on fine motor and sensory function of the hand.
  • Tip pinch strength is measured using a digital pinch dynamometer, used for measuring a patient's hand strength to evaluate the degree of patient's APB muscle dysfunction. This tip pinch applies force of the thumb pulp to index pulp. The patient is seated with the test arm at his/her side and the elbow flexed 90°. The palm faces down and pinch strength is measured between the pad of the thumb and the pad and the index finger. The patient squeezes, holds, and releases. This test is performed in three consecutive measurements within 2 minutes inter-measurement interval.
  • Ultrasound volume measure of the APB Ultrasound has been used to assess the volume of the APB and the other small muscles in the hand. Ultrasound can detect several aspects of muscle. First, the ultrasound can identify the size of the muscle. This is routinely done by measuring the cross sectional area (CSA). CSA of the APB is strongly correlated with muscle strength. The APB muscle is measured by placing the probe at the proximal third of the first metacarpal bone. The images of the CSA are saved as bitmap image files and transferred to a personal computer. The analysis of the images is performed using Adobe Photoshop CS6 Extended. The lasso tool is used to identify the muscle in question. The CSA is computed using the analysis option. The fascia delineates the margins of APB muscles and allows separation of the APB from the opponens pollicis (an adjacent thenar muscle).
  • CSA cross sectional area
  • the muscle's echo intensity is also measured and is a sign of denervation. Indeed the echo intensity and homogeneity of the muscle correlate with severity of CTS.
  • the APB muscle is measured by ultrasound using B-mode with a 5-10 MHz transducer and the following equipment settings: 50 dB gain, 56 dB dynamic range, and 3 cm depth. The subject sits with hands fully supinated. CSA is measured. All measures are repeated three times and the mean is taken as the final measure.
  • the ten test is an efficient method to assess sensation and is a marker of severity of the carpal tunnel syndrome. This test is performed with the patient seated palm up. The patient is advised of the 0-10 score of the test. The examiner uses the pulp of the index fingertip and strokes lightly an area of normal sensation (often the contralateral digit). The participant is instructed that this represents a score of 10 on the scale. Subsequently, the abnormal area and normal area are stimulated simultaneously using identical pressure and the participant scores the stimulus on the affected limb (0-10) in comparison to the normal anchor area. From these measurements, a sensory ratio is derived.
  • Intervention At 2 months after surgical release, patients are re-evaluated for persistent weakness of the APB on tip pinch strength. Those who continue to have weakness participate in the trial and are randomized to placebo vs. combination of PGE2 and bupivacaine.
  • the dose is extrapolated from the optimal dose determined in mice as described above in Examples 5 and 6.
  • 10 ⁇ g PGE2 was administered per average GA muscle mass (135 mg).
  • the dose in humans can be extrapolated from the dosage used in mice since the drug is not being delivered systemically.
  • the dose for use in the APB muscle is well below the dose clinically used as a drug to induce labor in pregnant women (i.e., 1-5 mg per treatment).
  • antiseptic technique is used and the skin is anesthetized with a weal of 1% lidocaine. Then 0.5 cc of either a combination of PGE2 and bupivacaine or a combination of saline and bupivacaine is injected in 4 aliquots into the APB muscle using a 30 gauge needle. Patients are monitored for half an hour post-injection. The half-life of PGE2 is 5 minutes, thus 30 minutes is sufficient to monitor for any acute reaction to the medication.
  • Exercise is an important component to muscle regeneration. All patients are given an exercise program to strengthen their APB muscles with instructions to perform exercises at least 10 minutes/day. Theraputty is provided to each patient to assist with their home therapy program. Patients are contacted weekly to encourage them to perform the activities every day.
  • Post-Surgery Data Acquisition Patients are assessed at 4 months and 6 months after surgery (2 and 4 months post-intervention). Post-operative assessments will include:
  • FIG. 26 An exemplary subject timeline is shown in FIG. 26 .
  • Microendoscopy Two groups are selected to undergo microendoscopy. This is performed on 5 healthy volunteers at the beginning of the trial to understand healthy muscle architecture. Microendoscopy is also performed on 20 subjects pre-intervention and 4 months post-intervention to assess improvement. Since this is a double-blind study, subjects will be included from both groups by random selection. Thus, it is expected that at least 5 of each group (PGE2 vs. placebo) will be represented. In previous studies, this number has sufficed to yield significant findings. The technique is the same for all. Subjects are seated comfortably with the hand at rest in supination. Antiseptic technique is used and ultrasound guidance is used to place the microendoscope into the APB muscle. The ultrasound helps determine the muscle location and fiber orientation. The microendoscope is extracted slowly at 1 mm increments. At least 3 different fibers are imaged.
  • Endpoints and Measurements The trial has three types of endpoints: feasibility endpoints, safety endpoints, and efficacy endpoints.
  • Feasibility endpoints are designed to provide reliable measures of efficacy at completing study processes.
  • the primary feasibility endpoint is the percentage of people screened that complete the study in the group to which they were randomized.
  • the primary efficacy endpoint is force measure of APB using tip pinch strength in kg measured by dynamometry.
  • the secondary endpoint includes changes in APB muscle cross sectional area. This is recorded using ultrasound and is measured in cm 2 .
  • Demographic and background information is summarized with descriptive statistics (e.g., mean, standard deviation, percentages, and the like)
  • Protocol adherence Methods for handling missing data and non-adherence to protocol: Primary analysis is intent-to-treat. Separate efficacy analysis on those with complete protocol adherence is also performed.
  • Subgroup analysis examines the treatment efficacy in pre-defined high risk subgroups defined by age greater than 70 and severe entrapment score for nerve conduction studies.
  • Sample size justification 60 patients are recruited for the study.
  • the basis for the sample size is as follows.
  • the Null hypothesis is no change in force measurements of the APB between treatment groups.
  • the alternative hypothesis is that the combination of PGE2 and bupivacaine significantly changes the force measurements of the APB.
  • a two-sample t-test with equal variance is used to test for differences in force measurement of the APB between the placebo and PGE2-bupivacaine groups.
  • the number of subjects needed per group to have 80% power with a one-sided alpha of 0.05 is determined to be 25 patients per group.
  • the recruitment pool can be expanded to include those with entrapment of the ulnar nerve at the elbow with intrinsic muscle wasting. This disease process is similar to carpal tunnel syndrome with wasting of multiple small muscles of the hand. If recruitment is altered in this manner, changes to the protocol are made, as follows.
  • the study population may not be representative of the general population. For example, military veterans are older and have a higher male population. However, intervention with PGE2 appears to be particularly effective for the lack of regeneration in older mice. Thus, having an older population may be best suited for seeing the benefits of this intervention.
  • PNI is a common combat injury that prevents many soldiers from returning to active duty. In addition, many older veterans have PNI from compression injuries that result in loss of ability to perform activities of daily living. Loss of muscle function after PNI continues to be a difficult and unsolved question. Research to improve nerve regeneration continues but less has been done to improve muscle regeneration with re-innervation. A medication treatment to improve the amount of muscle recovery after nerve injury and repair is needed. The potential applications beyond this focused CTS trial are broad and would allow treatment of both the nerve and the muscle.
  • Nature Publishing Group, (Nature Publishing Group) pp. 295-303; Lavasani, M., Thompson, S. D., Pollen, J. B., Usas, A., Lu, A., Stolz, D. B., Clark, K.
  • Pax7-CreERT2 Rosa-LSL-Luciferase mice (2-4 months old) were treated with tamoxifen for five consecutive days in order to obtain Pax7 promoter expressing luciferase mice in vivo.
  • baseline tetanic force of the tibialis anterior was measured using a foot plate force measurement instrument before injection of drugs (timepoint day 0).
  • FIG. 27A shows bioluminescence (BLI, measured as radiance) measured every 3 days for 2 weeks to measure muscle stem cell expansion.
  • FIG. 27B shows the resulting tetanic force measured at week 4 from the same mice, where the percent difference to baseline force was calculated.
  • the combination of PGE2 and bupivacaine induces muscle stem cell expansion that is greater than that of PGE2 alone or bupivacaine alone.
  • the observed muscle stem cell expansion is greater than the sum of muscle stem cell expansion for PGE2 alone, and bupivacaine alone.
  • the synergistic effect on muscle regeneration is also confirmed with another assay.
  • FIG. 27B the increase in tetanic force for muscles treated with PGE2 and bupivacaine combined is greater than the sum of the increase in tetanic force for muscles treated with PGE2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
US16/148,976 2017-06-09 2018-10-01 Compositions and methods for preventing or treating muscle conditions Abandoned US20190167695A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US16/148,976 US20190167695A1 (en) 2017-06-09 2018-10-01 Compositions and methods for preventing or treating muscle conditions
US17/399,490 US11738031B2 (en) 2017-06-09 2021-08-11 Compositions and methods for preventing or treating muscle conditions
US18/317,752 US20240115583A1 (en) 2017-06-09 2023-05-15 Compositions and methods for preventing or treating muscle conditions
US19/386,538 US20260144801A1 (en) 2017-06-09 2025-11-12 Compositions and methods for preventing or treating muscle conditions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517758P 2017-06-09 2017-06-09
PCT/US2018/036727 WO2018227134A1 (en) 2017-06-09 2018-06-08 Compositions and methods for preventing or treating muscle conditions
US16/148,976 US20190167695A1 (en) 2017-06-09 2018-10-01 Compositions and methods for preventing or treating muscle conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/036727 Continuation WO2018227134A1 (en) 2017-06-09 2018-06-08 Compositions and methods for preventing or treating muscle conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/399,490 Continuation US11738031B2 (en) 2017-06-09 2021-08-11 Compositions and methods for preventing or treating muscle conditions

Publications (1)

Publication Number Publication Date
US20190167695A1 true US20190167695A1 (en) 2019-06-06

Family

ID=64566381

Family Applications (4)

Application Number Title Priority Date Filing Date
US16/148,976 Abandoned US20190167695A1 (en) 2017-06-09 2018-10-01 Compositions and methods for preventing or treating muscle conditions
US17/399,490 Active US11738031B2 (en) 2017-06-09 2021-08-11 Compositions and methods for preventing or treating muscle conditions
US18/317,752 Abandoned US20240115583A1 (en) 2017-06-09 2023-05-15 Compositions and methods for preventing or treating muscle conditions
US19/386,538 Pending US20260144801A1 (en) 2017-06-09 2025-11-12 Compositions and methods for preventing or treating muscle conditions

Family Applications After (3)

Application Number Title Priority Date Filing Date
US17/399,490 Active US11738031B2 (en) 2017-06-09 2021-08-11 Compositions and methods for preventing or treating muscle conditions
US18/317,752 Abandoned US20240115583A1 (en) 2017-06-09 2023-05-15 Compositions and methods for preventing or treating muscle conditions
US19/386,538 Pending US20260144801A1 (en) 2017-06-09 2025-11-12 Compositions and methods for preventing or treating muscle conditions

Country Status (9)

Country Link
US (4) US20190167695A1 (enExample)
EP (1) EP3634424A4 (enExample)
JP (2) JP7372911B2 (enExample)
KR (1) KR102698911B1 (enExample)
CN (1) CN111212648B (enExample)
AU (1) AU2018280264B2 (enExample)
CA (1) CA3065945A1 (enExample)
GB (1) GB2578539B (enExample)
WO (2) WO2018227134A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114107272A (zh) * 2021-12-15 2022-03-01 徐州医科大学 mPGES-2作为预防和/或治疗衰老疾病的药物靶点的应用
WO2022082009A1 (en) * 2020-10-15 2022-04-21 Epirium Bio Inc. Inhaled formulations of pgdh inhibitors and methods of use thereof
CN116457014A (zh) * 2020-10-23 2023-07-18 莱兰斯坦福初级大学评议会 通过抑制前列腺素降解酶15-pgdh提升线粒体生物合成和功能
US11738031B2 (en) 2017-06-09 2023-08-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
CN117473328A (zh) * 2023-12-26 2024-01-30 南京麦豆健康科技有限公司 一种基于大数据的阴道松弛评估训练系统及方法
US11969433B2 (en) 2016-03-04 2024-04-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
US12558549B2 (en) 2022-10-28 2026-02-24 Medtronic, Inc. Lead based measurements for tongue movement determination
US12559493B2 (en) 2020-01-23 2026-02-24 Myoforte Therapeutics, Inc. PGDH inhibitors and methods of making and using

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
WO2020106998A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
GB2599292A (en) * 2019-06-11 2022-03-30 Univ Leland Stanford Junior Methods of rejuvenating aged tissue by inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH)
WO2021011747A1 (en) * 2019-07-16 2021-01-21 Children’S National Medical Center Method for treatment of muscular dystrophy
AU2021224268A1 (en) 2020-02-21 2022-09-15 Case Western Reserve University Compositions and methods for treating renal injury
US20230187041A1 (en) * 2020-05-08 2023-06-15 Intime Biotech Llc Real-time method of bio big data automatic collection for personalized lifespan prediction
CN117377668A (zh) * 2020-10-15 2024-01-09 迈欧伏特治疗公司 Pgdh抑制剂的吸入制剂及其使用方法
JP7501333B2 (ja) * 2020-12-07 2024-06-18 コニカミノルタ株式会社 超音波診断装置、超音波診断装置の制御方法、及び、超音波診断装置の制御プログラム
JP2023552832A (ja) * 2020-12-09 2023-12-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 関節の構造および機能を改善するためのプロスタグランジン分解酵素１５－ｐｇｄｈの阻害法
CN113327235B (zh) * 2021-06-04 2022-07-01 杭州健培科技有限公司 基于ct影像肌少症评估的图像处理方法和装置
CN117142939B (zh) * 2023-10-30 2024-01-16 成都中医药大学 一种倍半萜化合物及其制备方法和用途及其制备的药物
CN118351102B (zh) * 2024-05-06 2024-11-19 上海交通大学医学院附属瑞金医院 基于脑白质磁共振信号强度的图像处理方法和系统
CN119331890B (zh) * 2024-12-24 2025-03-07 中国农业科学院蜜蜂研究所 基因15-pgdh在调控蜜蜂工蜂体重、体长中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927213A (en) 1973-07-10 1975-12-16 American Home Prod Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents
US5143842A (en) 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
WO1991012329A2 (en) 1990-02-12 1991-08-22 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5833978A (en) 1995-03-16 1998-11-10 Universite Laval Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success
US5599561A (en) * 1995-08-04 1997-02-04 Gonzalez, Jr.; Angel Method of making poultice
ATE327751T1 (de) 2000-01-31 2006-06-15 Pfizer Prod Inc Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
US6410591B1 (en) 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
JP4273407B2 (ja) 2001-07-23 2009-06-03 小野薬品工業株式会社 Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
HUE029417T2 (en) * 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
US6841573B2 (en) 2002-11-27 2005-01-11 Molecular Nutrition Use of arachidonic acid as a method of increasing skeletal muscle mass
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
AR059430A1 (es) 2006-02-09 2008-04-09 Schering Corp Novedosas combinaciones y metodos de inhibidores del vhc
EP1999255A2 (en) 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
CA2652040C (en) 2006-05-17 2015-07-21 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors
AU2007280130B2 (en) 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
WO2008157753A1 (en) 2007-06-21 2008-12-24 Sma Foundation Methods of treatment for spinal muscular atrophy
US7632848B1 (en) * 2007-10-04 2009-12-15 Alan Brown Scott Medical treatment of muscles by exposure to anesthetic drugs
BRPI0819707A2 (pt) 2007-11-29 2015-06-16 Allergan Inc Ciclopentanos substituídas tendo atividade de prostaglandina
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
CN102057037B (zh) 2008-04-11 2014-06-18 学校法人庆应义塾 平滑肌干细胞的分离方法
US20110004589A1 (en) 2009-07-06 2011-01-06 Rockwell Automation Technologies, Inc. Diagnostics in a distributed directory system
US8193220B1 (en) 2009-08-20 2012-06-05 Alan Brown Scott Method of changing muscle lengths with anesthetic drugs
EP2637702A4 (en) 2010-11-11 2014-11-26 Univ Miami METHODS, COMPOSITIONS, CELLS AND KITS FOR TREATING ISCHEMIC INJURIES
US9782417B2 (en) 2011-06-16 2017-10-10 Presidents And Fellows Of Harvard College Methods of increasing satellite cell proliferation with kinase inhibitors
WO2012174537A2 (en) 2011-06-16 2012-12-20 President And Fellows Of Harvard College Small molecule screening for mouse satellite cell proliferation
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
CA2870666A1 (en) * 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
KR101244964B1 (ko) 2012-05-30 2013-03-18 조선대학교산학협력단 15-히드록시프로스타글란딘 디히드로게나제 및 ｐｇｅ2 활성을 조절하는 황칠나무 추출물의 용도
US20130331389A1 (en) 2012-06-11 2013-12-12 National Cheng Kung University Methods and Compositions for Cardiomyocyte Replenishment by Endogenous and Progenitor Stem Cells
US9154479B1 (en) 2012-09-14 2015-10-06 Amazon Technologies, Inc. Secure proxy
CA2927730A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CA2974903A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
EP4538365A3 (en) 2016-03-04 2025-07-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin e2
GB2578539B (en) 2017-06-09 2022-08-10 Univ Leland Stanford Junior Compositions and methods for preventing or treating muscle conditions

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11969433B2 (en) 2016-03-04 2024-04-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
US11738031B2 (en) 2017-06-09 2023-08-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
US12559493B2 (en) 2020-01-23 2026-02-24 Myoforte Therapeutics, Inc. PGDH inhibitors and methods of making and using
WO2022082009A1 (en) * 2020-10-15 2022-04-21 Epirium Bio Inc. Inhaled formulations of pgdh inhibitors and methods of use thereof
CN116457014A (zh) * 2020-10-23 2023-07-18 莱兰斯坦福初级大学评议会 通过抑制前列腺素降解酶15-pgdh提升线粒体生物合成和功能
CN114107272A (zh) * 2021-12-15 2022-03-01 徐州医科大学 mPGES-2作为预防和/或治疗衰老疾病的药物靶点的应用
US12558549B2 (en) 2022-10-28 2026-02-24 Medtronic, Inc. Lead based measurements for tongue movement determination
CN117473328A (zh) * 2023-12-26 2024-01-30 南京麦豆健康科技有限公司 一种基于大数据的阴道松弛评估训练系统及方法

Also Published As

Publication number Publication date
GB201919382D0 (en) 2020-02-05
CN111212648A (zh) 2020-05-29
EP3634424A1 (en) 2020-04-15
JP7372911B2 (ja) 2023-11-01
GB2578539A (en) 2020-05-13
JP2020523409A (ja) 2020-08-06
US11738031B2 (en) 2023-08-29
US20240115583A1 (en) 2024-04-11
US20260144801A1 (en) 2026-05-28
EP3634424A4 (en) 2021-06-09
WO2018227134A1 (en) 2018-12-13
JP2023139260A (ja) 2023-10-03
AU2018280264A1 (en) 2020-01-02
KR20200015735A (ko) 2020-02-12
WO2018227138A1 (en) 2018-12-13
KR102698911B1 (ko) 2024-08-23
US20220265677A1 (en) 2022-08-25
CN111212648B (zh) 2024-07-09
CA3065945A1 (en) 2018-12-13
AU2018280264B2 (en) 2024-07-11
GB2578539B (en) 2022-08-10

Similar Documents

Publication Publication Date Title
US11738031B2 (en) Compositions and methods for preventing or treating muscle conditions
US20240415849A1 (en) Compositions and methods for muscle regeneration using prostaglandin e2
Alvarez et al. Ectopic uterine tissue as a chronic pain generator
Silver et al. Livedo reticularis in Parkinson's disease patients treated with amantadine hydrochloride
Bellamy Temporal pattern of type II fibre-specific satellite cell expansion to exercise correlates with human muscle hypertrophy: potential role for myostatin
Sugiura et al. Parasympathetic overdrive as a cause of overactive bladder in a high‐fat‐diet‐induced obesity mouse model
Perry Volumetric Muscle Loss: The Role of Physical Activity and Autologous Repair on Force Recovery and Signaling Pathways
US11655506B2 (en) Therapeutic target for musculoskeletal inflammation
Padilla Interval Versus Continuous Single-leg Training on Capillarization and the Satellite Cell Response
Lian On the causes of patellar tendinopathy
Fraser et al. 195: Effects of a Combined 5HT3 Receptor Antagonist and Noradrenaline Reuptake Inhibitor on Lower Urinary Tract Activity
HK40001925A (en) Compositions and methods for muscle regeneration using prostaglandin e2
BR122025016540A2 (pt) Composição compreendendo um pge2, um derivado de pge2, um análogo de pge2, um pró-fármaco de pge2 ou um agonista do receptor ep4 de prostaglandina, e seu uso

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLAU, HELEN M.;PALLA, ADELAIDA R.;TRI VAN HO, ANDREW;SIGNING DATES FROM 20181003 TO 20181004;REEL/FRAME:048375/0540

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION